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Abstract  
Hepatocytes are the primary cell type of the liver, they play a key role in drug toxicity 
and therefore represent an ideal model for preclinical toxicity testing.  However, 
current primary hepatocyte models resist in vitro proliferation and immortalised 
models are often not fully metabolically competent.  One solution is the rodent B-13 
cell line which forms hepatocyte-like B-13/H cells in response to glucocorticoid 
treatment.  This thesis aimed to investigate the metabolic activity of B-13/H cells and 
assess the role of mitochondrial dysfunction in cytotoxicity.  Cells were challenged 
with the anti-diabetic drug, troglitazone, which was withdrawn from the market 
following reports of liver injury, mitochondrial liabilities have since been associated 
with its toxicity.  Extracellular flux analysis showed that basal levels of respiration 
were comparable between B-13 and B-13/H cells, however, reserve capacity was 5-
fold greater in the B-13/H cells.  In response to troglitazone, there was a 
concentration dependent decrease in oxygen consumption rate in B-13/H cells 
compared to a stimulation of respiration in B-13 cells and a concomitant increase in 
lactate levels and oxygen demand for ATP production.  After 24 hours troglitazone 
treatment, there was a concentration dependent decrease in B-13/H viability.  B-13 
cell viability was unaffected.  A larger baseline reserve capacity suggested a greater 
mitochondrial mass in B-13/H cells concomitant with a greater role in metabolism, 
similarly, B-13/H cells were more susceptible to troglitazone than B-13 cells.  A drop 
in oxygen consumption rate suggested that there was mitochondrial dysfunction; this 
was supported by a drop in total ATP levels.  In B-13 cells, troglitazone had a 
stimulatory effect on respiration and a concentration dependent increase in lactate 
suggested a switch from oxidative phosphorylation to glycolysis.  The data presented 
indicate that B-13/H cells could potentially form the basis of a toxicity screening 
platform. This work could also underpin the development of a human equivalent 
model.
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1.1 Hepatocytes and the liver  
The liver is the largest visceral organ in the body and represents approximately 2% of 
adult body weight.  The liver has two main vascular systems, the first is supplied by 
the hepatic artery and the second by the portal vein (Malarkey et al., 2005).  The 
portal vein drains from the gastrointestinal tract and as such is enriched with nutrients 
from the intestine.  This subsequently means that the liver is also vulnerable to high 
exposure from orally ingested xenobiotics and plays a vital role in the 
biotransformation and metabolism of exogenous substances.  The liver is made up of 
approximately 15 different cell types, of which, hepatocytes are the most abundant, 
which represent approximately 60% of total cell content of the liver and 80% of total 
liver volume (Ishibashi et al., 2009).  
Hepatocytes are responsible for the majority of liver function and are the primary cells 
in which drug metabolism occurs due to their high content of phase I and II metabolic 
enzymes as well as high expression of uptake and efflux transporter proteins and 
therefore hepatocyte cell models play a huge role in preclinical studies as they can 
provide a useful high throughput screen for the assessment and understanding of the 
diverse mechanisms by which a compound can elicit toxic outcomes (Ishibashi et al., 
2009). 
1.2 Preclinical Toxicology 
The drug development process consists of four main phases: early discovery, late 
discovery, preclinical and clinical.  Preclinical toxicity testing is vital in understanding 
or predicting adverse responses to potential new drug candidates both at therapeutic 
and supra-therapeutic does to ensure the safety of participants in human clinical 
trials.  Safety studies are crucial in the drug development process; in recent years the 
failure to predict toxicity has overtaken lack of efficacy as the primary reason for drug 
attrition.  In 1991 40% of drugs that dropped out of the development process were 
due to poor pharmacokinetics or bioavailability, by 2000 this had been reduced to 
less than 10% with the development of better in vitro predictive systems (McKim Jr, 
2010).   
In recent years there has been a push to update the tools used to predict toxicity and 
to align the search for toxicity with the search for new compounds so that toxicity 
issues can be established earlier in the process to reduce the costs incurred with 
dropping a compound further in the development stages (McKim Jr, 2010).  Broadly 
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speaking there are 4 main arms of exploratory safety studies: in silico, safety 
pharmacology, general toxicology and genetic toxicology.   
1.2.1 In silico studies 
In silico studies are initial computational predictions of a drugs toxicological potential 
based on its chemical structure. It is useful early on in the drug development process 
as many compounds can be screened quickly to identify leads and prioritise certain 
structures.  However, the utility of in silico testing is restricted by the size of the 
database meaning it is not a fully comprehensive predictive system and it also lacks 
the ability to detect complex outcomes (Ahuja and Sharma, 2014).   
1.2.2 Safety Pharmacology 
The focus of safety pharmacology testing is to assess potential undesirable toxic 
effects in major physiological systems, predominantly, cardiovascular, central 
nervous system, respiratory, renal and gastro intestinal.  By assessing functional 
end-points the results of safety pharmacology studies can inform testing by ruling out 
further studies with a drug that has a problematic profile at this stage.  If these tests 
can be performed using high throughput in vitro screens, then it also reduces the 
number of animals required for further endpoint testing (Hamdam et al., 2013).   
1.2.3 Genetic toxicology 
Genotoxicity studies provide a short term surrogate for longer term carcinogenicity 
studies and aim to understand if a drug candidate will be mutagenic.  Mutagenicity 
tests identify whether a compound has the potential to cause chromosomal 
aberrations or DNA damage in the form of structural aberrations to DNA such as 
deletions, insertions, duplications or translocations as well as changes to the base 
sequence the results of which suggest the potential for the compound to be 
carcinogenic.  Carcinogenicity studies are not part of the standard battery of tests 
unless a drug is expected to be required chronically or to treat a recurring condition 
(Ahuja and Sharma, 2014).   
1.2.4 General toxicology  
General toxicology tests aim to identify the maximum tolerated dose and to 
subsequently establish a dose range for the drug candidate.  General toxicology also 
explores the toxicokinetics of a drug candidate by using cytotoxicity screens to 
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provide mechanistic information regarding a drugs bioactivation, mode of metabolism 
and potential toxic effects.  It is at this stage when hepatocyte models are used as 
they can provide useful information about the mechanism(s) by which a molecule 
causes toxicity. Hepatocytes also allow for rapid, high throughput screening and 
when used with a panel of cell lines can provide accurate and reproducible data in a 
cost-effective manner (Ahuja and Sharma, 2014). 
1.3 Current Models for Toxicity Testing 
For many years’ in vitro cell models have frequently been used for the determination 
of liver toxicity in pre-clinical regulatory toxicology experiments as well as for disease 
modelling.  Cell models provide a useful tool early in the drug development process 
for high throughput screening of potential new chemical entities because they can be 
grown in quickly and in volume.  Cell lines can be easily manipulated depending 
upon the particular toxicity being studied, making choosing a subsequent animal 
model more accurate as in vitro models help to identify any species specific toxicities 
(Ahuja and Sharma, 2014).  As a result, a wealth of cell and tissue models have been 
developed that can be tested in conjunction as a panel to provide an overview of 
chemical toxicity.  Amongst the most commonly used cell lines are the HepG2 and 
HepaRG which are derived from human liver tissue and immortalised.  It is estimated 
that approximately only 1 in 10,000 chemicals that enter into the discovery process 
ever make it to the market and 40% of new chemical entities that enter preclinical 
safety testing will fail because of toxicity issues, indicating that there is still a need for 
more accurate and reliable predictive methods (McKim Jr, 2010).  The issue is further 
compounded by the drive to reduce testing in whole animals, with the introduction of 
the National Centre for 3Rs (NC3Rs) initiative it is more important than ever that new 
methods can be developed utilising cell based in vitro models. 
1.3.1 The 3Rs 
In 2004, the UK government established the NC3Rs in order to highlight the 
importance of animal welfare in research by producing a range of resources in order 
to educate researchers and funding 3Rs related research (Perry and Joynson, 2007).  
The 3Rs are guiding principles for the ethical use of animals in medical research, 
described by M. S. Russell and R. L. Burch in 1959 and stand for replacement, 
reduction and refinement and suggest that where possible the use of animals must 
be completely avoided (replacement), when this is not possible, studies must be 
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designed to use as few animals as possible (reduction) and at all times the welfare of 
the animal must be paramount; the methods used in the study must be adapted to 
ensure as little pain and distress as possible is experienced by the animal 
(refinement) (Holmes et al., 2010). 
In the UK, regulations for animal research are some of the strictest in the world.  
Researchers must obtain a number of government licenses before any work using 
animals can be performed and a comprehensive justification of the use of animals 
and cost-benefit analysis must be provided before work can begin. This includes 
demonstration that the 3Rs (reduction, replacement and refinement) have been 
considered (Perry and Joynson, 2007).  Since the inception of animal models, 
medical research has advanced rapidly; sophisticated predictive in silico models and 
tissue models have been developed, making widespread use of whole animals less 
relevant in many areas of scientific research (Holmes et al., 2010). 
There are currently many alternative models for use instead of animals in all areas of 
medical research including primary models of human hepatocytes as well as 
immortalised cell lines and even liver microsomal fractions for studies of particular 
organelle functions.  In pre-clinical toxicity testing, however, the issue of alternative 
models is more complex as the results obtained need to be predictive of human 
response to a chemical compound and as such liver cell models are rather more 
challenging to replace.  However, when combined, different models can form a useful 
platform for establishing toxic effects. 
1.3.2. Human Hepatocytes  
A whole liver perfusion would be the ideal model for predicting drug induced liver 
injury (DILI) as it retains all original cell types and structure thus allowing for a 
response that is as close to the in vivo situation as possible. However, due to the 
scarcity of liver tissue for research, it cannot be obtained on demand and any 
experimental replicates are often from different donors and as such do not always 
provide consistent responses. Furthermore, any good quality livers are reserved for 
transplantation (Wallace et al., 2010). 
Human hepatocytes are considered the “gold standard” for drug metabolism and 
toxicity studies as they are fully competent metabolic cells derived from human liver 
tissue. Unfortunately, supply is limited and small fragments of tissue are often 
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variable in quality (Castell et al., 2006).  Furthermore, hepatocytes do not proliferate 
in vitro and thus cannot be expanded because they are resistant to subculture 
(Probert et al., 2014). 
Human hepatocytes do, however, present an adult phenotype and express functional 
phase I and II enzymes as well as enzyme co-factors and will respond to CYP 
inducers providing an overall metabolic profile of a compound (Castell et al., 2006).  
A particular advantage human hepatocytes have over immortalised cell lines is that 
they show phenotypic variation dependent on the CYP expression of the individual 
hepatocyte donor; there will potentially be polymorphisms due to diet, age, social 
habits such as smoking and drinking as well as changes due to the donors’ exposure 
to other drugs.  This means that during the drug screening process susceptible 
individuals based upon genotype are more likely to be discovered.  However, such 
variation in hepatocytes can also lead to variation in cell viability and attachment, 
making experimentation difficult (Castell et al., 2006).   
Long term drug toxicity studies are problematic in human hepatocytes as their 
phenotype is not stable in culture for more than a few days. CYP expression can 
become down regulated over time meaning that studies are restricted to acute dosing 
and chronic analysis is not possible (Castell et al., 2006).  Furthermore, routine 
testing is often hindered due to lack of access to fresh human hepatocytes. 
Additionally, there is often considerable variation in CYP expression between 
batches of isolated hepatocytes.  This is largely due to the fact that cells are often 
significantly damaged prior to isolation because they have come from patients who 
have been on long term treatment which has caused hepatotoxicity and cellular 
damage.  Furthermore, age, environmental factors and lifestyle factors such as 
drinking alcohol and smoking can all contribute to an altered CYP profile (Maes et al., 
2016).  Consequently, generating reproducible and consistent data from human 
hepatocytes is often challenging (Rodríguez-Antona et al., 2002). 
1.3.3 Immortalised Cell Lines  
Hepatic cell lines derived from human hepatomas are among the most commonly 
used hepatic cell lines as they are able to grow continuously in simple growth media, 
have an unlimited life span and a stable phenotype.  These reasons along with their 
ease of availability make them an attractive option for hepatocyte studies and due to 
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the frequency with which they are used have become standardised across labs, 
making cross-comparison easier (Castell et al., 2006). 
The HepG2 line is a commonly used hepatocyte cell line as it exhibits many liver 
specific functions and has expression of some liver specific enzymes. However, the 
cells do not provide a useful predictive model as they lack functional expression of 
nearly all CYP enzymes.  HepG2 cells only show a similar susceptibility as human 
hepatocytes to drugs that do not require metabolism such as amiodarone and 
chlorpromazine (Guillouzo et al., 2007). 
In contrast the HepaRG cell line has been reported as being much closer in CYP 
expression to human hepatocytes than the HepG2 cells (Guillouzo et al., 2007; Hart 
et al., 2010; Gerets et al., 2012).  HepaRG cells were originally derived from a female 
hepatocarcinoma patient. At sub-confluence they are proliferative but retain an 
undifferentiated form. With the addition of differentiation inducing media (William’s E 
media supplemented with 10% FCS, 100 units/ml penicillin, 100 μg/ml streptomycin, 
5 μg/ml insulin and the addition of 2% DMSO and 50 µM hydrocortisone for 
differentaition) the cells will differentiate into hepatocytes or biliary epithelial cells at 
which point they will remain stable for several weeks (Hart et al., 2010).  Interestingly, 
both undifferentiated and differentiated HepaRG cells show similar functionality to 
primary human hepatocytes, however, when differentiated there is an up regulation 
of drug metabolising enzymes.  It has been reported that at the mRNA level, 
HepaRG cells express most phase I genes, including CYP1A2, CYP2B6, CYP2C9, 
CYP2E1 and CYP3A4 as well as most phase II genes, including UGT1A1, GSTA1, 
GSTA4 and GSTM1 (Hart et al., 2010; Gerets et al., 2012).  The level of mRNA 
present of phase I and II enzymes was found to be comparable to that of primary 
human hepatocytes and were similarly as inducible using β-naphthoflavone to induce 
CYP1A2, PB for CYP2A6 and rifampicin for CYP3A4.  CYP3A4 and CYP2B6 were 
found to be particularly highly inducible in the HepaRG cells and at much more 
consistent levels than those found in primary human hepatocytes (Gerets et al., 
2012).  As mentioned previously, HepG2 cells show low expression of CYP enzymes 
and are poorly inducible. The only inducible gene found is CYP1A1 which is typically 
only expressed in the foetal liver in vivo.  This suggests that HepG2 cells do not 
retain an adult phenotype and would explain why cells have low metabolic capacity 
(Gerets et al., 2012).  Changes in gene expression that occur during processes such 
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as differentiation are mostly controlled at a transcriptional level (Ramji and Foka, 
2002).  Liver specific gene expression in adult hepatocytes relies upon four families 
of transcription factors; C/EBP, HNF-1, HNF-3 and HNF-4 (Rodríguez-Antona et al., 
2002).  It has been suggested that a decrease in these liver enriched transcription 
factors causes a downregulation of CYP expression during culture.  One of the most 
commonly expressed transcription factors in the regulation of CYP enzymes in the 
liver is C/EBP-β.  C/EBP-β can be transcribed in a full length form or a truncated 
form.  It has been found that the truncated form lacks the specific domain which 
causes the activation of CYP transcription and furthermore, antagonises the full 
length form.  This means that, when the truncated form is dominant, not only are 
functional CYP enzymes unable to be transcribed but they are also inhibited from 
being transcribed by functional C/EBP-β (Rodríguez-Antona et al., 2002). 
Unfortunately, although the CYP mRNA levels are comparable to primary human 
hepatocytes and they show a similar level of induction this does not correlate with 
functionality.  The enzyme activity in HepaRG cells is much lower than primary 
human hepatocytes and is more comparable to the enzyme activity found in HepG2 
cells. Gerets et al reported that in order to achieve comparable LC50 values with 
primary human hepatocytes, higher concentrations and longer incubation times were 
required with HepaRG cells.  It was suggested that this could be because in HepaRG 
cells, higher levels of basal CYP may be required in order to successfully metabolise 
drugs, it is also possible that the cells express more phase II than phase I enzymes 
and thus drugs are more efficiently metabolised by alternative pathways that do not 
generate toxic metabolites (Gerets et al., 2012). 
Immortalised cell lines such as HepG2 and HepaRG are an attractive option when 
looking for a hepatocyte cell line to study as they are readily available, easy to 
culture, they are proliferative, do no de-differentiate in culture and have a stable 
phenotype.  However, while they address many of the issues found with primary 
hepatocytes they may not be suitable for toxicity profiling of drug compounds as they 
may underestimate toxicity due to a reduced or dysfunctional cytochrome P450 
profile. 
In order to overcome the limitations of immortalised lines a lot of work in recent years 
has focussed on the development of new ways in which to generate human 
hepatocytes using stem cells.  Because of their human physiology, stem cells could 
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be useful in regenerative medicine as well as predicative toxicity studies and disease 
modelling, thus offering huge potential. 
1.3.4 Embryonic Stem Cells 
Embryonic stem cells are pluripotent cells derived from the inner cell mass of a 
blastocyst. This means that upon exposure to specific growth factors the cells can be 
directed towards any cell linage in the body and have the potential for continuous 
differentiation in vitro (Zhang et al., 2013).  The aim is to derive fully functioning adult 
human hepatocytes from pluripotent embryonic cells, however, as there is no 
standardised method for doing this, the procedure is still being refined.  Similarly, 
once the cells have differentiated there is currently no set method for the 
characterisation of the cells to determine how like primary human hepatocytes the 
derived cells are.  This would not only be important in order to assure batch to batch 
consistency in cells but also to ensure comparable results between labs using the 
same cells.  Currently the cells are assessed based on the purity of the batch i.e. the 
proportion of mature hepatocyte like cells present, and their gene expression profile.  
Similar to the HepG2 and HepaRG cells mentioned in Section 1.1.3, a fully 
functioning and inducible CYP profile is yet to be seen in any successfully derived 
hepatocyte like cells (Kia et al., 2013).  Additionally, there are many ethical concerns 
with the use of embryos because the isolation of the inner cell mass results in the 
destruction of the embryo and thus progress in this field is often very slow (Zhang et 
al., 2013). 
1.3.5 Induced Pluripotent Stem Cells 
Pluripotent cells are able to differentiate into any cell derivate of the 3 germ layers 
(endoderm, mesoderm and ectoderm). Therefore, when these cells are exposed to 
certain growth factors and hormones they can be directed down a particular 
differentiation pathway and as a result form any cell type within the body. 
Pluripotency can be induced in cells by transducing particular genes that cause the 
cells to revert to endoderm cells. iPS cells were first used to generate human 
hepatocytes in 2004 by Song et al (Song et al., 2009). Endoderm induction was 
initiated by transduction of a lentivirus containing the genes Oct-4, Sox-2, Klf4 and 
Utf1 into human fibroblasts. Following induction of pluripotency, the cells could then 
be directed down a hepatocyte differentiation pathway by culture in hepatocyte 
culture medium containing specific fibroblast growth factors. Following 21 days 
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differentiation the resulting cells exhibited liver specific functions such as albumin 
secretion, urea production and cytochrome P450 activity as well as expression of 
specific hepatic markers such as albumin (Song et al., 2009). 
Hepatocytes generated in this way are comparable to human embryonic stem cell 
derived hepatocytes without the ethical implications. Furthermore, they proliferate 
extensively and therefore are preferential to human hepatocytes extracted from liver 
tissue. Finally, iPS technology could be harnessed to produce patient specific cells 
allowing for their transplantation in vivo, however, this is currently not possible as the 
cells do not expand in vivo (Zhang et al., 2013).  There are also additional concerns 
over the use of iPS cells in humans as their production requires the use of viral 
vectors which could potentially introduce genomic insertions of exogenous 
sequences into the DNA of hepatocytes which could potentially pose a tumour risk in 
humans (Kia et al., 2013).  It has also been highlighted that iPS cells may retain 
epigenetic memory and overcoming this represents another challenge of developing 
a genetically stable model.  Epigenetic memory is the term given to cells that return 
to the original phenotype of the parent cells, thought possibly to be due to incomplete 
DNA methylation (Kia et al., 2013).   
Stem cells have huge potential not only in academic research but also clinically. It is 
possible that if a stable cell line can be generated, hepatic like stem cells could have 
the necessary functional genotype that would allow them to be used in regenerative 
medicine.  While huge steps have been taken to achieve this there are still many 
remaining challenges, not least that the production of hepatocyte equivalents from 
stem cells is very expensive.   
Over the past decade, work has been done to develop a novel cell line derived from 
the pancreatic acinar cells of rats following the observation that simple steroid 
treatment caused the cells to transdifferentiate into hepatocyte like cells.  Creating 
hepatocytes via this method has been reported as being an estimated 5 million times 
cheaper than generating hepatocytes from stem cells (Probert et al., 2014). If the 
mechanisms behind this transdifferentiation could be established and harnessed it 
could pave the way for a human equivalent. 
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1.4 B-13/H Cells 
1.4.1 Origins of the B-13/H Cell Line  
B-13 cells are a sub-clone of the exocrine pancreatic AR42J cell line developed from 
rat adenocarcinoma cells.  The AR42J cell line, which is still used today in exocrine 
pancreas research, was created by treating inbred Wistar/Lewis rats with the 
naturally occurring antibiotic, azaserine, known to be capable of producing 
carcinomas and isolating the cells from the pancreatic tumours.  The Kojima lab 
developed the B-13 sub-clone in 1996 by treating AR42J cells with hepatocyte 
growth factor and activin A.  Following treatment, it was found that the cells that were 
able to differentiate into insulin producing, endocrine, β-like pancreatic cells in vitro 
(Probert et al., 2015).  In 2000, Shen et al. reported that, following glucocorticoid 
treatment, there was a distinct change in phenotype as cells altered from pancreatic 
to hepatic morphology (Shen et al., 2000).  This observation was later confirmed with 
studies that showed these hepatic like cells to express certain hepatic specific genes 
(Tosh et al., 2002a; Tosh et al., 2002b).  This work was built upon in 2003 by the 
Wright group, it was demonstrated that following 12 days of treatment with 
dexamethasone, B-13/H cells expressed significant levels of 4 constitutively 
expressed cytochrome P450 enzymes- CYP2C11, CYP2A, CYP2E1 and CYP3A1, 
which were undetectable in B-13 cells.  Furthermore, for the first time it was found 
that the CYP enzymes expressed were also found to be metabolically active as B-
13/H cells were sensitive to the hepatotoxin, paracetamol.  Paracetamol metabolism 
is dependent upon CYP2E1 activity in order to be toxic. This enzyme metabolises 
paracetamol to the electrophilic intermediate, N-Acetyl-p-benzoquinone imine 
(NAPQI). Observation of paracetamol-dependent toxicity in B13-H cells could, 
therefore,  suggest the presence of functionally active CYP2E1 (Marek et al., 2003). 
1.4.2 Mechanism of Differentiation 
B-13 cells readily proliferate in basic cell culture media supplemented with serum.  
There are no additional growth factors or culture modifications required.  The cells 
will grow and expand on plastic substrate but will not grow in agar.  This suggests 
that B-13 cells have anchorage dependent growth and are potentially non-cancerous 
(Fairhall et al., 2013a).  To transdifferentiate the cells from B-13 to B-13/H 10nM 
dexamethasone is added to the media. This is the only media supplement that is 
required to initiate the transdifferentiation process.  Conversion takes between 7-14 
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days and following this period >80% of cells will have trans-differentiated, remaining 
cells maintain a B-13 phenotype (Fairhall et al., 2013a). 
B-13 cells respond to dexamethasone treatment through the glucocorticoid (GR) 
receptor.  Many other glucocorticoids work via the GR receptor and will elicit a similar 
initiation of transdifferentiation in B-13 cells as dexamethasone.  Dexamethasone 
was preferentially chosen, however, due to its high specificity for the GR receptor 
and rapid metabolism (Probert et al., 2015).  Other classes of steroids, such as 
mineralocorticoids, fail to initiate trans-differentiation. Furthermore, glucocorticoids 
that can act via mineralocorticoid receptors also fail to elicit a response, suggesting 
that it is a very specific glucocorticoid mediated process.  Glucocorticoids have wide 
ranging metabolic actions in vivo and promote gluconeogenesis, lipolysis and protein 
breakdown as well as immunosuppressant and anti-inflammatory effects. However,  
perhaps more relevant when trying to understand B-13 differentiation, glucocorticoids 
are also known to have a developmental role in the foetus in tissue maturation 
(Probert et al., 2015). 
While the full mechanism behind the transdifferentiation process is yet to be 
established, it is thought to be, in part, due to changes in expression of the serum 
and glucocorticoid kinase (SGK1) gene.  Microarray studies have shown that SGK1 
has the highest induced transcript in response to dexamethasone treatment of 5000 
transcripts (Probert et al., 2015).  The SGK1 gene encodes for serum and 
glucocorticoid-regulated kinase 1 (Sgk1). It is an enzyme involved in ion channel 
regulation, mediating a stress response to low sodium salt levels by promoting 
reabsorption in the kidney (Wallace et al., 2010).  It is thought that Sgk1 is able to 
cross talk with the Wnt signalling pathway which leads to an inhibition of Wnt 
signalling activity and promotes induction of C/EBP-β (Fairhall et al., 2016).  C/EBP-β 
is an enhancer binding protein that promotes proliferation, differentiation, metabolism 
and inflammation, primarily in hepatocytes, adipocytes and haematopoietic cells 
(Ramji and Foka, 2002).  It was found that Wnt signalling was highly active in B-13 
cells and inhibition of this pathway alone was enough to initiate transdifferentiation 
into B-13/H phenotype.  While it is thought that SGK1 expression provides the link 
between initial GR receptor activation and subsequent Wnt signalling repression its 
importance in pancreatic cell transdifferentiation is unclear.  SGK1 has a clear 
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functional role in the kidney but its utility and significance in other tissues remains to 
be fully understood (Wallace et al., 2010). 
1.4.3 Functional Similarity of B-13/H Cells to Hepatocytes 
Initial studies into the similarity of B-13/H cells to hepatocytes focussed on 
immunofluorescence detection of genes.  While this provided excellent preliminary 
data to suggest these cells were potentially hepatocyte-like, functionality was not 
assessed.  In 2003 the Wright group established that the CYP enzymes expressed 
by B13/H cells were functional and this work was built upon in a further study that 
aimed to establish a potential use for B-13/H in toxicity and genotoxicity studies.  
Cytochrome P450 induction, toxin susceptibility and transporter gene expression 
were studied further and it was found that regulation of major CYP families remained 
intact and that functional transport across cell membranes was detected. The 
expression of transporter mRNAs was upregulated relative to B-13 levels and some 
were expressed at levels similar to those found in vivo, although most were below 
levels seen in the adult rat liver.  CYP3A enzymes were significantly functional and 
inducers of the nuclear receptor that upregulates CYP3A expression, PXR, were 
found to be effective (Probert et al., 2014).  There were however, some major 
differences seen between the B-13/H cells and hepatocytes. CYP2B1 mRNA was 
present, it was not, however, translated into functional protein, similarly other CYP2B 
isoforms show low levels of activity.  CYP1A2 was not expressed in the B-13/H cells, 
however, it was successfully genetically engineered to be expressed and in doing so 
humanised the line, demonstrating that the B-13 cell line can be readily manipulated 
to suit the needs of the experiment (Probert et al., 2014).  
1.4.4 Human Equivalents of B-13/H Cells 
It was hypothesised that B-13 cells are hyper-responsive to GR receptor activation 
due to over induction or sustained exposure to elevated SGK1. If the genetic 
mechanism behind the response can be deciphered and reproduced in a human cell 
line, there is the possibility that a B-13/H human equivalent can be established.  
The significance of a human equivalent would mean that the potential of these cells 
would go beyond the lab and possibly have clinical applications (Fairhall et al., 2016). 
It has been reported by Fairhall et al. that these mechanisms do exists in humans, in 
vivo (Fairhall et al., 2013b).  Pancreatic tissue samples from patients that had been 
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treated with systemic glucocorticoids for at least 20 years were compared to control 
samples where there had been no long-term therapy.  It was found that the hepatic 
specific markers, CPS1 and albumin were expressed in the pancreatic cells of 
patients on glucocorticoid therapy at levels normally seen in the liver.  Furthermore, 
enzymes expressed at high levels in the liver such as CYP3A4 were also discovered 
at high levels in the pancreatic cells.  In the control cells, from patients with no 
glucocorticoid therapy, CPS1, albumin and CYP3A4, were undetectable.  This 
suggested that the pathophysiological response exists in humans and could possibly 
be harnessed as a cell line.  Further experiments showed that when these pancreatic 
cells were grown in culture with dexamethasone treatment, the control cells began to 
show hepatic markers at the mRNA level and the cells from patients with 
glucocorticoid therapy retained the expression of pre-existing markers.  This 
suggested that there is potential for continued culture of these cells and development 
of a novel hepatic cell line (Fairhall et al., 2016). 
Unpublished work has shown that there is potential for Human Pancreatic Acinar 
Cells (HPACs) to be used as a progenitor to hepatocyte-like cells using DEX 
treatment identical to that used on B-13 cells to stimulate trans-differentiation.  
Currently, there are two different HPAC variants that are being studied both of which 
have been transfected with a different human growth factor in order to help maintain 
a hepatocyte-like genotype; H-13 cells are human equivalents transfected with HNF-
4a and H-14 cells are human equivalents transfected with HNF-1a (Fairhall, 2013). 
B-13/H cells represent a cell line that provides an on demand and unlimited supply of 
functional hepatocytes for the screening of drug toxicity and metabolism.  However, it 
is important to bear in mind that once the cells have differentiated from their B-13 
phenotype they stop proliferating and subsequently there is also not 100% 
conversion.  Yield is very high, >80%, however there remains a sub population that is 
resistant to differentiation and continues to proliferate (Wallace et al., 2010).  While 
there is a lack of expression of some functional CYP metabolising enzymes, it has 
been shown that there is near functional comparability of B-13/H cells to hepatocytes 
including functional CYP3A isoform which, in vivo, is one of the most commonly 
implicated isoforms in xenobiotic metabolism and liver specific enzymes, such as 
albumin, are expressed as well.  It is important when assessing drug toxicity in vitro 
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that responses are comparable to in vivo as they are a predictive assessment of 
human susceptibility.   
At a time when adverse drug reactions are the leading cause of drug attrition in the 
UK and the reduction of whole animal studies is of paramount importance, finding an 
in vitro cell model that is capable of predicting human response is more relevant than 
ever before.  A model cell line needs to be capable of high throughput screening of 
compounds, thus needs to be able to be produced in large quantities that are 
genetically uncompromised and have batch to batch comparability in order to 
generate reliable predictive data.  B-13/H cells represent a cost effective and 
functional platform that has potential to provide the basis for a human equivalent to 
be developed. 
1.5 Mitochondria  
1.5.1 Mitochondrial Structure and Function  
Mitochondria are often described as the powerhouse of the cell. They produce 
energy in the form of ATP which is used by all other cells in the body to function and 
survive.  Mitochondria are a two membraned organelle; an outer membrane and an 
inner membrane that surrounds a matrix.  The smooth outer membrane is highly 
permeable as it contains a large channel forming protein that is permeable to any 
molecule of 10,000 daltons or less.  This makes it susceptible to the transport of 
xenobiotics as well as endogenous compounds.  The inner membrane is highly 
folded into structures called cristae to maximise the surface area available for 
oxidative phosphorylation. The inner membrane also contains the proteins of the 
electron transport chain (ETC) required to generate ATP embedded within it.  The 
mitochondrial matrix also contains the mitochondria’s own genome which consists of 
the circular mtDNA and transcripts that encode for 13 proteins required for oxidative 
phosphorylation (Alberts, 2002). 
1.5.2 Cellular Respiration  
Cellular respiration is a multi-step process, the first part of which, glycolysis, does not 
occur in the mitochondria itself but in the cytoplasm of the cell.  Glycolysis is the 
process by which a glucose molecule, with 6 carbon atoms, is broken down into 2 
pyruvate molecules each with 3 carbon atoms as a priming reaction before entry into 
the mitochondria.  While the reaction itself is able to generate energy as ATP it is not 
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very efficient and for every 4 ATP molecules generated from glycolysis an input of 2 
ATP molecules is required.  The pyruvate molecules enter into the mitochondrial 
matrix where they undergo a link reaction which decarboxylates and dehydrogenates 
the pyruvate molecules to 2 carbon acetate molecules.  Coenzyme A accepts acetate 
to form acetyl coenzyme A which is then able to enter the Krebs cycle (Alberts, 
2002). 
The purpose of the Krebs cycle is to reduce carrier molecules which can be used to 
transport hydrogen to the ETC.  Acetate is added to oxaloacetate to form citrate 
which is sequentially oxidised in a series of decarboxylation and dehydrogenation 
reactions before regenerating oxaloacetate (Dashty, 2013).  The first decarboxylation 
and dehydrogenation of citrate forms α-ketoglutarate, a 5 carbon compound.  The 
lost carboxy group forms carbon dioxide and the hydrogen atom reduces a molecule 
of the carrier, NAD to form NADH.  α-ketoglutarate is decarboxylated and 
dehydrogenated to the 4 carbon compound, succinate, forming another molecule of 
NADH.  Succinate is oxidised to fumarate, the by-product of which is a molecule of 
reduced FAD (FADH2).  Fumarate is hydrated to form malate which in turn is 
dehydrogenated to regenerate oxaloacetate and produce another molecule of NADH.  
The energy carried by the activated hydrogen as part of NADH and FADH2 is used to 
generate ATP in the ETC (Alberts, 2002; Dashty, 2013). 
1.5.3 The Electron Transport Chain 
The ETC is the final step in mitochondrial respiration (figure 1.1).  It is here that the 
most ATP can be generated.  NADH and FADH2 carrier molecules need to be 
oxidised in order to release their energy, however the hydrogen atoms that NADH 
and FADH2 carry are not directly transferred to oxygen. Instead, it is the electrons 
that are transferred through a series of protein complexes until they reach the final 
electron acceptor, molecular oxygen, to generate water as seen in figure 1.1 (Dashty, 
2013).  The four protein complexes: I, II, III and IV, are embedded within the inner 
mitochondrial membrane.  Electrons from NADH enter the ETC at complex I whereas 
electrons from FADH2 enter at complex II.  Co enzyme Q is a lipid soluble molecule 
that transports the electrons from complexes I and II to complex III.  From complex III 
electrons are transported to complex IV via cytochrome C.  At complex IV electrons 
are transferred to molecular oxygen to generate water.  Electron transport is coupled 
to the transport of protons out of the matrix and into the intermembrane space.  
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Protons are electrically charged so there is a generation of an electrochemical 
gradient which can be utilised for the generation of ATP.  Because the phospholipid 
bilayer is impermeable to ions the passage of protons back into the matrix can only 
occur through a protein channel.  A fifth protein complex- ATP synthase, catalyses 
the synthesis of ATP from ADP by utilising this gradient and transporting protons 
back into the matrix down the electrochemical concentration gradient (Cooper, 2000). 
 
Figure 1.1 The Electron Transport Chain.  The electron transport chain is found in the 
inner mitochondrial membrane of mitochondria.  It is the process by which most of a 
cells energy, in the form of ATP, is produced.  Electrons are transferred to the 
electron transport chain by carrier molecules NADH and FADH2 then passed down a 
series of complexes (I to IV).  Electron transport is coupled to the movement of 
hydrogen ions out of the matrix creating an electrochemical gradient which is 
harnessed at complex V (ATP-synthase) where it is driven down the concentration 
gradient, through the protein channel, to synthesise ATP from ADP.  Adapted from 
(Ow et al., 2008) 
1.5.4 Free Radical Production 
The ETC is not 100% efficient. Electrons can leak from complexes and can 
prematurely cause the one electron reduction of oxygen to the superoxide free 
radical (O2¯)  (Hamanaka and Chandel, 2010).  A free radical is an atom or molecule 
with unpaired electrons making them highly reactive and unstable.  If a free radical 
specifically contains oxygen it is known as a reactive oxygen species (ROS).  
Mitochondria are the biggest source of physiological ROS and complexes I, II and III 
are all capable of prematurely reducing oxygen (Deavall et al., 2012).  Under normal 
physiological conditions, O2¯is catalysed to hydrogen peroxide (H2O2) by manganese 
superoxide dismutase (Mn-SOD) in the mitochondria.  Hydrogen peroxide is a 
reactive non-radical species that is reduced to water by the antioxidant, glutathione.  
However, when a cell is stressed and there are excessive levels of superoxide it is 
possible that H2O2undergoes another reaction, known as Fenton’s reaction, and 
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generate the highly reactive hydroxyl radical (OH).  Under normal conditions, free 
iron is sequestered into ferritin clusters and kept in a reduced state, however, these 
clusters can be oxidised by O2¯, releasing Fe2+ ions which participate in the Fenton’s 
reaction by catalysing the formation of OH from H2O2 (figure 1.2).  Hydroxyl radicals 
are extremely reactive and damaging, however, due to an extremely short half-life 
(~ 10-9 s) only react close to the site of their formation (Valko et al., 2007). The 
physiological leakage of O2¯, therefore, has important consequences for 
mitochondrial drug induced liver injury, as it presents a possible initial site for 
subsequent oxidative stress. 
1.6 Mitochondrial Toxicity  
1.6.1 Drug Induced Liver Injury  
Drug induced liver injury (DILI) is a severe and off target response to a drug, it is a 
broad term that describes many manifestations within the liver, the most common of 
which is hepatocyte death after drug ingestion. DILI can be predictable, as is the 
case with paracetamol, or unpredictable, as is the case with idiosyncratic DILI.  
Idiosyncratic toxicities occur at therapeutic pharmacological doses and are defined 
by their delayed onset and rare occurrence, less than 1 in 10,000 patients.  An 
idiosyncratic response is not a single mechanism of toxicity, and, again, is a term that 
describes all unexpected toxicities (Dykens and Will, 2007).  Idiosyncratic DILI is one 
of the major reasons for cessation of new drug development as well as 
discontinuation of current marketed treatments. It presents a major problem for drug 
companies not only financially but also because of the difficulty in predicating toxic 
outcomes during drug development due to the elusive nature of the mechanisms of 
toxicity. These may be due to the intrinsic chemistry of the drug or individual variation 
in patients due to acquired or genetic factors (Boelsterli and Lim, 2007).   One of the 
most common reasons underlying DILI is mitochondrial dysfunction.  Mitochondria 
play a fundamental role in energy production through ATP generation and as such 
are often a major target of toxicity.  The mechanisms through which mitochondrial 
dysfunction can occur are varied and can lead to severe pathologies in patients.  If 
the process of energy production is disrupted the consequences can lead to the 
necrosis or apoptosis of hepatocytes causing cytolytic hepatitis which can ultimately 
result in liver failure. It is, therefore, vitally important that mitochondrial abnormalities 
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are investigated in the drug development process in order to prevent such severe 
consequences in patients (Labbe et al., 2008). 
1.6.2 Mitochondrial Susceptibility to Damage 
The unique structure of mitochondria make them particularly susceptible to toxic 
insult.  The inner mitochondrial membrane contains the cells cytochrome P450 
enzymes, which play a crucial role in the metabolism, and sometimes activation, of 
drug compounds to potentially toxic metabolites.  Rather than cholesterol, the inner 
mitochondrial membrane contains a high level of a lipid called cardiolipin, which is 
almost exclusively found here.  As a lipid it contains a high level of unsaturated 
carbon bonds that are vulnerable to oxidation by ROS.  Cardiolipin has a high affinity 
for lipophilic drugs and their binding brings the drug molecules in close proximity to 
the ETC and mtDNA (Boelsterli and Lim, 2007).   
The structure of mtDNA makes it particularly vulnerable to damage, its small circular 
form lacks the protective structure of histone packaging and repair mechanisms that 
can be found in nuclear DNA.  The lack of histone protection means that mtDNA is 
exposed to oxidative damage from ROS (Meyer et al., 2013).  The knock-on effect of 
damaged mtDNA is a failure in the mechanism of replication and translation of 
mitochondrial complexes. This has severe consequences for electron transport which 
becomes inhibited and as such there is an increase in the build-up and release of 
O2¯.  As a state of oxidative stress develops, mtDNA will become further damaged by 
the O2¯, and a vicious cycle develops (Boelsterli and Lim, 2007). 
Besides energy production, mitochondria also play an important role in the initiation 
of cell death via apoptosis.  Mitochondria contain inactivate ‘death proteins’ (one of 
which is cytochrome c) in the inter membrane space. When a cell is stressed, these 
proteins become activated and translocate to the nucleus where protease cascades 
can be initiated and apoptosis or necrosis follows (Boelsterli and Lim, 2007).  
1.7 Mechanisms of Drug Induced Mitochondrial Damage  
It is often difficult to determine the mechanisms behind observed DILI as damage can 
occur via many different routes and in many different regions of the liver, however, 
frequently, mitochondrial damage is implicated.  Mitochondrial damage itself is also 
difficult to understand as the effects can be subtle and go undetected for a long time 
before serious pathology emerges. This is due to the compensatory effect enabled by 
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the large numbers of mitochondria within liver cells.  Furthermore, a drug itself may 
not be directly toxic to mitochondria and may require metabolism to a toxic metabolite 
before damage is caused (Begriche et al., 2011).  Most commonly, damage is seen 
at the mitochondrial permeability pore or at the level of the mitochondrial respiratory 
chain via inhibition of oxidative phosphorylation or inhibition of fatty acid oxidation. 
1.7.1 Mitochondrial Permeability Transition Pore Opening 
The mitochondrial permeability transition pore (MPTP) is a contact site between the 
outer mitochondrial membrane and the inner mitochondrial membrane.  The role of 
the MPTP is unclear because, in healthy cells the pore remains closed and it is only 
under the influence of stressful stimuli such as increased cellular ROS or calcium that 
the pore opens. It is at this point that there is a cascade of other effects that can 
ultimately lead to cell death via apoptosis or necrosis (Pessayre et al., 2012).  
Opening of the pore leads to disruption of the proton gradient that is generated to 
drive ATP production. The passive re-entry of protons into the inner mitochondrial 
membrane bypasses ATP-synthase, uncouples oxidative phosphorylation and stops 
the production of ATP.  Depletion of ATP ultimately results in bioenergetic failure of 
the cell.  It is not only proton gradient dissipation that leads to cell damage.   When 
the pore is open, it allows the passage of all small molecular weight molecules 
through the inner mitochondrial membrane and diminishing the gradients present 
between mitochondria and cytosol whilst retaining all larger protein molecules in their 
respective cellular compartments.  This drives an osmotic force as the protein 
concentration within the mitochondrial matrix is greater than in the outer membrane 
space.  This influx of water causes the mitochondria to swell and the cristae inside to 
unfold. When the pressure of the swollen matrix gets too high the outer mitochondrial 
membrane can rupture and release pro-apoptotic proteins which have the potential to 
initiate cell death signalling (Halestrap, 2009; Pessayre et al., 2012).  The exact 
mechanisms by which drugs can initiate the opening of the MPTP are largely 
unknown but it is thought that there are three likely routes by which opening can be 
initiated: a) direct interaction of the drug with the pore, b) as a result of oxidative 
stress causing oxidation of thiol groups present on components of the pore and c) 
activation of endogenous inducers such as JNK (Begriche et al., 2011). 
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1.7.2 Impairment of Oxidative Phosphorylation 
Uncoupling of oxidative phosphorylation occurs when a drug is able to inhibit the 
coupling of electron transport to the production of ATP through ATP synthase.  A 
well-known example of a drug that is toxic via this mechanism is Carbonyl cyanide 4-
(trifluoromethoxy) phenylhydrazone (FCCP).  FCCP is a lipophilic weak acid that is 
membrane permeable in both its protonated and unprotonated state.  FCCP is able 
to diffuse, in its protonated form, through the lipid membrane into the mitochondria 
matrix due to the mitochondrial membrane potential.  In the matrix FCCP dissociates 
into an anion and a proton, the anion is able to diffuse back through the membrane 
and become protonated again.  In this mechanism, electron transfer is not changed 
but there is no ATP production at the end of the chain (Labbe et al., 2008).  This not 
only means that ATP production is inhibited but that there is a greater opportunity for 
O2¯ build up and subsequent oxidative stress. 
1.7.3 Inhibition of Fatty Acid Oxidation  
Fatty acids are oxidised in the mitochondria during cellular respiration to yield fatty 
acyl-adenylate, which is then bound to co-enzyme A to produce acetyl-CoA for entry 
into the Krebs Cycle.  If this process is damaged there is an accumulation of free 
fatty acids and triglycerides.  This can occur directly, by drug inhibition of FAO 
enzymes or indirectly as a consequence of drug damage to the mitochondrial 
respiratory chain which becomes unable to regenerate oxidised co-factors (NAD+ and 
FAD) that are required in the oxidation of fatty acids (Labbe et al., 2008). 
1.7.4 Oxidative Stress 
As mentioned in section 1.6.2, mtDNA is highly susceptible to drug induced oxidative 
damage, this has a knock-on effect on the proteins transcribed, most of which form 
the ETC.  If the ETC is damaged there can be an increased in production of O2¯.  
Under normal physiological conditions ROS are not damaging to mitochondria as 
mitochondria contain a battery of antioxidants that are able to neutralise the ROS.  
However, in extreme circumstances, these antioxidant mechanisms can become 
overwhelmed.  It is at this point that oxidative damage can occur (Deavall et al., 
2012).  
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1.8 Oxidative Damage 
1.8.1 Protein Damage 
The effects of protein damage are incredibly broad and varied due to the abundance 
and physiological roles of proteins. For example, enzymes such as kinases and 
phosphatases, DNA replication and transcription machinery and protein channels are 
all vulnerable to damage.  There are susceptibility factors, however, such as the 
amino acid residues contained within the protein.  Disulphide bonds, found between 
cysteine residues, for example, are particularly prone to ROS induced oxidation and 
cross linking, changing the tertiary structure of the protein and thus its ability to 
function.  If the enzymes involved in oxidative phosphorylation become oxidised, then 
there are implications for mitochondrial respiration.  It is likely that electron transport 
may become inhibited, ATP production will decrease and ultimately, cell death may 
follow (Deavall et al., 2012).  
1.8.2 Lipid Damage 
Lipid damage by ROS is known as lipid peroxidation.  This occurs when ROS oxidise 
unsaturated hydrocarbon bonds in lipid membranes forming lipid hydroperoxides.  
This increases the membranes fluidity and can cause inactivation of membrane 
receptors and enzymes (Deavall et al., 2012). 
1.8.3 DNA Damage 
ROS react with DNA bases to form lesions, many of which are mutagenic if not 
repaired. The hydroxyl radical is able to react with DNA by addition to double bonds 
within DNA bases.  Depending upon the location depends upon the nature of the 
adduct radical formed, for example, addition to the C5-C6 double bond of pyrimidines 
leads to the formation of C5-OH and C6-OH radicals with the C5-OH radical being 
reducing and the C6-OH radical being oxidising.  One of the most well studied 
adducts is the C8-OH radical formed on adenine molecules giving rise to 8-OH-Gua 
which when oxidised, forms the stable product, 8-Oxo-2'-deoxyguanosine (8-oxo-
dG).  8-oxo-dG is a well-established biomarker of oxidative stress and is widely 
studied in vitro (Cooke et al., 2003). 
1.8.4 Anti-Oxidants  
The antioxidant defence system maintains the redox balance, preventing a state of 
oxidative stress from developing by reducing oxidising molecules so that they are no 
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longer harmful.  Endogenous antioxidants can broadly be divided into 2 categories: 
enzymatic antioxidants, including SOD, catalase and glutathione peroxidase, and 
non-enzymatic antioxidants including vitamin E, glutathione and bilirubin (Oyewole, 
2015).  Antioxidants are widely distributed throughout the body and most are found in 
cellular cytosol, however there are some variants localised in mitochondria.  
Superoxide is removed from cells by a one electron transfer between O2¯ molecules 
forming molecular oxygen or H2O2.  This reaction is catalysed by SOD which is 
present as Cu-SOD or Zn-SOD in the cytosol or Mn-SOD in the mitochondria 
(Jaeschke et al., 2012).   
Figure 1.2 shows that H2O2, while not a free radical, in the presence of free iron 
(Fe2+) is capable of forming the OH and the hydroxide ion (OH¯) which are highly 
reactive and can cause oxidative damage as previously mentioned.  Ferritin, a metal 
chelator, is present in cells to prevent the formation of hydroxyl radials and hydroxide 
ions by binding iron in its ferric state, stopping it from being reactive (Jaeschke et al., 
2012). 
 
Figure 1.2: ROS production and anti-oxidant mechanisms.  When there is superoxide 
leakage from the electron transport chain it is rapidly dismutated to form H2O2, which, 
if not neutralised by catalase or glutathione peroxidase can lead to the production of 
OH¯ and OH which can subsequently go on to cause oxidative damage such as lipid 
peroxidation. Adapted from (Jaeschke et al., 2012) 
 
1.8.5 Paracetamol Toxicity  
One of the most well studied drugs with associated mitochondrial toxicity is 
paracetamol.  At its recommended dose, paracetamol is a safe and effective 
analgesic, however, in a situation of overdose, it can cause severe hepatotoxicity.  It 
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is the most common cause of liver failure on both the UK and US and is a common 
indication for liver transplant.  For a long time, its mechanism of action was 
controversial due to its varied effects within the cell. 
When taken at normal doses 85-90% is metabolised by glucuronidation or sulphation 
and excreted into the urine, 2% enters into the urine unchanged and the remaining 8-
13% undergoes phase I metabolism by CYP2E1 to form metabolite, N-Acetyl-p-
benzoquinone (NAPQI) which is further metabolised by glutathione conjugation to a 
non-toxic metabolite (Lancaster et al., 2014).  In a situation of overdose, however, 
glucuronidation and sulphation pathways become saturated and metabolism is 
shifted towards CYP2E1 and consequently NAPQI can accumulate and as 
glutathione levels deplete, can reach toxic levels.  NAPQI it is able to conjugate to 
sulphydryl groups present on mitochondrial proteins and form protein adducts.  This 
in turn leads to mitochondrial dysfunction due to membrane disruption and depletion 
of ATP production.  As previously mentioned, if there is damage to the ETC there is a 
build-up of superoxide leakage and subsequent oxidative stress within the 
mitochondria.  The reaction of ROS with other cellular components leads to mtDNA 
damage, mitochondrial permeability pore opening and a complete shut down in ATP 
production.  Depending on the extent of the damage to the cell this can result in 
apoptosis or necrosis.  In severe cases paracetamol overdose can lead to permanent 
liver damage (Lancaster et al., 2014). 
1.9 Troglitazone 
Troglitazone was an oral anti-diabetic introduced to the market in 1997 for treatment 
of adult onset, insulin resistant, type II diabetes (Yokoi, 2010).  However, in 2000, it 
was withdrawn from the market after reports of severe idiosyncratic hepatotoxicity 
(Yokoi, 2010).  The main effects of Troglitazone are to decrease blood glucose levels 
by increasing glucose uptake in skeletal muscle but also to sensitise target tissues: 
hepatocytes, adipose tissue and skeletal muscle, to insulin and promote the anabolic 
effects of insulin.  Troglitazone is a high affinity ligand of PPARγ receptors, and it is 
through binding to these receptors that troglitazone has pharmacological effect 
(Hauner, 2002).   
1.9.1 Mechanism of Action   
Troglitazone was developed as part of a programme to produce new antioxidants 
with antilipidemic properties and this, in part, explains its chemical structure.  
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Troglitazone molecules contain the same chroman ring moiety as vitamin E 
(conferring antioxidant properties) attached to a thiazolidinedione ring (Smith, 2003).  
The structure of troglitazone means that it is highly lipophilic and consequently 
rapidly enters the cell and binds to PPARγ receptors, with high affinity.  PPARγ 
receptors are predominantly expressed in white and brown adipose tissue and are 
found within the nucleus of the cell bound to a retinoid X receptor (RXR) forming a 
heterodimer.  Upon troglitazone binding there is a conformational change in the 
PPARγ-RXR complex and a co-repressor is displaced which allows for binding to 
PPARγ response elements and subsequent activation of DNA sequences that control 
the expression of a number of genes involved in lipid metabolism thus mimicking the 
actions of insulin (Day, 1999). 
1.9.2 Mechanism of Toxicity 
The mechanism by which troglitazone elicits toxicity has been the source of 
controversy for many years and there have been many proposed theories without 
one clear pathway.  When considering toxicity of a drug, it is pertinent to remember 
that it may not be the parent compound that causes damage.  Troglitazone is 
metabolised by 3 main pathways: sulphation, glucuronidation and by phase II 
cytochrome P450 enzyme reactions (Yokoi, 2010).  Sulphation is the main route of 
metabolism and sulphates account for approximately 70% of the troglitazone 
metabolites found in the plasma, along with glucuronide metabolites they are 
excreted into the bile and thus, the main route of excretion is faecal and not urinary 
(Smith 2003).  The third metabolite is a quinone, formed from the oxidation of the 
chroman ring structure, a process metabolised predominantly by CYP34A (Yokoi, 
2010).    
Quinones are well-established cytotoxic compounds, their structure allows them to 
undergo redox cycling to generate ROS that have the potential to cause cellular 
damage such as lipid peroxidation and protein oxidation.  The one electron reduction 
of a quinone molecule forms a semi-quinone radical species that can be 
subsequently oxidised by molecular oxygen, regenerating the parent quinone and 
forming a superoxide molecule in the process.  The parent quinone is then free to 
cycle again resulting in the persistent generation of superoxide and consequently, 
secondary ROS in the form of hydrogen peroxide and hydroxyl radicals (Bolton et al., 
2000). 
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CYP3A4 is responsible for the formation of quinone metabolites in humans as it 
catalyses the formation of the quinone moiety from the chroman ring structure.  The 
quinone can then be further metabolised to break the ring structure, generating even 
more electrophilic intermediates that can cause damage (Yokoi, 2010).   
The paradox of troglitazone is that it was developed to have antioxidant properties 
that can neutralise ROS. This makes the detection of ROS in vitro very complicated, 
however, it is thought that the antioxidant properties of troglitazone can be exhausted 
and toxicity is elicited through simple intrinsic mechanisms similar to paracetamol.  
Naranyan et al. found that when N1S1 Novikoff rat hepatoma cells were treated with 
troglitazone, concentration of 5 µM and above could induce oxidative stress 
(Narayanan et al., 2003). An increase in O2¯ levels was concomitant with alteration to 
mitochondrial membrane potential and membrane peroxidation.  It is thought that this 
is due to the formation of quinone moieties as described above.  However, there is 
also a second mechanism postulated that could account for the development of 
oxidative stress, the 2 electron s-oxidation of the thiazolidinedione ring is also able to 
undergo redox cycling and generate superoxide.  While Narayanan found evidence 
of oxidative stress it was also found that at equimolar concentrations the quinone 
metabolite was unable to induce a similar toxic response to the parent compound.  
This suggests that there may be a direct acting effect of troglitazone rather than 
quinone cycling (Narayanan et al., 2003).  Yamamoto et al. further supports this idea 
and found that while there was some toxicity seen with the quinone metabolite in 
HepG2 cells, the parent drug was more toxic (Yamamoto et al., 2001).   The idea that 
it is the parent drug rather than a reactive metabolite that contributes most to 
cytotoxicity is well supported (Kostrubsky et al., 2000; Tettey et al., 2001; Yamamoto 
et al., 2001; Tirmenstein et al., 2002) however, there is some evidence to corroborate 
the theory that cellular damage is a result of direct formation of ROS suggesting a 
limited role for quinone metabolites in toxicity.  Masubchi et al. suggested that the 
ROS observed following troglitazone treatment could be secondary to mitochondrial 
permeability pore opening and mitochondrial damage and therefore not a direct 
mechanism of damage but a consequence (Masubuchi et al., 2006). 
There is huge inter-individual variation in functional capacity of drug metabolising 
enzymes and it is possible that this is responsible for the idiosyncratic nature of 
troglitazone toxicity.  Cryopreserved human hepatocytes with low CYP3A4 activity 
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and more extensive sulphation capacity (therefore limited capacity for generation of 
quinone metabolite and increased sulphate conversion) have been shown to have 
high sensitivity to the cytotoxic effects of troglitazone.  This suggests that there could 
be a susceptible genotype in which a subpopulation is more likely to have 
hepatotoxic effects but also that an increased level of troglitazone sulphate could 
also be damaging and high levels of CYP3A4 could be protective (Hewitt et al., 
2002).  In agreement with these findings, Funk et al. found that, in male Wistar rats, 
the sulphate metabolite rather than the parent compound had greater impact on 
hepatobiliary elimination due to competitive inhibition of the bile salt export pump 
(BSEP), accumulation of toxic bile salts and mitochondrial damage due to their 
intrinsic detergent properties (Funk et al., 2001). 
Kostrubsky et al. investigated the action of troglitazone in human and porcine 
hepatocytes with the aim of identifying whether troglitazone or its sulphate metabolite 
was responsible for hepatotoxicity.  Porcine hepatocytes were chosen because of 
their low sulphation capacity. It was found that following 2-hours treatment with 
troglitazone, concentrations of ≥25 µM produced an irreversible inhibition of protein 
synthesis and concentrations ≥50 µM were cytotoxic in human hepatocytes.  In 
contrast, at 50 µM protein synthesis was reversible in porcine hepatocytes and 
concentrations of 100 µM were cytotoxic (Kostrubsky et al., 2000).  Toxicity 
correlated with an increase in un-metabolised troglitazone, suggesting that the parent 
drug was the cause of toxicity in human hepatocytes.  The resistance to toxicity in 
porcine hepatocytes was attributed to high levels of glucuronide conjugation 
(Kostrubsky et al., 2000).  
HepG2 cells are known to have a low P450 profile and subsequently are a useful tool 
for assessing the involvement of P450 enzymes in drug metabolism.  Tirmenstein et 
al. reported that treatment with troglitazone was cytotoxic, suggesting that the parent 
compound was more toxic than its metabolites (Tirmenstein et al., 2002).    
Mitochondrial dysfunction is often observed alongside troglitazone cytotoxicity 
suggesting a role for mitochondria in the mechanism of toxicity (Haskins et al., 2001; 
Tirmenstein et al., 2002; Rachek et al., 2009; Hu et al., 2015) .  Dan et al. reported 
significant inhibitory effects of troglitazone on the enzymatic activity of the ETC in 
HepaRG cells.  Cells treated with troglitazone for 48 hours showed significantly lower 
levels of basal mitochondrial respiration than untreated control cells, the oxygen 
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consumed for production of ATP was almost entirely halted. Interestingly, levels of 
ATP, although reduced, were not completely inhibited.  It was postulated that the 
cells switched to glycolysis as a compensatory mechanism of generating ATP.  In 
addition to this, a subsequent decline in mitochondrial membrane potential and 
activation of pro-apoptotic caspase 3 was seen.  Troglitazone at a concentration of 
50 µM elevated cellular levels of ROS 2-fold, but this was considered a secondary 
effect to initial mitochondrial damage.  ROS are able to cause structural changes in 
mitochondria and it was postulated that increased ROS levels initiated a vicious circle 
of toxic effects including mtDNA damage (Hu et al., 2015).  In concordance with this, 
Masubuchi et al. found that troglitazone induced the MPT pore and postulated that 
the toxic effects were a result of the direct effects of troglitazone on the ETC or MPT 
pore (Masubuchi et al., 2006), similarly Rachek et al. found that significant mtDNA 
damage was associated with a drop in ATP concentration and overall decline in cell 
viability (Rachek et al., 2009).   Conversely, Bova et al. reported no significant 
change in ATP levels in HepG2 cells treated with troglitazone up to 100 µM despite 
seeing a marked reduction in membrane potential, indicative of cytotoxicity.  This 
suggests that perhaps different cell lines have differing capacities to compensate via 
glycolysis (Bova et al., 2005). 
1.9.3 Apoptosis 
Apoptosis is the most likely route of troglitazone induced cell death and has been 
observed in human and rodent cells lines (Haskins et al., 2001; Yamamoto et al., 
2001; Bae and Song, 2003; Bova et al., 2005).  It has previously been shown that 
troglitazone causes concentration dependent depletion of ATP, opening of the MPT 
pore and a reduced membrane potential; these are all steps that can lead to the 
release of pro-apoptotic proteins and subsequent initiation of apoptosis.  Experiments 
in HepG2 and Chang cells found that troglitazone can induce apoptosis via the 
classical c-Jun N-terminal protein kinase (JNK) pathway.  Troglitazone directly 
activates JNK and p38 via a stress activated pathway.  Subsequently, there is an 
increase in the pro-apoptotic proteins Bad, Bax and cytochrome c (Bae and Song, 
2003).  Apoptosis is an energy consuming process and therefore if ATP is depleted 
too much, or the compensatory mechanisms of glycolysis cannot produce enough 
additional ATP, then it is possible that hepatocytes can revert to necrosis as a 
mechanism of cell death instead of apoptosis and therefore it is possible that 
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troglitazone can induce apoptosis and necrosis dependent upon the availability of 
ATP (Smith, 2003).   
While there are many possible mechanisms of toxicity reported for troglitazone, 
current literature suggests that troglitazone is a direct acting hepatotoxin that elicits 
cytotoxicity through causing mitochondrial damage due to dysfunction of respiration.  
The consequences of dysfunctional respiration are reduced cellular ATP and thus 
energy starvation in the mitochondria and loss of membrane potential which can 
initiate mechanisms of cell death including apoptosis and necrosis.  There appears to 
be secondary generation of ROS which have widespread intracellular damaging 
effects including mtDNA binding which further damages the production of a healthy 
ETC resulting in a state of oxidative stress due to superoxide leakage.  It is also 
possible that the damage can go undetected for long periods of time because the 
damage is silent as apoptosis does not raise serum liver enzymes (Smith, 2003). 
1.9.4 Why was toxicity not predictable? 
The effects of toxicity ultimately depended upon the cell model studied. There was 
some interspecies variation as well as variation due to differing expression of 
metabolic enzymes.  Consequently, pinpointing the exact mechanism of damage is 
very challenging. Furthermore, in pre-clinical tests, no troglitazone toxicity was 
reported in whole animal studies.  It has been postulated that this is due to 
physiologically normal rats being used and that potentially the humans in which 
toxicity was seen had impaired liver function due to their diabetic condition and thus 
decreased ability to metabolise troglitazone (Tirmenstein et al., 2002). 
1.9.5 New Applications of Troglitazone 
Troglitazone was withdrawn from the market in 2000 after several reports of liver 
failure, however, there has been a resurgence in interest in the compound as it is 
thought its PPARγ mediated effects could be harnessed in anti-cancer treatments to 
halt the division of tumour cells (Day, 1999).  The theory is based upon the finding 
that PPARγ is involved in cellular proliferation.  The binding of different ligands to 
PPARγ can initiate different downstream effects depending on whether they are 
inhibitory or stimulatory. As a result of the wide variation in responses to activation of 
PPARγ the effects in cancer cells are complex and dependent upon the nature of the 
cancer (Fröhlich and Wahl, 2015).  Positive effects of glitazones in anticancer 
therapy have been shown in colorectal cancer and bladder cancer (Mueller et al., 
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2000; Ogino et al., 2009).  Conversely PPARγ expression was found to be linked with 
poor prognosis in lung cancer and it has also been reported that there was no 
therapeutic effect in patients with early stage breast cancer (Theocharis et al., 2002; 
Burstein et al., 2003).  Interestingly it has also been reported that there may be off 
target effects of troglitazone.  It was found that troglitazone was able to elicit anti-
tumour effects in cancers where PPARγ expression was low possibly thought to be 
mediated by glitazone ability to inhibit pro-apoptotic proteins (Shiau et al., 2005; Wei 
et al., 2009). 
A fuller understanding of the mechanisms involved in troglitazone toxicity may enable 
the drug to be redesigned and repurposed as a novel chemotherapy. 
1.10 Study Objectives 
One of the biggest challenges facing drug development today is reducing the high 
attrition rate of new chemical entities in the face of reducing the number of animal 
studies performed.  Current hepatocyte cell models exist in order to do this, however, 
many are lacking a comprehensive drug metabolism profile. As such they are not 
suited to toxicity testing, where it is imperative that results are predictive of human 
response.  New and more efficient cell models need to be developed that can be 
used for high through-put screening and can provide meaningful predictive data to 
ultimately enable the translation of laboratory findings into clinical practice.   
Recently it has been reported that mitochondria are often implicated in the drug 
induced liver injury which is the major cause of drug attrition. Often mitochondrial 
dysfunction can be silent due to the compensatory effects of other mitochondria 
within the cells, however, ultimately, when damage is too great liver failure may 
result. 
With this in mind the aims of my project were to: 
 Study the effect of differentiation on mitochondrial function in B-13/H cells. 
 Study the effect of differentiation on toxicity in B-13/H cells. 
 Attempt to use B13/H cells in a novel drug screening platform for the 
intracellular and extracellular detection of reactive oxygen species.  
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 To discover if Troglitazone, a known hepatotoxin, is more toxic to B-13/H cells 
than B-13 cells? 
 Investigate whether the results could be repeated in a human equivalent cell 
line: H-13 and H-14. 
1.11 Statistical Analysis  
Statistical significance between groups were determined using the Student’s 2- tailed 
t-test, unless otherwise specified. Significance was achieved where p<0.05.  
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2.1 Introduction 
2.1.1 Physiological ROS Production  
Generation of ROS and oxidative stress is frequently associated with the cellular 
damage seen in the pathologies of diseases such as atherosclerosis, cancer and 
neurodegenerative disorders.  Physiologically, the main site of ROS production is in 
the mitochondria as a by-product of respiration, however, exposure to exogenous 
drugs can also stimulate the production of ROS either directly or through metabolism.  
Traditionally ROS have been considered a toxic product that needed to be 
neutralised in order to prevent cell death. However, in recent years low level ROS 
production has been suggested to have a role in cell signalling, cell fate and cell 
proliferation (Hamanaka and Chandel, 2010).  Therefore, increasing understanding of 
the production of ROS and their location of action in normal physiological and 
disease states could help in treatment of the numerous pathologies. 
A role for mitochondrial ROS has been described in several cell signalling pathways.  
When a tissue is deficient in oxygen, cellular respiration is diminished and a state of 
hypoxia is induced, mitochondrial ROS production is able to stimulate the activation 
of signalling pathways that reduce cellular oxygen usage and decrease cellular 
oxygen consumption (Hamanaka and Chandel, 2010).  In addition to this, 
mitochondrial oxidants have a role in the formation of the inflammasome, a 
component of the innate immune system that promotes activation of the inflammatory 
response by stimulating maturation of cytokines.  ROS also have other, non-
mitochondrial derived, functions in host defences.  NOX enzymes present in 
neutrophils are able to generate ROS in response to inflammatory mediators and 
neutralise microorganisms engulfed by macrophages (Holmström and Finkel, 2014). 
In the metabolism of endogenous and exogenous compounds, poor coupling of the 
cytochrome P450 catalytic cycle will also result in the production of ROS.  P450 
enzymes are heme thiolate enzymes that are involved in the monooxygenation of 
lipophilic compounds in preparation for phase II metabolism and excretion.  
Monoxoygenation reactions require the input of 2 electrons, transferred to the P450 
enzyme by NADPH P450 reducatase.  The input of electrons is required to activate 
oxygen and insert one oxygen atom into the substrate molecule (Zangar et al., 2004).  
The coupling efficiency of electron transfer varies depending on the P450 isoform, 
however, it is usually less than 50%.  In severe cases the inefficient coupling can 
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lead to ROS levels great enough to cause the onset of oxidative stress (Banerjee et 
al., 2016). 
The intermediate stages of metabolism of exogenous compounds usually results in a 
quinone metabolite capable of redox cycling and producing superoxide (O2¯) as a by-
product.  The quinone is reduced via NADH to form a semi-quinone moiety.  The 
semi-quinone is subsequently oxidised by molecular oxygen which regenerates the 
parent compound and forms O2¯ as a by-product.  Once the parent compound is 
regenerated it is free to be reduced again and so a redox cycle is initiated and large 
amounts of O2¯ are formed (Klotz et al., 2014).  Menadione is a classic example of a 
compound that contains a quinone structure able to undergo redox cycling, while not 
used as a therapeutic agent in the western world, Menadione is frequently used for 
research purposes for causing hepatotoxicity through a redox cycling mechanism. 
Doxirubicin is used as a cancer chemotherapy agent and is used to treat a wide 
range of solid tumour and blood cancers.  It is a good example of the mechanisms by 
which an exogenous compound can generate ROS as it is able to drug that is able to 
generate ROS through more than one route.  In the presence of the electron carrier, 
NADH, doxorubicin is able to undergo similar quinone cycling to that previously 
mentioned.  However, if the semi-quinone moiety is not oxidised to regenerate the 
parent compound, the semi-quinone is able to interfere will cellular iron homeostasis, 
dissociating it from the ferritin that keeps it bound, and initiating the production of 
highly reactive hydroxyl radicals from hydrogen peroxide (Banerjee et al., 2016). 
While there are a whole range of ROS that can cause damage and contribute to 
oxidative stress, the study of O2- remains of particular interest as it is formed in vivo 
by many enzyme systems and is the progenitor to the formation of other ROS 
(Dikalov and Harrison, 2014).   
2.1.2 Methods of ROS Detection  
Due to the high inter-reactivity between ROS species and their short life span, 
measuring their production is extremely challenging, for example, O2¯is notoriously 
difficult to measure as it is rapidly dismutated to form H2O2 and water by SOD.  
Hydrogen peroxide is not a free radical and is much more stable than O2¯, it is also 
much less reactive due to being much more weakly oxidising.  However, H2O2 has 
the potential, in the presence of free iron, to be broken down by Fenton’s reaction 
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and give rise to the hydroxyl radical (OH˙) which is highly toxic and indiscriminately 
reactive (Thannickal and Fanburg, 2000).  
Traditionally, electron paramagnetic resonance (EPR) spectroscopy has been used 
to study materials with unpaired electrons.  Electron spins are excited in a magnetic 
field in which they absorb and re-emit electromagnetic radiation at a specific 
resonance frequency depending on the compound being studied.  Due to the short 
half-life and high reactivity of O2¯, EPR spectroscopy can be utilised to study its 
production. However, O2¯ has to be immobilised using spin traps which form covalent 
bonds with the radical making a more stable adduct that can be measured.  One of 
the most common spin traps in 5,5-Dimethyl-1-Pyrroline-N-Oxide (DMPO).  While the 
technique has O2¯ specificity and can be very useful in studies of isolated enzymes 
in solution, where the reaction with O2¯ has a slow reaction rate, its use in biological 
systems is limited due to the presence of SOD which is able to outcompete the spin 
trap.  Furthermore, intracellular reductants are able to react with the O2¯/ DMPO 
adducts and reduce them to a spin inactive state, severely limiting the use of the 
technique (Dikalov and Harrison, 2014). 
Manning et al. described a simplified method for O2¯ detection using a functionalised 
gold electrode.  The gold electrode surface was modified with 3,3'-
Dithiobis(sulfosuccinimidylpropionate) (DTSSP) which covalently bound to the 
surface and acted as a linker molecule between the gold surface and the redox 
protein cytochrome c.  O2¯ generation in a sample in liquid media caused the one 
electron reduction of cytochrome c3+ to cytochrome c2+.  The reduced protein was 
reoxidised at the electrode surface (at a potential of +100mV vs Ag/AgCl) causing a 
change in current that was directly proportional to the rate of O2¯ produced (figure 
2.1) (Manning et al., 1998).   
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Figure 2.1: Electrochemical measures of O2- 
Fluorescent dyes are frequently utilised in biological research for investigating 
cellular production of ROS as they are membrane permeable and able to diffuse into 
cells and therefore get closer to the site of production; a crucial feature given the 
transient nature of ROS (Yazdani, 2015). Most dyes for studying ROS are based on 
oxidation/ reduction reactions between ROS and a reduced probe (Woolley et al., 
2013).  2’,7’ –dichlorofluorescin diacetate (DCFDA) is a membrane permeable dye 
that passively diffuses into cells where its acetate groups are cleaved, forming 2’-7’-
dichlorodihydrofluorescein.  Free radicals present within cells then oxidise this 
molecule to form the fluorescent compound, 2’-7’-dichlorfluorescein, which can be 
detected using a spectrophotometer at excitation 485 nm and emission 535 nm.  
Similarly, dihydrorhodamine-1,2,3 is a lipophilic non-fluorescent compound that is 
oxidised by free radicals upon crossing the cell membrane. The oxidised product is a 
fluorescent probe, rhodamine-1,2,3 (excitation 507 nm and emission 529 nm) 
(Yazdani, 2015). 
Fluorescent dyes are incredibly easy and quick to obtain results from, however, their 
use is fraught with problems, including auto-oxidation, phot-oxidation, photo-
bleaching, photo-conversion and cytotoxicity.  In addition to this, when considering 
O2¯sensing, dyes also tend not to be ROS specific, despite claims, due to their 
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similar chemistry and reactive nature.  For example, dihydroethidium can form two 
fluorescent products, 2-OH-E+ which is O2¯ specific and ethidium which is formed 
following non-specific redox reactions (Dikalov and Harrison, 2014).  The fluorescent 
spectra of 2-OH-E+ and ethidium overlap, making fluorescent detection difficult.  The 
only way to determine between the different products is to quantify 2-OH-E+ using 
high performance liquid chromatography (HPLC) which separates out products 
based upon molecular size.  This technique, although extensively validated, is time 
consuming (Zielonka et al., 2008).  
One solution to overcome the drawbacks of free dyes is to encapsulate them in a 
nanosensor.  PEBBLE nanosensors (Probes Encapsulated by Biologically Localised 
Embedding) represent a major development in sensor based technology (figure 2.2). 
By encapsulating free dyes in a porous polyacrylamide shell, some of the limitations 
inherent with free dyes are overcome.  Acrylamide non-covalently traps an indicator 
dye inside a porous matrix.  The polymer spheres are bioinert and minimally invasive 
to living cells due to their sub-micron size (typically 10-20nm in diameter). 
Furthermore, due to their use of commercially available dyes, PEBBLES can be 
incredibly versatile.  To date methods have been described for the detection of H+, 
Ca2+, K+, Na+, Mg2+, Zn2+, Cl-, NO2-, O2 and NO (Clark et al., 1999).  In addition to 
this, due to the simplicity of manufacture, multiple dyes can be added to the 
monomer mixture before polymerisation, generating a nanosensor capable of 
determining multiple parameters simultaneously.  Alternatively, a second dye, 
unresponsive to the analyte of interest can be added, thus allowing for ratiometric 
analysis (Buck et al., 2004).  Ratiometric analysis is a technique that measures two 
different signals, one from a ROS unresponsive dye and one from a ROS responsive 
probe dye.  This allows for a proportional rather than an absolute measure of 
fluorescence, the benefit of which is that the ratio between the two peaks is 
unaffected by the amount of PEBBLEs within the cell or changes in the intensity of 
the excitation light. 
PEBBLE nanosensors have two distinct advantages over free dyes; firstly, the 
polyacrylamide shell protects the surrounding cell from any inherent toxicity from the 
dye and secondly it protects the dye, via size exclusion, from any unwanted 
interactions with cellular proteins that would otherwise produce artefacts. Using 
nanosensors is a novel way of dynamically studying the intracellular environment. 
Combining this approach with the electrochemical technique for O2¯ detection 
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described in Section 2.1.2 would enable the simultaneous intra- and extracellular 
measurement of ROS production This in turn could form the basis for a novel drug 
screening platform that would give unparalleled information about the effect 
pharmaceuticals have on the oxidative state of a cell.  
 
Figure 2.2: Representation of PEBBLE nanosensor 
2.1.3 Aims 
The aim of this chapter was to combine fluorescence-based intracellular 
nanosensors and extracellular electrochemical sensing technology into a system that 
would enable a better understanding of the role that ROS play in drug-mediated cell 
death. B13/H hepatocyte-like cells would be used to demonstrate the effectiveness of 
this combined approach in understanding the importance of drug-induced changes to 
oxidative metabolism. 
Key objectives were: 
 To develop and characterise fluorescent nanosensors suitable for real-time 
intracellular ROS sensing. 
 To characterise an electrochemical system for the direct, real-time 
extracellular detection of O2¯.  
 To combine the intracellular ROS nanosensors with extracellular 
electrochemical O2¯ detection. This combination could ultimately lead to the 
development of a novel platform for drug screening. 
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  To validate this system using B13 (pancreatic, control cells) and B13/H 
(hepatocyte-like, test cells) exposed to a range of hepatotoxins. 
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2.2 Methods 
2.2.1 Materials  
Superoxide Detection:  A Uniscan Bi Stat 3200 potentiostat with proprietary software 
and gold working electrodes (2mm O.D.) were supplied by Alvatek (Gloucestershire, 
UK). Ag/AgCl reference electrodes were supplied by Harvard Apparatus Ltd 
(Cambridge, UK), DTSSP was supplied by Thermofischer (Loughborough, 
Leicestershire, UK).  Cytochrome c (from horses’ heart) was supplied by Sigma 
Aldrich (Poole, Dorset, UK). Electrodes were prepared prior to surface modification 
by using a BASi® PK-4 electrode polishing kit (Alvatek, Gloucestershire, UK). The 
electrodes were calibrated using xanthine (sodium salt) and xanthine oxidase (from 
buttermilk) which were both supplied by Sigma Aldrich (Poole, Dorset, UK). 
PEBBLE manufacture:  TAMRA, FAM, Oregon Green, DCFDA were supplied by Life 
technologies (Glasgow UK).  All other materials were supplied by Sigma-Aldrich 
(Poole, UK) unless otherwise stated. 
2.2.2 Cell Culture  
B-13 cells were a gift from Prof. Matthew Wright (Newcastle University).  Cells were 
routinely cultured in low glucose (1000 mg/l) DMEM which was supplemented with 
10% FBS, 500 U/ml penicillin and streptomycin, 2 mM L-Glutamine and 1% 
amphotericin B.  Cells were incubated at 37°C in a humidified environment containing 
5% CO2.  The medium was changed every 2-3 days. 
When cells reached 70-90% confluence, the cells were passaged.  The medium was 
removed from the flask and the cell layer was washed once with pre-warmed PBS to 
remove traces of media.  As cells were adherent, 2 ml of 10x trypsin in EDTA was 
added to the flask.  The flask was gently tilted back and forth and then tapped gently 
to encourage the detachment of the cell layer from the surface.  Culture medium (~8 
ml) was then added to the flask to inhibit the action of the trypsin and the full 10 ml 
was then transferred to a 15ml falcon tube which was then centrifuged at 720G for 5 
minutes.  Supernatant was subsequently removed and the cell pellet was re-
suspended in fresh medium for counting using a haemocytometer.  Finally, cells were 
seeded as required, either into a fresh t75 culture flask for maintenance of the stock 
or for a specific experiment. 
For B-13/H cells, B-13 cells were routinely cultured before being seeded at the 
relevant density; 1 x 105 for electrochemistry into a 24 well plate and 1 x 104 into a 96 
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well plate for cell viability assays.  B-13 cells were incubated overnight to attach and 
B-13/H cells were incubated for 5-10 days in media containing 10 nM 
dexamethasone made from a serial dilution of a 100 µM stock in ethanol to allow for 
an optimal response to be determined. 
2.2.3 Long Term Cell Storage 
For long term storage, cells were placed in liquid nitrogen.  Cells were detached from 
the culture vessel as previously described.  After the supernatant was removed the 
cell pellet was resuspended in a freezing mixture of 10% DMSO and 90% FBS.  This 
was aliquoted into sterile cryovials at 1 ml per tube.  Cryovials were placed in a -80 
°C freezer overnight before being transferred to liquid nitrogen for long-term storage. 
2.2.4 Cell Stock Revival  
Cryovials were removed from the liquid nitrogen and place in a pre-warmed water 
bath at 37 °C.  Once thawed, cells were transferred to a 15 ml centrifuge tube and 
made up to 10 ml with fresh media.  Cells were centrifuged at 2000 rpm for 5 
minutes, supernatant was removed and cells were resuspended in fresh media and 
transferred to a culture flask. 
2.2.5 Electrode Preparation  
The working electrode consisted of a 2mm OD solid gold electrode encased in a 
chemically inert plastic (KEL-F). The gold electrode was prepared by first polishing on 
a micro-cloth pad containing aluminium oxide slurry followed by sonication for  
5 minutes in distilled water to remove any residue. The electrode was then carefully 
dried and clamped upside down before a bead of DTSSP (50 mM in PBS) was 
dropped onto the gold surface. The surface modification reaction was allowed to 
proceed for 1 minute at room temperature. Excess DTSSP was removed and the 
electrode placed in 2mM cytochrome c in PBS solution overnight at 4°C. 
  
2.2.6 Electrode Calibration  
The modified electrode was rinsed in DI water immediately before use and the 
electrode was then calibrated using the reaction between xanthine/ xanthine oxidase 
(XOD) to generate O2¯ as previously described by Cooper 1992 and Manning 1998 
(McNeil et al., 1992; Manning et al., 1998).  The gold working electrode was poised 
at +100mV vs an Ag/AgCl reference electrode that also secondarily acted as a 
counter electrode. Both were placed in the well of a 24 well plate containing 1.5 mM 
xanthine (an excess) in PBS. Upon achieving a stable baseline reading varying 
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concentrations of XOD were added and the corresponding change in current was 
observed. The system was stirred to enable even and rapid distribution of reagents 
within the well.  To test the specificity of the electrode for O2¯ over other reactive 
oxygen species the ability of SOD to quench current responses was assessed at 
concentrations ranging from 0.005 U/ml - 0.5 U/ml.  
2.2.7 Cellular Superoxide Measurement in B-13 and B-13/H Cells  
B-13 cells were left to attach to the well surface overnight, B-13/H cells were left for 
between 3-10 days to determine at what stage optimal response could be obtained.  
Cells were tested for their ability to produce O2¯ using the electrode system. A variety 
of chemical stimulants including phorbol 12-myristate 13-acetate (PMA) (0.25 µM- 
1.00 µM), menadione (5 µM- 100 µM) and ethanol (1.7 M- 8.6M) were used to try and 
induce the production of O2¯ radicals which would in turn alter the current at the 
electrode and produce a measurable response that was recorded using Uiscan 
software.  Ethanol was chosen as an initial extreme insult in order to prove the 
concept before more physiologically relevant compounds were tested; menadione, a 
known redox cycler and PMA, a tumour promoter known to stimulate O2- production. 
In all cases unless otherwise stated cells were seeded at a density of 1 x 105 cells 
per well.  The stimulants used to try and generate O2¯ production included 
menadione used at concentrations ranging from 1 μM- 100 μM. Stimulants were 
added to the wells without disturbing the probes and gently pipetted up and down to 
cause diffusion across the bottom of the well. Between each measurement the 
electrodes were rinsed with deioninsed water.  Unlike the stirred system of the 
calibration experiment, the electrodes had to be placed as close to the cell layer as 
possible without contact as a magnetic stirrer would have disturbed the cell layer. In 
addition to this the electrodes were placed over the region of the well where there 
was greatest cell coverage in order to maximise the response obtained.  
 
2.2.8 Nanosensor Production  
The PEBBLE nanosensors were synthesised in a multi-stage process adapted from 
Chauhan et al (2011). Briefly, Acrylamide (7.6 mM) and N,N methylene bisacrylamide 
(1.3 mM) were dissolved in 1.5 ml of deionised water by sonication to create a 
monomer solution. To the monomer solution, 5mg/ml of the reference dye, 5-
Carboxytetramethylrhodamine (TAMRA), and 10 mg/ml of the indicator dyes, (FIT-C 
and Oregon Green or pH nanosensors, DCFDA for ROS nanosensors) were added 
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and covered to avoid exposure to light as the dyes are photosensitive. A surfactant 
mixture was prepared of Dioctyl sulphosuccinate (3.6 mM) and Brij30 (8.5 mM) and 
deoxygenated before being added to 42ml of deoxygenated hexane to form a micro-
emulsion. The monomer/ fluorophore solution was added to the surfactant mixture 
and left for 10 minutes. Following this the polymerisation process was initiated by 
immediate addition of 30μl of ammonium persuphate (10% w/v) and 15μl of 
N,N,N’,N’-tetramethylethylethylenediamine. After 2 hours’ polymerisation in the 
absence of oxygen, hexane was removed by rotary evaporation and the remaining 
nanosensors washed 5 times in absolute ethanol with the ethanol being removed by 
rotary evaporation after the last wash. The remaining sensors were stored in a 
covered airtight container in the refrigerator. 
2.2.9 pH Nanosensor Calibration  
Stock solutions of 0.2 M sodium phosphate dibasic and 0.1 M citric acid monohydrate 
were used to make buffer solutions between pH 4 and 8.  Nanosensors were 
dissolved in the buffer solutions for a final concentration of 5 mg/ml. The PEBBLE 
nanosensors contained 3 dye probes: Oregon Green, FIT-C and TAMRA. As TAMRA 
is not pH sensitive it acted as a reference probe to allow for ratiometric analysis of 
the fluorescent signals obtained from Oregon Green and FIT-C. Buffer/ nanosensor 
mix (200 μl) was added in triplicate to the wells of a 96 well plate along with a blank 
that contained buffer alone to ensure that any background fluorescence did not 
interfere or overlap with the response achieved from the dye sensors. Fluorescence 
intensity measures were taken using a Tecan Infinite M200 spectrophotometer 
(Tecan, Austria). 
2.2.10 Free Dye ROS Assay 
A free dye assay was performed as a comparison to the nanosensor platform as it is 
a widely-accepted technique in its own right for the study of ROS production in cells.  
Cells were routinely cultured and seeded at 2.5 x 104 cells per well.  For B-13 cells, 
plates were left overnight for cell attachment to the well surface, for B-13/H cells, 
plates were left in DEX media for 7 days to allow for trans-differentiation.  Media was 
changed every 2-3 days.  The rest of the experiment was carried out as per the 
manufacturer’s instructions.  On the day of the experiment DCFDA dye solution was 
made to a concentration of 30 µM in buffer solution.  The cells were removed from 
the incubator and the media was removed.  The cell layer was washed with buffer 
before being replaced with 100 µl DCFDA solution.  Plates were then incubated at 37 
Chapter 2:  Simultaneous Intracellular and Extracellular ROS Detection 
51 
 
°C for 45 minutes.  Menadione concentrations were made separately at 10x desired 
concentration in unsupplemented, phenol red free DMEM.  DCFDA was removed 
from the cells and replaced with unsuplemented media and a 1 in 10 dilution of 
Menadione for final concentrations between 1 µM and 50 µM.  Plates were incubated 
for 3 hours at 37 °C.  Plate fluorescence was measured at 485 nm excitation and 535 
nm emission.  
2.2.11 Resazurin Cell Viability Assay 
B-13 and B-13/H cells were routinely cultured and seeded into 96 wells plates at a 
seeding density of 1 X 104 cells per well.  B-13 cells were incubated overnight to 
allow for cell attachment whereas B-13/H cells were left for 7 days in DEX media to 
allow for transdifferentiation.  On the day of the experiment, the media was removed 
and cells were washed with PBS, media was replaced with unsupplemented DMEM 
containing a range of concentrations of blank nanosensors (containing no DCFDA) or 
a range of concentrations of DCFDA.  Cells were incubated at 37 °C for 3, 6 and 24 
hours.  Cell viability was measured by adding resazurin (0.03% w/v) to each well.  
Resorufin, produced as a result of bioreduction of resazurin was measured 
fluorometrically at excitation 530nm and emission 590 nm using the Tecan-I plate 
reader. 
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2.3 Results  
2.3.1 Calibration of Superoxide response using Electrochemistry  
The gold electrode was calibrated using the generation of superoxide from the reaction of 
xanthine in water catalysed by xanthine oxidase (Equation 2.1).   
Xanthine + O2 + H2O XOD > Uric acid + O2¯∙ + H+ 
Equation 2.1: Production of superoxide from xanthine catalysed by xanthine oxidase 
Figure 2.3 showed that as there was a linear relationship between superoxide 
production and the current response.  A strong response was obtained with a 
maximum current of 50 nA seen with 1 µM xanthine oxidase. 
 
Figure 2.3: Calibration of the gold electrode to superoxide in a stirred system.  The 
superoxide radical was produced during the reaction of xanthine with water.  The 
reaction was catalysed by Xanthine Oxidase   As the concentration of XOD 
increased, there was an increase in current production.  The response was 
concentration dependent. Data presented as mean of 3 replicates ±S.D. R2= 0.99. 
2.3.2 Stimulated Extracellular O2¯ Production in B-13 and B13/H Cells 
2.3.2.1: Ethanol  
Measuring O2¯ in a cell based system presented challenges as the system was 
unstirred so as not to disturb the cell layer attached on the well surface.  However, it 
was shown that with an increasing concentration of ethanol there was a linear 
increase in the current produced.  To characterise the specificity of the electrode 
response to O2- the effect of a highly specific O2¯ scavenger, SOD (500 U/mL, an 
excess) on recorded current values was assessed.  Figure 2.4 showed that the 
response was completely abolished upon addition of SOD.  The maximum response 
attained, however, was approximately 25 times smaller than that observed in the 
xanthine/ XOD calibration system.  In addition to this, a linear response to ethanol 
was only observed in B-13/H cells and no response could be obtained from B-13 
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cells under equivalent conditions; B-13 cells were unresponsive to ethanol 
stimulation.  
 
Figure 2.4: Response of B-13/H cells to ethanol.  There was a linear relationship 
between ethanol concentration and current produced over concentration range tested 
(R2=0.96).  As the total well percentage of ethanol increased the current generated 
increased in a dose dependent manner. The responses were quenched at all ethanol 
concentrations by the addition of 500 U/ml SOD.  This was a novel finding in this cell 
line and suggests that B-13/H cells are capable of responding to a toxin such as 
ethanol with the generation of O2-, a response that was not seen prior to 
differentiation in pancreatic B-13 cells. Data presented as mean of 3 replicates ±S.D. 
Figure 2.5 showed that a response to ethanol was only observed in B-13/H cells 
treated for 5 days with DEX.  Ethanol was not seen to produce a consistent response 
in B-13 cells (0 days) or at 7 or 10 days (data not shown). 
 
 
Figure 2.5: O2ˉ production by B-13 and B-13/H cells during the transdifferentiation 
process following stimulation with 5% v/v ethanol. Data presented ±SD, n=3. 
2.3.2.2: Menadione  
The extracellular O2¯ response of B-13 and B-13/H cells to known hepatotoxin, 
Menadione, was assessed.  Menadione was shown in figure 2.6A to have a mild 
stimulatory effect in B-13/H cells but not at all in B-13 cells (figure 2.6B).  The 
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response of the B-13/H cells was concentration dependent up to 50 µM.  At 100 µM 
the response was completely abolished.  Again, even at peak response, the 
maximum current achieved was still only about 0.5 nA.  Figure 2.7 shows a typical 
trace containing the raw data from a single electrochemistry experiment, specifically, 
B-13/H cell response to stimulation with 10 µM menadione. 
 
Figure 2.6: Current production from B-13 and B-13/H cells treated with menadione 
(A) Response of B-13/H cells following a 5 day transdifferentiation period to varying 
concentrations of menadione.  Increasing concentrations of menadione appeared to 
cause an increase in the production of superoxide until 100µM when the effect was 
completely abolished (R2=0.91).  Data presented as mean of 3 replicates ±S.D. (B) 
Response of B-13 cells to Menadione.  There was no response seen in B-13 cells to 
Menadione treatment. Data is presented as mean of 3 replicates ±S.D. 
2.3.2.3 PMA 
PMA was unable to elicit a response at the electrode when tested with B-13 and B-
13/H cells. 
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Figure 2.7: Example electrochemistry trace showing 5-day B-13/H cell response to      
10 uM menadione 
 
2.3.3 Development of PEBBLE nanosensors for the detection of intracellular ROS 
based on a pH sensor proof of concept. 
 
Figure 2.8: Calibration of pH sensitive nanosensors FAM  and Oregon green. 
Fluorescent ratio was shown to be linearly dependent upon pH. The data is 
presented as mean  ± S.D, n=5, R2=0.99 
pH nanosensors have been previously described and were used as a template for 
the development of ROS responsive sensors (Clark et al., 1999). The synthesised pH 
responsive sensors (25 mg/ml) responded linearly to pH values as seen in figure 2.8. 
The nanosensors contained two pH responsive dyes in order to increase the dynamic 
range of the sensors (fluorescent response from Oregon green / 5(6)-
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Carboxyfluorescein N-hydroxysuccinimide ester (FAM)) and a pH unresponsive dye, 
TAMRA, that was used as a reference dye and allowed ratiometric analysis.  The 
response obtained is presented as the ratio of fluorescent response from Oregon 
green / 5(6)-Carboxyfluorescein N-hydroxysuccinimide ester (FAM) to the response 
from TAMRA.  As the pH increased the fluorescent signal increased linearly, the 
PEBBLE nanosensors were sensitive to pH levels between pH4 and pH8.  The 
successful production and calibration of pH nanosensors provided the rationale to 
develop a similar nanosensor for detection of intracellular ROS production. 
 
 
Figure 2.9: Calibration curve of DCFDA in response to the catalysis of Xanthine by 
Xanthine Oxidase to produce Superoxide in a cell free system.  At a concentration of 
25µg/ml DCFDA and an excess of xanthine there is a linear increase in the 
fluorescent signal with an increase in xanthine oxidase (R2=0.93) (n=3 ± S.D.) 
The ROS responsive dye, DCFDA was calibrated in its free state, DCFDA, although 
not O2- specific, was responsive to O2- production.  Albeit over a narrow range, figure 
2.9 showed that there was a concentration dependent linear response. Nanosensors, 
when calibrated for response to ROS in a system similar to that used for the free dye, 
showed no response.  There was no relationship observed between increasing O2- 
concentration and fluorescent response, in fact, at all concentrations; the response 
was equivalent to that seen in the untreated controls (figure 2.10). 
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Figure 2.10: Calibration curve of DCFDA PEBBLE nanosensors.  No response was 
seen to Xanthine Oxidase (n=3 ± S.D.) 
2.3.4 Toxicity of PEBBLE nanosensors 
 
Figure 2.11: (A) Cell viability following 3-hour exposure to blank nanosensors. 
PEBBLEs were manufactured to contain no active dye, just polyacrylamide matrix.    
B-13 cells were more susceptible than B-13/H cells and all concentrations reduced 
viability to below 20%.  B-13/H cells showed a concentration dependent decrease in 
viability. (B) Cell viability following 3-hour exposure to DCFDA free dye.  
Concentration dependent decrease was seen in B-13 cells which were less 
susceptible to lower concentrations of DCFDA than B-13/H cells, at 20 µM DCFDA B-
13 cells were more susceptible.  In B-13/H cells there was very little variability in 
viability.  Cell death was between 40% and 55%. (n=3 ± S.D.) 
0
200
400
600
800
1000
1200
1400
0 1 2 3 4 5
FI
 (
ar
b
. U
)
Xanthine Oxidase (µM)
0
20
40
60
80
100
0.5 5 10 20
C
el
l V
ia
b
ili
ty
 (
%
 o
f 
u
n
tr
ea
te
d
 c
o
n
tr
o
l)
DCFDA (µM)
B-13/H
B-13
0
20
40
60
80
100
5 10 15 20
C
el
l V
ia
b
ili
ty
 (
%
 o
f 
u
n
tr
ea
te
d
 c
o
n
tr
o
l)
Blank Nanosensors (mg/ml)
B-13/H
B-13
A 
B 
Chapter 2:  Simultaneous Intracellular and Extracellular ROS Detection 
58 
 
PEBBLE nanosensors were designed to be biologically inert.  The polyacrylamide 
matrix should provide a way of trapping the dye without participating in the reaction, 
in addition to this, free dyes also have an inherent toxicity that the polyacrylamide 
shell was designed to prevent. 
However, figure 2.11B showed that DCFDA was toxic on both B-13 and B-13/H cells.  
When using DCFDA free dye, it is recommended that cells are not incubated with the 
dye for longer than 3-4 hours.  At 3 hours there was a concentration dependent 
decrease in viability observed in B-13 cells, in B-13/H cells viability was reduced 
below 50% at concentrations of 10 µM and above.  In contrast, when cells were 
exposed to blank nanosensors i.e. nanosensors made via the same process but 
without the addition of reactive probes, it was observed that following 3 hours 
exposure, cell viability was less than 20% in B-13 cells at all concentrations.  B-13/H 
cells were less susceptible but a concentration dependent decrease in viability was 
observed, at concentrations of 10 mg/ml and above, cell viability was less than 50%. 
The data presented, suggested that the PEBBLE nanosensors were more toxic than 
the free dye and were more toxic to the B-13 cells than the B-13/H cells.  Following 
24 hours’ exposure, cell viability in both cells lines was negligible at all nanosensor 
concentrations.   
2.3.5 ROS measures using DCFDA Free Dye 
Menadione is a known hepatotoxin that elicits damage through excess superoxide 
production via redox cycling.  It was shown that there was a greater level of ROS 
produced in B-13/H cells compared to B-13 cells where there was no apparent ROS 
production greater than that seen in untreated control cells.  However, the levels of 
ROS production seen in B-13/H cells was not significantly greater than that seen in 
untreated cells (figure 2.12).   
2.3.6 ROS measures using PEBBLEs in Ethanol Treated Cells 
No response was elicited from the use of PEBBLE nanosensors in B-13 or B-13/H 
cells treated with ethanol. 
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Figure 2.12: ROS production in response to treatment with redox cycler, menadione.  
Cells were pre-treated with ROS responsive dye, DCFDA for 45 minutes before being 
incubated with menadione for 3 hours.  A response above untreated controls was 
only observed in B-13/H cells at concentrations of 10 µM and 25 µM.  In B-13 cells 
response remained consistently around 80% of untreated cells.  Data is presented as 
mean of 3 replicates ±S.D. 
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2.4 Discussion 
Many challenges still exist in the detection of reactive oxygen species due to the 
speed at which they react and, particularly in whole cell experiments where there is, 
competition with antioxidants.  Furthermore, O2- specificity is often difficult to achieve 
due to the similarity of the chemistry of reactive oxygen species. 
Electrochemistry offers a technique that is able to selectively measure O2- owing to a 
low operating potential (Manning and McNeil, 2011).  When the functionalised gold 
probe was calibrated in a xanthine/ xanthine oxidase system, it was seen that there 
was a XOD concentration dependent increase in current produced.  The response 
was also shown to be O2- specific in the cell system, as when the antioxidant SOD 
was added to wells, the signal was completely abolished.  Although a strong 
response was observed in a stirred system, when the probe was used over a cell 
layer the response was significantly diminished.  Never-the-less, ethanol was still 
able to stimulate a concentration dependent response in B-13/H cells, albeit at 
incredibly high concentrations that would not be physiologically relevant.  It is thought 
that ethanol is able to generate ROS during metabolism via CYP 2E1.  CYP 2E1 
forms part of a minor pathway through which ethanol is broken down to 
acetaldehyde, using NADPH, two electrons are transferred to ethanol, however, due 
to poor coupling of this reaction often electrons leak and form O2- (Diesen and Kuo, 
2010).   
In order to try and obtain a physiologically relevant response, the next step was to 
investigate the effects of a known hepatotoxin on the cells.  Menadione is known to 
be toxic via a redox cycling mechanism that can stimulate the production of oxidative 
stress through over production of O2- .  Menadione was shown to increase O2- 
production in B-13/H cells up to a concentration of 50 µM.  The effect was abolished 
at 100 µM.  In contrast, there was no observed effect in the B-13 cells at any 
concentration.  This would be the expected result as menadione is a hepatotoxin, 
suggesting that the B-13/H cells had transdifferentiated into hepatocyte like cells that 
were responsive to toxins in a similar way to hepatocytes.  However, these results 
were observed after only 5 days transdifferentiation and all further experiments 
described here using B-13/H cells were used at (and showed an optimal response at) 
a 7-day time point as shown in chapter 3, section 3.3.2, figure 3.7.  It was observed 
in the preliminary experiments with ethanol that a response could only be found at 
early in the transdifferentiation process and at 7 and 10 days no response could be 
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obtained from the electrode (figure 2.5). The transdifferentiation process is only 
partially complete after 5 days and as all further work was conducted at a later stage 
it would seem likely that the cells were not fully differentiated and the response seen 
was from an intermediate cell type (Marek et al., 2003).  When B-13/H cells were 
tested later in the differentiation process, however, a stable and consistent response 
was not observed.  
The responses obtained from electrochemical detection of O2¯ in a non-cell system 
were much larger than those in a cell system.  This could be because when the 
electrode is placed in a well with a cell layer attached, it is not possible to stir the 
system with a magnetic flea, thus, the system relies upon diffusion of the analyte 
thorough the surrounding media and as O2- is rapidly neutralised by antioxidants 
present in the cells or even spontaneously to H2O2 and water.  Therefore, it is 
possible that the O2- was not present for long enough in the media to be reactive at 
the probe surface.  In order to minimise this effect, the probe was placed as close to 
the cell layer as possible.  This also introduces a further variable in the technique as 
there is no set way of ensuring that the probe remained at a constant distance from 
the cell layer between experiments and could have impinged upon the strength of the 
signal obtained and contributed to the variation in the results obtained.  It is possible 
that the technique was not sensitive enough to accurately detect O2¯ at the low levels 
produced by the cells.  Figure 2.7 showed raw data from a typical electrochemistry 
trace before normalising for blank values.  Peak response to menadione was only 
1.2x greater than the response from the blank value suggesting that the minimum 
detection level was not obtained and could account for variable and inconsistent 
results.  The limit of detection should be 3x that seen in blank controls.  When using 
whole cells it is also important not to stress the cells in the well and generate 
unwanted artefacts.  This means working as quickly as possible so that when the 
cells were removed from the incubator there was as little time as possible for the 
media to cool down but also meant that the cells remained in media while being 
tested, however, there is also a complex mix of substrates within the media that 
could also react with the O2- generated and reduce the O2- present at the electrode 
surface. In addition to these factors it is likely that the concentration of O2¯ producing 
XOD was far in excess of any physiological relevant model when calibrating the 
electrode. Since the aim of electrode calibration was to establish responsiveness and 
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not to quantify the amount of O2¯ being produced by the cells this was not 
considered to be a significant issue.  
Nanosensors have already been shown to be a useful way of measuring intracellular 
analytes (Clark et al., 1999).  As a proof of concept, pH nanosensors made with the 
responsive dyes, FAM and Oregon green and the unresponsive dye, TAMRA were 
calibrated.  Combining both FAM and Oregon green fluorophores extended the 
dynamic range of pH measurements. The ratio of response from the active dyes was 
calculated in a range of pH solutions.  Ratiometric methods are based on the ratio of 
2 fluorescent indicators allowing for correction for artefacts, photo-bleaching and 
uneven dye loading.  As can be seen in figure 2.8, as pH became more basic the 
fluorescent response increased.  pH nanosensors were also a good example of how 
multiple active dyes can be added to a sensor to maximise sensitivity.  In this case 
Oregon Green is responsive at the acidic end of the pH range and FAM is responsive 
closer to the neutral end.  Recently a method has been described for a nanosensor 
containing 4 fluorophores; difluoro-oregon green, Oregon green 488, fluorescein and 
non-responsive dye, Alexa 568, for an even broader measurement range between 
pH 1.4 and pH 7.0.  In doing so, the pH of acidic compartments including lysosomal 
fluctuations was able to be measured (Zhang et al., 2015).  pH nanosensors have 
also been successfully utilised for measuring the pH of whole organisms. Using 
nanosensors containing Oregon green and FAM, the full physiological pH range of C. 
elegans was visualised.  As whole organisms were being used the nanosensors were 
internalised by ingestion, the C. elegans worms were then imaged under a 
microscope, a pH range from pH 5.96 in the anterior pharynx to pH 3.59 in the 
posterior intestine was observed (Chauhan et al., 2013). 
Nanosensors have wide ranging potential for sensing of intracellular analytes.  The 
ability to sense intracellular ROS production would provide information on the source 
of ROS in relation to the pathology of disease but also possible information on ROS 
production in response to drug treatment.  For example, in research and 
development of new compounds, if ROS production is witnessed it may be indicative 
of a potential to cause oxidative damage. 
A ROS nanosensor has been described previously in the literature, this project aimed 
to replicate the results and develop a sensor for ROS detection within hepatocytes 
(Henderson et al., 2009).  The first step was to calibrate the PEBBLE nanosensors in 
a system known to generate O2- in a similar manner to the electrochemistry 
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experiments.  The DCFDA was calibrated first, in a xanthine/ xanthine oxidase 
system and, although it has a narrow functional range, showed that an increase in 
O2- resulted in a linear increase in fluorescent response, thus demonstrating that the 
dye is suitable for the detection of ROS.  When PEBBLES, containing DCFDA, were 
calibrated in the same process there was no resultant fluorescence.  As the 
concentration of O2- in the solution increased there was no change in fluorescence 
above control levels.  There are several explanations for the unresponsiveness 
observed.  As ROS are so transient, it is possible that with the polyacrylamide matrix 
adding an extra barrier between the analyte and probe the dye was unable to interact 
with the ROS as quickly and subsequently it is possible that the ROS had already 
been neutralised.  A nanosensor described for the detection of the hydroxyl radical 
(OH˙), was also found to only sense OH˙ on the surface of the sensor due to high 
reactivity (King and Kopelman, 2003).  However, it is more likely that the small size of 
the fluorescent molecules resulted in leaching from within the matrix with the result 
that most of the dye was lost during ethanol washing stages in the PEBBLE 
manufacturing process. This was evidenced by the colouration of the ethanol wash 
effluent. It has previously been found that fluorophores can leach from nanosensors 
once internalised and form fluorescent artefacts within the cells (Chauhan et al., 
2013).    It was hypothesised, therefore, that had the nanosensors been washed 
fewer times some of the dye might have been retained and produced a higher 
fluorescent signal.  The method for PEBBLE manufacture states that the sensor mix 
should be washed between 7 and 12 times to ensure that all the surfactant is washed 
away.  It was found that fewer than 7 washes left behind surfactant that created a 
waxy layer to the nanosensors that also caused aggregation and as a consequence 
was insoluble in PBS and therefore not possible to test.   
It is possible to enlarge the size of the DCFDA molecules without altering their 
reactivity to the analyte of interest. Dextran is a long inert carbohydrate chain 
structure that can be covalently bound to the DCFDA structure making a physically 
larger molecule that should not be able to leach from the pores of the polyacrylamide 
matrix.  While some dyes can be purchased already dextran linked, ROS sensing 
dyes with dextran are not commercially available.  Methods have been described for 
in-house dextran linking and this is something to be considered in the future for 
developing a ROS nanosensor.  This concept has been previously demonstrated by 
Henderson et al in macrophage cells stimulated with PMA.  An OH˙ nanosensor has 
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been described, using the fluorophore, coumarin-3-carboxylic acid.  The nanosensor 
was calibrated using the photolysis of H2O2 which generates OH˙, this, however, was 
only a proof of concept study and the cells have not been used in vitro (King and 
Kopelman, 2003).  Similarly, a H2O2 nanosensor has also been described, but this 
utilised the dye DCFDA, so it has questionable specificity (Oh et al., 2012). There is 
definite potential for development in this area but as of yet, ROS nanosensors have 
not progressed beyond the development stage and into common practise.  
Furthermore, free dye experiments may still be preferential to the use of PEBBLE 
nanosensors as it is not possible to quantify the concentration of dye within the 
nanosensor, this made calibration comparisons between PEBBLEs and free dye 
difficult as an absolute comparison of equivalent dye concentrations is not possible. 
Finally, one of the biggest advantages of the PEBBLE nanosensors over free dye 
based assays is, purportedly, their ability to protect cells from the inherent toxicity of 
free dyes.  However, the data presented here showed that over a 3-hour time period, 
the blank nanosensors were far more toxic to B-13 and B-13/H cells than the DCFDA 
free dye counterpart.  It is likely that residual surfactant may have resulted in cell 
membrane damage and ultimately cell lysis.  Additionally, this could, in part, be due 
to bacterial infection of the cells that occurred when introduced to the nanosensors 
which are not sterile.  Autoclaving of the nanosensors was considered but the dye 
integrity would have been lost at high temperatures.  Chauhan et al. also found 
toxicity in C. elegans with the use of nanosensors that could only be compensated for 
by reducing exposure time to the nanosensors (Chauhan et al., 2013).   
The use of free dye based assays is not without problems.  As a means of 
comparison to the PEBBLEs, an equivalent ROS detection assay was performed 
using menadione and free dye to detect ROS in B-13 and B-13/H cells.  No response 
was seen in B-13 cells and only the higher concentrations of menadione elicited a 
response in the B-13/H cells, however this response was not significantly different to 
that seen in untreated cells and therefore is itself not a necessarily a reliable 
technique in its own right. 
While there is great potential for the development of a PEBBLE nanosensor for 
intracellular ROS detection, there are many issues with the development that are still 
to be addressed to make them a more attractive alternative to free dye based 
assays. Similarly, with the electrochemistry, a method for continuous stirring of the 
system and closer proximity of the probe to the cell layer is required before 
Chapter 2:  Simultaneous Intracellular and Extracellular ROS Detection 
65 
 
meaningful data can be obtained.  Unfortunately, the work that was needed to solve 
these problems was beyond the scope and time frame of this project and as such 
alternative methods for the detection of drug induced damage were sought.  
Subsequent chapters will discuss the use of known hepatotoxins to cause cellular 
death and damage and assess the role of mitochondria, one of the largest 
physiological sources of O2- in drug damage to B-13 and B-13/H cells. 
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3.1 Introduction 
3.1.1 Thiazolidinediones  
As shown in Chapter 2, many challenges still exist with the direct measurement of 
reactive oxygen species (ROS), including substrate specificity.  An alternative 
technique for the detection of ROS is the addition of antioxidants to measure the 
quenching of a signal.  While not quantitative, it is possible to get an idea of ROS 
production by a change in response of cells in the presence of an antioxidant. For 
example, if antioxidants can be used during a resazurin cell viability assay and 
maintain cell viability in the presence of a toxic drug it is indicative of the drug 
causing ROS induced damage.  In addition to this, as antioxidants can be specific to 
particular ROS, experiments can be designed to discover which species are causing 
damage and build a detailed picture of ROS generation.  Furthermore, if it is 
observed that antioxidants can preserve cellular viability this could provide a rationale 
for a possible preventative treatment options for oxidative cell damage. 
Troglitazone is a drug that is part of a wider group of drugs known as the 
thiazolidinediones (TZDs) which were used in the treatment of type 2 diabetes.  The 
TZDs were first discovered as part of a screen to search for compounds with lipid 
lowering properties (Sarafidis, 2008).  The prototype drug, ciglitazone, was 
discovered in 1982, but due to a lack of efficacy it never made it into clinical use.  
Troglitazone was the first TZD to be approved for clinical use in 1997, closely 
followed by pioglitazone and rosiglitazone.  Like ciglitazone, all clinically used TZDs 
have the same pharmacologically active core, a thiazolidine-2-4-dione structure with 
the addition of different side chains (figure 3.1).  It is the addition of an α-tocopherol 
side chain that is thought to be a potential cause of the hepatotoxicity that saw the 
drug withdrawn from the market in 2000 after reports of severe liver injury (Rachek et 
al., 2009).  Rosiglitazone and pioglitazone were adapted from the troglitazone 
structure by replacement of the α-tocopherol side chain with an aminopyridyl and a 
pyridine side chain respectively (Sarafidis, 2008).  Rosiglitazone stayed on the 
market longer that troglitazone but was similarly removed in 2010 and the use of 
pioglitazone has been greatly restricted due to a potential increased risk of bladder 
cancer (Fröhlich and Wahl, 2015). 
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Figure 3.1: The structure of thiazolidinediones (adapted from (Day, 1999)) 
TZDs act through a novel mechanism to reduce insulin resistance.  In healthy 
individuals, insulin acts to suppress glucose production in hepatocytes and stimulates 
the uptake of glucose instead (Owens, 2002).  In type 2 diabetes a state of 
hyperglycaemia develops due to peripheral insulin resistance in the muscles and the 
liver, causing pancreatic β cells to compensate and secrete increased levels of 
glucose (Owens, 2002).  This continues until the β cells begin to fail to compensate 
and insulin deficiency develops, insulin levels fall and fasting levels of glucose 
increase (Sarafidis, 2008).  TZDs act through a novel mechanism to reduce insulin 
resistance, involving activation of the nuclear receptor, PPARγ.   Troglitazone acts as 
a ligand at the PPARγ receptor and binding initiates heterodimer formation with the 
retinoid X receptor (RXR).  The PPARγ- RXR complex then stimulates the binding of 
the complex to PPARγ response elements (PPREs).  PPREs are found in numerous 
genes involved with lipid metabolism, including those involved in fatty acid transport 
and acetyl co-A synthesis, and is thus able to mimic the action of insulin (Hauner, 
2002). A few months after approval there were reports of hepatotoxicity that were 
associated with liver failure, and even death in some cases.  Thus, in 2000, 
troglitazone was withdrawn from the market.  Toxicity of this scale had not been 
observed in clinical trials. Increased levels of ALT were noted in 1.9% of patients and 
0.6% of controls, however, as levels returned to normal, even in those that did not 
discontinue treatment, it was difficult to attribute these effects of troglitazone toxicity 
(Sarafidis, 2008).  It was later found that of the reported cases of hepatotoxicity 80-
90% of those patients ultimately developed acute liver failure (Gitlin et al., 1998). 
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Interestingly, troglitazone was found to have the lowest affinity for the PPARγ 
receptor of the 3 clinically approved TZDs, 10 times lower than pioglitazone which in 
turn has 10 times lower affinity than rosiglitazone. Since troglitazone was found to be 
the most hepatotoxic drug in the TZD family this finding suggested that toxicity was 
not PPARγ mediated (Hauner, 2002).  It has instead been suggested that it is the 
side chain of troglitazone that mediates the observed hepatotoxicity; a chroman ring 
containing an α-tocopherol group is attached to the thiazolidone-2-4-dione core which 
is able to be metabolised to a quinone that is subsequently able to undergo redox 
cycling (Rachek et al., 2009).  The generation of ROS and subsequent oxidative 
stress is one possible explanation for the toxicity observed with troglitazone.  By 
using specific antioxidants to try and prevent a loss of cellular viability, it would pave 
the way to a better understanding of the mechanism of troglitazone toxicity.  
Understanding this mechanism is of great importance because despite troglitazone 
having being withdrawn from the market, there has recently been a growing interest 
in repurposing the drug for other clinical uses, particularly as an anti-cancer 
treatment.  The first trial of anti-tumour effects was conducted in 3 liposarcoma 
patients and it found that troglitazone caused a decrease in proliferation of tumour 
cells (Fröhlich and Wahl, 2015).  Experimentally, troglitazone has also been found to 
have positive effects in rodent models of colon and oral cancer (Kohno et al., 2001; 
Yoshida et al., 2003). Therefore, if there is a central role for the production of ROS in 
troglitazone toxicity, prevention via co-administration of an antioxidant could allow it 
to be reused in the clinic.  
3.1.2 Antioxidants  
Antioxidants can broadly be divided into two categories, enzymatic and non-
enzymatic; their main function is to inhibit oxidising molecules by neutralising their 
activity, usually through reduction reactions (Oyewole, 2015).  Antioxidants are 
widely distributed throughout the body, however, they have different localisations and 
methods of action depending on the nature of the ROS.  ROS are not only produced 
as a toxic by-product of drug metabolism but also during endogenous metabolic 
reactions.  Most antioxidants are located within the cytosol of cells with a small 
number being specific to the mitochondria. 
Superoxide dismutase is an antioxidant that catalyses the near diffusion limited 
conversion of superoxide into molecular oxygen and hydrogen peroxide (Equation 
3.2) (Pisoschi and Pop, 2015): 
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Cu2+-SOD + O2− → Cu+-SOD + O2 
Cu+-SOD + O2− + 2H+ → Cu2+-SOD + H2O2 
Equation 3.2:The dismutation of O2- by SOD 
 It has 3 main isoforms: CuZn SOD (SOD1) which is localised in the cytosol, MnSOD 
(SOD2) which is localised within the mitochondrial matrix and ECSOD (SOD3) which 
is found in the extracellular matrix and is the only isoform expressed extracellularly 
(Pisoschi and Pop, 2015).  SOD is one of the most important antioxidants due to the 
fact that superoxide is produced as a by-product of many biological metabolic 
reactions.  Although there are 3 isoforms, 90% of SOD activity is via SOD1 (Weydert 
and Cullen, 2010). 
The dismutation of superoxide leads to the formation of H2O2, which, while not a 
radial itself, is still classed as a reactive species owing to its ability to form hydroxyl 
radicals (OH˙) (Equation 3.3).  H2O2 can diffuse out of the mitochondria where it is 
produced and into the cytoplasm.  In the presence of high iron concentrations H2O2 
can form OH˙ via Fenton’s reaction:   
Fe2+ + H2O2 → Fe3+ + HO• + OH− 
Fe3+ + H2O2 → Fe2+ + HOO• + H+ 
Equation 3.3: Fenton's reaction 
OH˙ is the most powerful oxidising agent, however, due to instability at physiological 
pH, it only reacts at the site of production.  This can, however, still cause damage 
including lipid peroxidation (figure 3.2) (Pisoschi and Pop, 2015).  Lipid peroxidation 
is the process under which oxidants attack the carbon/ carbon double bond of lipids, 
particularly polyunsaturated fatty acids.  Lipid peroxidation is a chain reaction that 
produces breakdown molecules that contain aldehyde structures which can form 
DNA adducts and protein molecules and initiate intra and intermolecular cross-linking 
which can lead to profound alterations in biological function and biochemical 
properties (Ayala et al., 2014). 
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Figure 3.2: Schematic representation of lipid peroxidation (McEneny, 2001). 
Catalase is an enzyme antioxidant that detoxifies H2O2, it is found in all major organs 
of the body, in particular, the liver, kidneys and erythrocytes (Glorieux et al., 2015).  
Catalase is not found in mitochondria in humans and is confined to the peroxisome. 
Interestingly, however, a functional catalase located in the mitochondrial cytoplasm of 
rat cardiomyocytes has been discovered (Radi et al., 1991).  Catalase exists as a 
tetramer of 4 identical monomers that contain heme groups at the active site which 
are sequentially oxidised and reduced by H2O2 yielding H2O and O2 (Equation 3.4) 
(Birben et al., 2012).   
H2O2 + Fe(III)-E → H2O + O=Fe(IV)-E(.+) 
H2O2 + O=Fe(IV)-E(.+) → H2O + Fe(III)-E + O2 
Equation 3.4: Action of catalase 
Glutathione (GSH) is a non-enzymatic antioxidant that also neutralises H2O2, albeit 
that it does require the enzyme glutathione peroxidase to function.  Due to its highly 
abundant nature in all cell compartments it is the major soluble antioxidant and the 
ratio of reduced to oxidised glutathione is often a determinant in the development of 
oxidative stress.  GSH detoxifies H2O2 by reducing it to H2O and O2, in the process 
GSH becomes oxidised to glutathione disulphide which is subsequently returned to 
its reduced GSH state by GSH reductase and NADPH as an electron donor (Birben 
et al., 2012). 
Co-enzyme Q10 (CoQ10), also known as ubiquinone, is an electron carrier in the 
mitochondrial respiratory chain but it also has a secondary role in its free enzyme 
form as a lipid soluble antioxidant (Hargreaves, 2014).  CoQ10 is the only lipid 
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soluble antioxidant that is produced endogenously (Littarru and Tiano, 2007).  It has 
a protective role towards cell membranes. In its reduced form CoQ10 is able to 
quench carbon centred lipid radicals and lipid peroxyradicals, furthermore CoQ10 is 
also able to regenerate the antioxidant properties of vitamin E to prevent it from 
becoming a free radical itself (Pisoschi and Pop, 2015).  There is currently a lot of 
research looking into CoQ10 as a potential therapy for mitochondrial disease due to 
its lipid soluble properties.  
Non-enzymatic antioxidants can also be obtained exogenously from the diet, 
including vitamin C (ascorbic acid) and vitamin E (α-tocopherol).  Vitamin E is 
hydrophobic, it is found concentrated in the interior area of cell membranes and acts 
as a key defence against oxidant induced membrane injury.  Vitamin E works via the 
donation of an electron to peroxyl radicals, thus stopping a radical chain reaction 
(Birben et al., 2012).  In contrast, vitamin C is water soluble and therefore is restricted 
to the cellular aqueous phase.  Vitamin C is a general antioxidant and is able to 
quench hydroxyl, alkoxyl and superoxide radicals by forming semihydroascorbic acid 
which is then subsequently reduced back to ascorbic acid by glutathione (Birben et 
al., 2012). 
Recent antioxidant research has focussed on the development of an antioxidant that 
can be localised to the mitochondria as this is the main physiological source of ROS 
production, a lipophilic antioxidant that could be targeted to the mitochondria by 
crossing the phospholipid bilayer would be able to quench ROS at their site of 
production before they have a chance to cause cellular damage (Oyewole, 2015).  
CoQ10, as mentioned, is the only endogenously produced lipophilic antioxidant, 
much work has been done to develop a similar synthetic analogue that will act in a 
similar way.  This has led to the production of MitoQ, a ubiquinone derivative that is 
attached to a lipophilic cation in order to make it membrane permeable and able to 
accumulate in mitochondria.  Development has so far been successful and it has 
already been tested in clinical trials for the treatment of Parkinson’s and liver damage 
(Gane et al., 2010; Snow et al., 2010).  Furthermore, there is also research currently 
underway looking into using existing antioxidants and targeting them directly to the 
mitochondria.  This has shown some success in mice with induced over expression 
of human catalase (Rehman et al., 2016). 
Troglitazone, unlike other TZDs is able to undergo redox cycling due to a quinone 
structure, however, this quinone structure is part of the α-tocopherol side group 
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attached to the core glitazone structure and originally designed to have anti-lipidemic 
effects.  This consequently means that troglitazone can also act as an antioxidant in 
the presence of low level ROS, making the measurement of ROS production quite 
difficult.  It is thought, however, that the antioxidant effects can eventually be 
exhausted and it is at this point that ROS production can be toxic (Masubuchi et al., 
2006) 
A resazurin assay is able to assess the ability of mitochondria to metabolise a non-
fluorescent dye, resazurin, to a fluorescent product, resorufin.  When mitochondria 
are functional and active, more fluorescence is measured.  If mitochondria are no 
longer functional it is also a reporter of cell health in general and therefore acts as a 
proxy for measurement of cell viability.  The quantity of resorufin produced is 
proportional to the number of viable cells. 
3.1.3 Aims 
 To investigate the toxic effect of known hepatotoxins, menadione and 
troglitazone, on B-13 cells and B-13/H cells. 
 To study the differences between pre and post differentiated cells in order to 
understand whether cells had a hepatic behaviour following DEX treatment. 
 To understand whether there was a role for ROS in any cytotoxicity observed 
by the addition of antioxidants to viability assays and to determine whether 
antioxidants have a protective effect on cell viability. 
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3.2 Methods  
3.2.1 Materials 
Unless otherwise stated all materials were supplied by Sigma Aldrich (Poole, UK). 
3.2.2 Cell Culture 
B-13 and B-13/H cells were cultured as previously described in section 2.2.2. 
3.2.3 Resazurin Cell Viability Assay 
B-13 and B-13/H cells were routinely cultured and seeded into 96 wells plates at a 
seeding density of 1 X 104 cells per well.  B-13 cells were incubated overnight to 
allow for cell attachment whereas B-13/H cells were left for 7 days in DEX media to 
allow for trans-differentiation.  On the day of the experiment, the media was removed 
and cells were washed with PBS. Media was replaced with unsupplemented DMEM 
containing a range of concentrations of menadione or troglitazone (1 µM-500 µM).  
Cells were incubated at 37 °C for 3, 6 and 24 hours.  Cell viability was measured by 
adding resazurin (0.03% w/v) to each well.  Resorufin, produced as a result of 
bioreduction of resazurin was measured fluorometrically at excitation 530 nm and 
emission 590 nm using the Tecan-I plate reader. 
3.2.4 Antioxidant Effect on Cell Viability  
B-13 and B-13/H cells were seeded into 96 well plates and incubated as previously 
described.  Cells were simultaneously treated with troglitazone at 100 µM, a 
concentration known to cause significant cytotoxicity, and then a range of 
concentrations of antioxidants- CoQ10, SOD or catalase.  Cells were then incubated 
at 37 °C for 3, 6 and 24 hours.  Cell viability was measured by adding resazurin 
(0.03% w/v) to each well.  Resorufin, produced as a result of bioreduction of 
resazurin was measured fluorometrically at excitation 530 nm and emission 590 nm 
using the Tecan-I plate reader.  
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3.3 Results 
3.3.1 Menadione Cytotoxicity and antioxidant effects in B-13 and B-13/H cells 
Menadione is a hepatotoxin, known for being metabolised to quinone that elicits toxic 
effects through redox cycling. It was found to be mildly toxic to the B-13 cells with a 
reduction in viability of no more than 20% even at high concentrations.  Similarly, 
there was no time-dependent effect as toxicity did not increase with increased 
incubation time.  Conversely, the B-13/H viable was drastically reduced by 
menadione. This effect was found to be both concentration and time dependent, as 
shown in figure 3.3.  
There was an acute effect seen with menadione. At a 3-hour time point 
concentrations as low as 10 µM were shown to decrease viability by 40% and at 
concentrations of 50 µM and above the viable population dropped to less than half 
that seen for untreated cells. The longer the cells were incubated with menadione the 
greater the reduction in viability.  At 24 hours, 80% of cells were no longer viable at 
all concentrations and there was a plateau in response. 
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Figure 3.3: (A): B-13 at a 3-hour time point there was a concentration dependent 
decrease in viability of B-13 cells up to 75 µM, viability plateaued above this at 
approximately 80%.  (B) B-13/H at a 3-hour time point there was a concentration 
effect of menadione, this was not seen at 6 hours and 24 hours.  There was a time 
effect of menadione.  At 6 hours all concentrations of menadione reduced viability to 
less than 50%. At 24 hours, all concentrations of menadione reduced viability to less 
than 20%.  Data presented as mean of 3 replicates ±SD, (***P<0.001). 
B-13 and B-13/H cells were subsequently exposed to a co-treatment of menadione 
plus antioxidant. As shown in figure 3.4, It was found that there was no effect of 
either catalase or SOD in the B-13 cells.  Results seen were equivalent to those 
obtained from cells treated with menadione only.  However, following 7 days’ 
treatment of DEX it was observed that there were differences in the response of the 
cells following antioxidant treatment.  While SOD still showed no discernible effect, 
Figure 3.5 showed that catalase did cause a concentration dependent increase in cell 
viability that was significantly greater than viability of cells treated with menadione 
only at the higher concentrations of 500 U/ml and 1000 U/ml.  At the highest 
concentration of catalase used (1000 U/mL) cellular viability had increased by 
approximately 25%.  Despite initial promising results, this effect was not seen at later 
time points.   
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Figure 3.4: Antioxidant effects of catalase and SOD on B-13 cells following 3 hours’ 
exposure to menadione at a concentration of 100 µM.  Without antioxidant treatment, 
100 µM menadione reduced B-13 cells viability to approximately 30%.  Treatment 
with either catalase or SOD did not increase viability above this level.  Data 
presented as mean of 3 replicates ±SD. 
 
Figure 3.5: Antioxidant effects of catalase and SOD on B-13/H cells following 3 
hours’ exposure to menadione at a concentration of 100 µM.  The SOD has no 
significant effect at any concentration on viability.  Catalase showed a concentration 
dependent increase in cell viability, at the higher end of the concentration range (500 
U/ml- 1000 U/ml). Viability was significantly greater than control cells which had only 
been exposed to menadione.   Data presented as mean of 3 replicates ±SD, 
(**P<0.01) 
3.3.2 Troglitazone Cytotoxicity and Antioxidant effects in B-13 and B-13/H cells 
Troglitazone is known to cause hepatic injury and while a mechanism of toxicity is yet 
to be elucidated it is thought that due to a quinone moiety in its structure it could be 
able to generate ROS which could lead to damaging levels of oxidative stress and 
subsequent cell death.  When the B-13 and B-13/ cells were exposed to a range of 
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concentrations of troglitazone over a range of time points, it was observed that the 
toxic effects were much more evident in the B-13/H cells than the B-13 cells.  
Interestingly, in the B-13 cells there appeared to be a plateau in cell viability, beyond 
which toxicity did not worsen.  Figure 3.6 showed that at concentrations of ≥50 µM 
and ≥6 hours there was no further loss in viability below 60%.  At a 24-hour time point 
there was a concentration dependent decrease in cellular viability, all concentrations 
of troglitazone above 1 µM had reduced the viable B-13/H cell population by half. 
To see if there was an effect from the stage of differentiation on the response to 
troglitazone cells were tested at an intermediate stage.  Results in figure 3.7 showed 
that following DEX treatment for 5 days there was a response to troglitazone that was 
similar to that seen at 7 days but was less pronounced, unlike the B-13 cells there 
was no plateau in viability.  At a 24-hour time point there was a concentration 
dependent response to troglitazone treatment, as the concentration increased, there 
was a decrease in viability.   
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Figure 3.6: (A) Following 3- hours treatment in B-13 cells there was a gradual decline 
from 80% to 70% viability up to 100 µM, beyond which there was a drop to 
approximately 40%.  At 6 hours and 24 hours a plateau was observed at 
concentrations ≥50 µ M. Troglitazone was similarly toxic at 6 hours and 24 hours. (B) 
B-13/H cells showed an initial plateau in cell viability at 3 hours and 6 hours up to 
concentrations of 50 µM and 25 µM respectively, beyond which there was a 
concentration dependent decrease in viability.  At 24 hours a concentration 
dependent decrease in cell viability was seen to a minimum level of approximately 
10% of untreated control cells at 500 µM.  Data presented as mean of 3 replicates 
±SD, (**P<0.01, ***P<0.001). 
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Figure 3.7: The effect of stage of differentiation on susceptibility to troglitazone.  Cells 
were exposed for 24 hours to a range of concentrations of troglitazone at 0, 5 and 7 
days transdifferentiation. When the experiment was repeated at an intermediate time 
point in differentiation there was an intermediate response.  At 5 days 
transdifferentiaton, there was a concentration dependent effect of troglitazone on cell 
viability.  The effect was not as pronounced as that seen at 7 days 
transdifferentiation.  Data presented as mean of 3 replicates ±SD. 
Following promising results from co-treatment of catalase with menadione at a 3-hour 
time point, it was hypothesised that if troglitazone elicited toxicity in a similar way to 
menadione that catalase might act in a similar way.  B-13/H cells were treated with  
100 µM troglitazone and a range of concentrations of catalase.  While a small 
increase in viability was observed, this was not significantly different from cells that 
had been treated with troglitazone only and catalase was not shown to prevent a loss 
in viability (figure 3.8).  
CoQ10 is a mitochondrial permeable antioxidant that should be able to scavenge 
ROS close to their site of damage.  Figure 3.9 showed what happens when B-13 and 
B-13/H cells were exposed to a co-treatment of 100 µM troglitazone and a range of 
concentration of CoQ10.  It was found that levels of viability did not increase above 
control levels in which no antioxidant was present.  There was no difference found 
between pancreatic B-13 cells and hepatic-like B-13/H cells. 
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Figure 3.8: Effect of a range of concentrations of catalase on the viability of B-13/H 
cells following exposure to 100 µM troglitazone.  Control cells were treated with 
troglitazone but not catalase, representing maximal death levels.  No response was 
seen from cells at any concentration of catalase.  Data presented as mean of  
3 replicates ±SD. 
 
Figure 3.9: Effect of a range of concentrations of Co-enzyme Q10 on the viability of 
cells following exposure to 100 µM troglitazone.  Control cells were treated with 
troglitazone but not Co-enzyme Q10, representing maximal death levels.  No 
response was seen from either B-13 or B-13/H cells at any concentration of Co-
enzyme Q10.  Data presented as mean of 3 replicates ±SD.  
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3.4 Discussion 
Menadione is a known hepatotoxin and has been used as a model for ROS 
production in hepatocytes for a number of years.  Therefore, it was expected that if 
B-13/H cells had become more hepatic they would be more susceptible to 
menadione treatment than B-13 cells.   
It was shown that menadione was not significantly toxic to B-13 cells at any 
concentration tested or any duration of time up to 24 hours.  Conversely there was a 
time and concentration dependent effect in the B-13/H cells.  As the concentration of 
menadione increased the viability of cells decreased.  Similarly, this effect was more 
pronounced the longer the cells were exposed to menadione.  This shows hepatic 
behaviour in the B-13/H cells, suggesting a more hepatic phenotype in B-13/H cells 
than B-13 cells. 
Troglitazone showed both time and concentration dependent effects on B-13/H cells.  
Toxicity was greater the higher the concentration of troglitazone, similarly, 
concentrations of troglitazone became more toxic as time progressed. This pattern of 
toxicity was not, however, observed in the B-13 cells.  B-13 cells were much more 
resistant to the toxic effects of troglitazone.  The plateau in viability observed in  
Figure 3.6 was seen up to at least 24 hours suggesting that acute toxicity was better 
tolerated in B-13 cells than in B-13/H cells.  Similar levels of toxicity to those 
observed in the B-13/H cells have been reported in multiple hepatocyte cell lines 
including HepaRG, HepG2, primary human hepatocytes (Bova et al., 2005; Rachek 
et al., 2009; Hu et al., 2015) .  Testing the cells over longer periods of time would be 
useful to understand if the plateau remains or if cells eventually become susceptible.  
B-13/H cells were highly susceptible to the toxic effects of troglitazone, at 3 hours 
there was not a significant drop in the viable population until the concentration was 
75 µM and above, at 6 hours this was 50 µM and above.  At 24 hours there was a 
concentration dependent decrease in the viable population suggesting that any 
compensatory mechanisms had been overcome by this point.  Any concentration of 
10 µM and above was significantly toxic at 24 hours.  Toxicity in B-13 cells did not 
drop below 60% whereas, at high concentrations of 100 µM and 500 µM, the viable 
population of B-13/H cells was almost completely abolished.  This indicated that at 7 
days transdifferentiation the cells were responding differently to a drug that is a 
known hepatotoxin, suggesting that cells were more hepatic in nature than pancreatic 
cells.  It has been reported that 10-14 days in DEX media was optimal for 
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transdifferentiation (Marek et al., 2003; Probert et al., 2014).  However, in the 
experiments described here, when the cells were grown in the confined space of a 96 
wells plate, 10 days was too long, even with media changes, as cell health declined.  
This was probably due to the overgrowth of a small population of undifferentiated 
cells.  Probert et al also reported that conversion was approximately 80%, converted 
cells do not proliferate, however, the remaining 20% form a subpopulation of cells 
that maintain their pancreatic phenotype and therefore continue to proliferate.   
To further investigate the cell differences, a midpoint in the differentiation process 
was chosen and cells tested again under identical treatment conditions to see if cells 
became gradually more hepatic over time or whether there was a determining 
change over point.  It was found that when cells were treated with DEX for 5 days 
and had subsequent 24 hours troglitazone treatment, the pattern of viability observed 
matched that in the 7d treated cells but was less pronounced.  This suggested that at 
5 days’ transdifferentiation cells are starting to take on a more hepatic phenotype and 
that while the process happens gradually cells become more hepatic than pancreatic 
very quickly after DEX treatment. 
It is likely that troglitazone is more toxic to B-13/H cells than B-13 cells because of a 
change in metabolic profile of the cells following trans-differentiation.  Hepatocytes 
have a repertoire of drug metabolising enzymes that are not found in pancreatic cells.  
This is because the liver is the main site of drug detoxification and receives blood 
directly from the gut following ingestion, thus the liver acts as the first line of defence.  
This subsequently means that hepatocytes are more susceptible to the by-products 
or reactive intermediates of drug metabolism.  While there is much dispute over 
whether it is troglitazone itself or a metabolite that results in cytotoxicity, the data 
here suggest that there is a potential role for a combination of effects as some 
toxicity was observed in B-13 cells with a maximum loss in viable population of 40% 
at high concentrations.  However, the toxicity was much greater in B-13/H cells with 
the population almost eradicated at higher concentrations.  It is therefore possible 
that there is secondary toxicity in the B-13/H cells caused by a metabolite that is not 
produced in the B-13 cells.  Previous research has suggested that troglitazone 
sulphate is partially to blame, although this remains controversial (Funk et al., 2001; 
Hewitt et al., 2002) .  It is known that troglitazone is also able to be metabolised to a 
quinone by-product which are known to take part in redox cycling, subsequent ROS 
production following troglitazone treatment is widely reported (Narayanan et al., 
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2003; Masubuchi et al., 2006).  The evidence supporting quinone metabolite toxicity 
is confounding as at low levels it can act as an antioxidant.  One potential method of 
determining whether ROS production from troglitazone is toxic is the addition of 
antioxidants to drug toxicity studies.  If viability can be retained in the cell population 
it would suggest that ROS was a cause of cytotoxicity. Furthermore, by specific 
tailoring of antioxidants it also becomes possible to suggest the toxic oxidant species 
as some antioxidants are radical specific.  Troglitazone and menadione toxicity was 
subsequently assessed in the presence of a range of different antioxidants. 
It was observed that catalase but not SOD could maintain some cell viability in B-
13/H cells treated with menadione.  This indicated that that H2O2 rather than O2- was 
responsible for subsequent damage in cells.  It is possible that endogenous 
antioxidant SOD dismutated the O2- produced more successfully than endogenous 
antioxidants for H2O2 and subsequently, as a by-product of dismutation, H2O2 was 
produced.  H2O2, as previously mentioned, can have a whole range of toxic effects, 
especially when further metabolised to OH˙ via the Fenton reaction.  There was no 
effect of catalase or SOD observed in B-13 cells, however, as there was no 
significant loss in viability with menadione exposure it is unlikely that ROS production 
is a significant feature of metabolism in B-13 cells.  Similarly, no effect on viability 
was observed in B-13/H cells exposed to troglitazone with subsequent catalase or 
SOD treatment.  It is known that troglitazone can produce ROS and ROS have been 
identified as one possible cause of hepatotoxicity.  However, neither catalase or SOD 
appeared to retain viability in cells.  It is possible that other mechanisms of toxicity 
are present, reports of mitochondrial damage caused by mitochondrial permeability 
pore opening and loss of mitochondrial membrane potential are gaining momentum 
and ROS may be a secondary mechanism of damage (Masubuchi et al., 2006).  It 
would therefore be of interest to extend the period of incubation of both drug and 
antioxidant in order to establish whether secondary ROS is produced that could be 
quenched, alternatively, the antioxidants may not have been able to get close 
enough to the source of ROS to elicit a beneficial effect.   
Troglitazone has been reported as causing mitochondrial damage, therefore, a 
mitochondrial membrane permeable antioxidant, CoQ10 was chosen in order to 
establish if an antioxidant that was able to enter the mitochondria could help to 
prevent loss of cell viability.  Both B-13 and B-13/H cells treated with troglitazone and 
CoQ10 did not show any significant changes.  Interestingly, mitochondrial targeted 
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analogues of CoQ10 have been shown to reduce ROS in liver patients subsequently 
preventing the onset of inflammation induced fibrosis.  It is known that in individuals 
with hepatitis C infection (HCV) there is evidence of the presence of mitochondrial 
oxidative stress concomitant with an increase in cell death and the development of 
liver tissue fibrosis.  Historically, antioxidant treatment has been largely unsuccessful 
in the treatment of mitochondrial oxidative stress and this has been attributed to the 
inability of mitochondria to take up the antioxidants. The development of MitoQ, a 
ubiquinone analogue with a mitochondrial membrane permeable moiety attached has 
shown promising results in clinical trials and possibly represents a potential 
antioxidant therapy in the treatment of HCV.  The presence of a lipophilic cation 
attached to the structure allows for the antioxidant to accumulate several hundred 
fold in the mitochondria.  In clinical trials, doses of 40-80mg a day for 28 days in 
patients with chronic HCV infection showed improvement in symptoms with reduced 
necroinflammation reported and decreased ALT and AST levels (Gane et al., 2010).  
More recently it has been found that in addition to antioxidant properties, MitoQ is 
also able to attenuate liver fibrosis through the direct inhibition of hepatic stellate cell 
(HSC) activation.  Male C57BL/6J mice treated with carbon tetrachloride to induce 
liver fibrosis showed decreased necrosis, apoptosis and inflammation.  Furthermore, 
it was reported that there was inhibition of HSC activation and profibrogenic factors 
such as TGF-β and as such, not only did MitoQ protect against hepatocellular injury 
there was direct prevention of liver fibrosis, suggesting that there was additional 
evidence to develop MitoQ for prevention and treatment of liver fibrosis (Rehman et 
al., 2016).  While MitoQ has shown great promise, other methods of treating 
oxidative stress have also shown promise.  Catalase is an endogenously produced 
antioxidant that successfully scavenges H2O2, however, it is not found within 
mitochondria.  Lee et al. found that lean healthy mice with targeted overexpression of 
the human catalase gene in mitochondria were found to be protected from age 
induced reduction in mitochondrial function associated with oxidative damage.  This 
suggests that there is potential for targeted antioxidant therapies in the future and it 
would therefore be of interest to repeat the experiments described here with a 
mitochondrial targeted antioxidant such as MitoQ in order to establish whether this 
would improve the viability of cells treated with menadione or troglitazone (Lee et al., 
2010). 
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The data presented here show that there are distinct differences in responses of B-
13 and B-13/H cells to known hepatotoxins, menadione and troglitazone.  While both 
drugs are known to be able to initiate redox cycling and generate superoxide, only 
catalase successfully prevented cell death in B-13/H cells exposed to menadione 
suggesting that superoxide may have been rapidly dismuted by endogenous 
antioxidants.  Similarly, when exposed to co-treatment of antioxidants and 
troglitazone, no antioxidant could be seen to maintain cell viability, including 
mitochondrial permeable CoQ10.  This suggested that there may be alternative 
mechanisms of cell death and ROS may only have a small or secondary role in the 
cytotoxicity observed.   
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4.1 Mitochondrial Role in DILI 
Mitochondrial DILI is more frequently becoming associated with the aetiology of drug 
toxicity. However, it has not historically been investigated during pre-clinical studies 
as it can often be difficult to detect. The sheer number of mitochondria within cells 
means that they can usually compensate for low level damage.  Despite this, in 
recent years, the focus of pre-clinical testing of NCEs has shifted so that toxicity is 
discovered earlier in the process and mitochondria are of increasing interest. 
The predominant role of mitochondria within cells is to produce energy, in response 
to demand, in the form of ATP.  Mitochondrial function has been studied in other 
research contexts for many years and there are many available in vitro investigations 
that could be harnessed to detect mitochondrial DILI in a pre-clinical setting, 
including, but not limited to:  oxygen consumption rates during mitochondrial 
respiration, ETC complex activity, mitochondrial transmembrane potential, 
measurement of lactic acid levels and assessment of mtDNA integrity.  Many drugs 
have multiple toxicities due to varied mechanisms of damage, furthermore, and 
particularly in hepatocytes, metabolites of parent compounds may also elicit their 
own toxicities.  Damage to mitochondria is often silent until the number of 
mitochondria affected reaches a threshold, beyond which damage can manifest itself 
in a variety of ways.  Moderate impairment to respiration can cause cell dysfunction 
but severe damage can lead to cell necrosis and potentially fibrosis. 
4.1.1 Consequences of Mitochondrial Impairment 
β-oxidation is the process by which fatty acid molecules are broken down in order to 
generate acetyl CoA for the Krebs cycle. When this is inhibited, fatty acids can 
accumulate and become esterified into triglycerides which can accumulate and lead 
to steatosis.  Drugs can either directly inhibit β- oxidation via interaction with FAO 
enzymes or indirectly (as discussed previously in chapter 1, section 1.7.3) by 
inhibiting β-oxidation through impairing the ETC.   
Ibuprofen is an example of a drug able to directly interact with the enzymes of fatty 
acid oxidation to elicit toxic damage.  By sequestering Co enzyme A in the form of 
thioester, it becomes unavailable for the formation of fatty Acyl-CoA within the 
mitochondria (Begriche et al., 2011; Pessayre et al., 2012).  Acyl-CoA is crucial in the 
Krebs cycle for the generation of reduced carrier molecules that transport hydrogen 
ions to the ETC. Therefore, as a result of blocking fatty acid oxidation, ATP synthesis 
will decrease which, again, leads to secondary inhibition of fatty acid oxidation and so 
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a vicious cycle of damage begins.  Troglitazone has also been shown to inhibit acyl-
CoA synthase, preventing the formation of long chain acyl-CoA (Begriche et al., 
2011). 
Severe inhibition of mitochondrial β-oxidation causes an increase in the free fatty 
acids in the cytoplasm.  If the fatty acids cannot be sufficiently oxidised they become 
esterified into triglycerides. The accumulation of triglycerides can form fatty deposits 
within cells in a process known as steatosis.  If hepatotoxicity is acute and severe, 
microsteatosis occurs, where lipid deposits in the form of small vesicles accumulate 
in hepatocytes. The lesion is associated with subsequent liver failure.  Conversely 
when the drug toxicity is sustained over a period of time, large fat vacuoles form 
within hepatocytes and this is known as macrosteatosis (Pessayre et al., 2012).  
Macrosteatosis is usually a benign lesion in the short term although there are longer 
term consequences of having these fatty cell deposits. As a result of ATP shortage 
within the cell there is reduced gluconeogenesis which can lead to hypoglycaemia 
(Begriche et al., 2011).  Furthermore, hampered energy production within a cell can 
trigger hepatic cytolysis- large scale cell death in the form of necrosis or apoptosis 
depending on the severity of ATP depletion (Labbe et al., 2008).  Apoptotic cells are 
usually removed via macrophage-based phagocytosis. However, when apoptosis is 
sustained over a long period of time, inflammatory cells can be recruited to the site 
which are able to generate ROS and initiate secondary necrosis within cells.  
Prolonged presence of inflammatory cells can have the knock-on effect of producing 
a state of cytolytic hepatitis which in its mildest initial stages can result in raised 
levels of liver specific enzymes such as ALT and AST. In more severe cases it can 
develop towards liver failure at which point liver transplant may be the only treatment 
option (Begriche et al., 2011). 
Another manifestation of damaged mitochondrial function is the presence of lactate.  
If the ETC is damaged and the flow of electrons is impeded, it can lead to an 
accumulation of electrons upstream in the chain.  As previously mentioned in chapter 
1, section 1.7.2, this can induce a state of oxidative stress due to O2¯ production 
from the damaged chain which can then lead to the formation of lesions in mtDNA 
due to oxidative damage.  However, there is also a secondary result of blocked 
electron flow; a switch in production of energy from oxidative phosphorylation to 
glycolysis.  Reduction in electron flow decreases the level of re-oxidation of the 
electron carrier NADH into NAD+.   Under normal, aerobic conditions pyruvate is 
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oxidised to acetyl co A for the Kreb’s cycle using NAD+ and generating NADH.  
NADH is then shuttled through the mitochondrial membrane in order to keep levels 
low, within the mitochondrial membrane it is able to donate electrons to oxidative 
phosphorylation (Phypers and Pierce, 2006).  In a situation of mitochondrial damage 
NADH remains reduced and therefore due to a high NADH/ NAD+ ratio, the oxidation 
of pyruvate by pyruvate dehydrogenase decreases and instead becomes reduced to 
lactate, the accumulation which can lead to lactic acidosis (Pessayre et al., 2012).   
In a state of overdose, paracetamol has been linked to the formation of lactic 
acidosis; hyperlactaemia is caused by inhibition of oxidative phosphorylation 
switching the primary energy production pathway to glycolysis and the reduction of 
pyruvate to lactate (Adeva-Andany et al., 2014).  Similarly, the anti-diabetic, 
phenoformin, was found to induce lactic acidosis due to its ability to cross the 
mitochondrial membrane and inhibit oxidative metabolism.  It was subsequently 
removed from the market and replaced with metformin, which, due to a low affinity for 
the mitochondrial membrane cannot cause lactic acidosis despite being capable of 
inhibiting gluconeogenesis and oxidative phosphorylation (Dykens et al., 2008; 
Adeva-Andany et al., 2014).  Interestingly, there have been numerous clinical cases 
of patients receiving metformin treatment that have developed lactic acidosis Despite 
this, however, no causative relationship has been proved (Adeva-Andany et al., 
2014).       
4.1.2 Current Technologies for Measuring Mitochondrial Respiration 
Prediciting the toxicity of a new chemical entitiy (NCE) is a difficult process when all 
of the complex interactions a drug and its metabolite can have within a cell are 
considered.  In order to investigate mitochondrial liabilities earlier in the development 
stage and provide meaningful predictive toxicity results, a simple high throughput 
early stage screen is required (Nadanaciva et al., 2007).  The predominant function 
of mitochondria is the generation of energy from oxidative phosphorylation, and the 
oxygen consumed by mitochondria can be a useful method for determining 
dysfucntion. Deviations of oxygen consumption away from the norm are indicative of 
altered metabolism (Dmitriev and Papkovsky, 2012).  For over 50 years the main 
method of assessing mitochondrial respiratory function has been the use of an 
oxygen sensing Clark electrode. However, with renewed interest in mitochondrial 
dysfuction with relation to drug development there has been active development over 
recent years for more sophisticated methods for oxygen measurement. 
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The Clark electrode, developed by Leland Clark 1953 is the current go-to technique 
for oxygen sensing (Clark Jr et al., 1953).  Working on the basis of amperometry 
principles, a platinum electrode is covered with an oxygen permeable membrane 
that, upon applying a voltage, electrochemically reduces oxygen at its surface.  The 
resulting current is proportional to the concentration of oxygen present in the solution 
(Wolfbeis, 2015).  The electrode is placed in a sealed chamber into which a 
mitochondrial preparation is added through an injection port.  Once a steady baseline 
has been obtained substrates can be added to the chamber and their subsequent 
effects on respiration can be measured.  ADP is generally the first substrate to be 
added in order to stimulate ATP synthase and accelerate electron transport through 
the chain and drive ATP production.  Following stimulation of respiration, the ATP 
synthase inhibitor, Oligomycin, can be added to terminate respiration by blocking the 
re-entry of H+ ions which stops production of ATP and slows the passage of electrons 
through the ETC (Brand and Nicholls, 2011).  If there is any residual oxygen 
consumption, either due to dysfunctional uncoupled ATP synthases or detoxification 
enzymes requiring oxygen.  Complete shut-down of respiration can be achieved by 
the addition of a combination of electron complex inhibitors which totally shut down 
any electron transport, usually antimycin A and rotenone. To maximally stimulate 
mitochondria Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP) is 
injected into the mix, FCCP acts to uncouple ATP synthase and maximally drive H+ 
ions through the membrane without the production of ATP (Brand and Nicholls, 
2011). 
The Clark electrode is a robust and simple method for the determination of 
mitochondrial function, hence its continued use for over 50 years.  Methods have 
become well established over the years and the Clark electrode is one of the most 
reliable ways of measuring mitochondrial respiration.  Despite this, the Clark 
electrode would not be suitable for screening for drug toxicity in a high-throughput 
format due to the short life span of the electrode and, more importantly, the 
implications of using mitochondrial fraction as a sample (Brand and Nicholls, 2011; 
Zhang et al., 2012).  When not using whole cell samples there is the confounding 
issue of not having cellular context, while it means that mechanistic studies can be 
easier as there is no interference from cytosolic factors, without surrounding 
interaction with other cellular signals and enzymes, a true response might not always 
be achieved.  Furthermore, the isolation process can damage some mitochondria so 
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that it is possible that some are already dysfunctional before exposure to drug 
treatment.  Using a cell fraction also means that the sample size must be much larger 
making the use of a Clark electrode impractical for high throughput screening (Zhang 
et al., 2012). 
An accepted alternative to the Clark electrode is the use of optical sensors for 
oxygen detection.  Optical sensors utilise luminescence quenching of a reporter dye 
to generate a signal that is proportional to the concentration of oxygen present in the 
sample (Wolfbeis, 2015).  Reporter dyes are usually metal-ligand complexes such as 
phosphorescent Pt (II) and Pd (II) that, upon collisional interaction with oxygen 
molecules, lose energy and enter a lower excited state.  In a lower excited state, the 
luminophore is deactivated and luminescence intensity decreases.  The shorter 
lifetime the dye has the faster the signal acquisition can be (Dmitriev and Papkovsky, 
2012). 
While the Clark electrode is better at detecting high levels of oxygen within a sample, 
the flexibility in design of optical electrodes mean that they can be adapted to detect 
very small concentrations of oxygen as well as higher levels.  In addition to this, by 
combining different types of sensors, multiple parameters can be sensed at the same 
time, such as oxygen level and pH.  Optical oxygen sensors can therefore provide a 
wealth of information about mitochondrial respiration.  However, the strengths of 
optical probes also cause weaknesses in the technique; sensor membranes are 
highly soluble for oxygen and will therefore extract oxygen from the sample being 
tested. This means that in low oxygen levels or small sample volumes erroneous 
results may be generated.  In addition to this, when using metaloporphyrins, there is 
the opportunity for artefacts to be generated under conditions of strong 
photoexcitation (Wolfbeis, 2015). 
A development of the optical sensor is the introduction of the oxygen nanosensor.  
While still very much being developed, a nanosensor for oxygen detection would 
allow for real time and direct sensing of oxygen within cells.  Nanosensors work on 
the same basis of the optical probes mentioned previously, an indicator probe in a 
polymer host, the difference being that it is nanoscale.  The small size of 
nanosensors enables non-invasive quantitative measures to be taken within living 
cells.  While this technique uses whole cells and so is more physiologically relevant 
there are still issues to improve sensitivity as the polymer coating of nanosensors can 
reduce the signal from the probes (Wolfbeis, 2015). 
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Regarding predictive toxicology, high throughput screening is essential to be able to 
assess a large number of compounds in a short space of time and key to aligning 
toxicity studies with early development studies.  There is currently only one technique 
that has the potential to become a mainstream measure of bioenergetic function- 
Seahorse extracellular flux analysis (Salabei et al., 2014).  
Like other techniques, oxygen sensing is based on the quenching of a probe, in this 
case an oxygen sensitive fluorophore.  The probes are embedded within a polymer 
and attached to a sensor cartridge, such that when the cartridge is placed on top of 
the cell culture plate (in either a 24 well or 96 well format) each well has its own 
sensor (Zhang et al., 2012).  Cells are grown in a multi-well plate to which they attach 
in a monolayer on the bottom.  The sensors are brought within 200µm of a cell 
monolayer to form a transient micro-chamber from which immediate measures can 
be taken.  Fibre optic bundles within the instrument emit light to excite the 
fluorophore at which point, any oxygen in the sample can quench the fluorescence at 
a rate proportional to the concentration of oxygen present (Figure 4.1).  The pistons 
within the machine that form the micro-chamber, work reversibly, so that they can be 
raised to allow the surrounding media to re-equilibrate the system, making it possible 
to take multiple measures (Ferrick et al., 2008). Within the sensor cartridge there are 
4 injection ports for each well, this allows for the sequential addition of 4 different 
compounds throughout the experiment and real time measures of the oxygen 
consumption.  
 
Figure 4.1: The parameters of mitochondrial respiration that can be assessed using a 
mitochondrial stress test and  illustration of a XF microplate and sensor cartridge as 
depicted by (Ferrick et al., 2008) 
The ability to make additions throughout the experiment is perhaps the biggest 
advantage over the traditional Clark electrode as it allows for multiple parameters of 
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respiration to be measured in one experiment.  Furthermore, in the 96 well format, 
there is the ability for multiple replicates and multiple experimental conditions 
allowing for a huge amount of data to be produced in a short space of time. 
Additionally, with regards to toxicity testing, it also allows for the specific location of 
mitochondrial dysfunction to be determined (Brand and Nicholls, 2011).  Further, 
measures are taken in whole cells and due to the microplate format, fewer cells than 
a Clark electrode set up can be used.  This does however, present the issue that if 
the cells are not grown in a uniform monolayer, that measures can be prone to error 
and lack reproducibility, this is more likely the smaller the area being measured, so in 
a 96 well format, often more replicates are required than a 24 well format in order to 
locate erroneous results (Zhang et al., 2012). 
Using carefully titrated drugs with known effects on the ETC and oxidative 
phosphorylation, it is possible to determine particular parameters about mitochondrial 
function as seen in figure 4.1:  
 Basal Respiration: The level of basal oxygen consumption is strongly linked to 
the demand a cell has for ATP and can therefore change dramatically 
depending on drugs present in the media. 
 Maximal Respiration Rate: reports the maximum activity of electron transport 
and can be stimulated by uncoupling H+ ion transport, allowing it to bypass 
ATP synthase. 
 Spare Capacity: indicates how closely a cell is operating to its energetic limit. 
 ATP Turnover:  Although not measured directly, the rate in ATP synthesis can 
be estimated from changes in oxygen consumption following the addition of 
Oligomycin which inhibits ATP synthase and shifts the entire production of 
ATP to glycolysis (Brand and Nicholls, 2011). 
 Proton Leak:  an increase in leak is indicative of mitochondrial damage 
(Brookes, 2005) 
4.1.3 Aims  
The aim of this study was to use extracellular flux analysis to investigate potential 
metabolic differences between B13 and B-13/H.  Troglitazone, a known hepatotoxin, 
was utilised to determine whether there were any mitochondrial liabilities from its use 
in hepatocyte like B-13/H cells and if so, how do these effects differ to those seen 
Chapter 4: Metabolic Differences Between B-13 and B-13/H Cells 
100 
 
prior to differentiation in B-13 cells. Information from extracellular flux analysis was 
supplemented by complimentary data from ATP and lactate assays.  
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4.2 Methods 
4.2.1 Materials 
Assay media and calibrant media were supplied by Seahorse Bioscience 
(Massachusetts, USA).  All other reagents were supplied by Sigma Aldrich (Poole, 
UK) unless otherwise stated. 
4.2.2 Cell Culture 
B-13 cells were a gift from Prof. Matthew Wright (Newcastle University).  Cells were 
routinely cultured in low glucose (1000 mg/l) DMEM which was supplemented with 
10% FBS, 500 U/ml penicillin and streptomycin, 2 mM L-Glutamine and 1% 
amphotericin B.  Cells were incubated at 37°C in 95% air and 5% CO2.  The medium 
was changed every 2-3 days. 
When cells reached 70-90% confluence, the cells were passaged.  The medium was 
removed from the flask and the cell layer was washed once with pre-warmed PBS to 
remove traces of media.  As cells were adherent, 2 ml of 10x trypsin in EDTA was 
added to the flask.  The flask was gently tilted back and forth and then tapped gently 
to encourage the detachment of the cell layer from the surface.  8 ml of culture 
medium was then added to the flask to inhibit the action of the trypsin and the full 10 
ml was then transferred to a 15ml falcon tube which was then centrifuged at 2000 
rpm for 5 minutes.  Supernatant was subsequently removed and the cell pellet was 
re-suspended in fresh medium for counting using a haemocytometer.  Finally, cells 
were seeded as required, either into a fresh t75 culture flask for maintenance of the 
stock or for a specific experiment.   
For B-13/H cells, B-13 cells were routinely cultured before being seeded at the 
relevant density into the relevant experimental plate in media containing 10 nM 
dexamethasone made from a serial dilution of a 100 µM stock in ethanol. 
4.2.3 Seahorse Extracellular Flux Optimisation 
Cells differ in their growth rates, energy demand and tolerance to stress.  Therefore, 
it is crucial to the success of the experiment that an optimisation experiment is 
performed prior to undertaking any work.  Extracellular flux (XF) assays were 
optimised for cell seeding density and concentration of injected compounds for a 
mitochondrial stress test, namely, Oligomycin, FCCP, antimycin A and rotenone.  
Typically, a working concentration of a drug was optimal when it stimulated the 
maximal response expected without exhibiting toxicity in its own right.  Initially 
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seeding densities of 5 x 103 and 1 x 104 cells per well were chosen.  Oligomycin 
concentrations of 1 µM and 2 µM were tested, FCCP concentrations of 0.5 µM and 1 
µM and an excess of rotenone and antimycin A, both at 0.5 µM.  The rest of the 
mitochondrial stress test was performed as described in Section 4.2.4. 
4.2.4 Mitochondrial Stress Test 
A mitochondrial stress test was used to assess differences in the mitochondrial 
responses to troglitazone shown by B-13 and B-13/H cells. Cells were seeded into 
Seahorse XF 96 cell micro-culture plates at 1 x 104 cells per well for B-13 cells and 5 
x 103 cells per well for B-13/H cells as per the results of the optimisation test 
described in section 4.2.3.  Seeding densities often differ between cell types 
depending upon how metabolically active they are.  To account for differences in cell 
number all results are normalised for protein content (section 4.2.5) to allow for direct 
comparisons to be made between cell lines.  Plates were left to settle for 1 hour 
before incubating at 37°C overnight for B-13 cells and for 7 days in DEX media for B-
13/H cells.  24 hours before testing, a range of troglitazone concentrations were 
made up at 10x concentration in DMEM before being diluted 1 in 10 in cell containing 
wells for final concentrations between 0.5 µM and 100 µM.  The 4 corner wells were 
left cell free to be used as control wells.  In addition to this a sensor cartridge was 
hydrated overnight in 200 µl/ well in Seahorse calibrant at 37°C in a non CO2 
incubator.   
Assay media was made fresh on the day of the experiment; Seahorse assay media 
was supplemented with 10 mM glucose, 1 mM pyruvate and 2 mM L-glutamine.  The 
media was warmed to 37°C and the pH was adjusted to pH7.4.  The warmed media 
was then used to wash the cells twice, before being placed in a non-CO2 incubator at 
37°C for 1 hour.  While the cells were in the incubator, mitochondrial stress test 
compounds were prepared at 100x concentration in assay media for addition to 
injection ports on the sensor cartridge.  25 µl of each compound was added to the 
injection ports of the microplate sensor cartridge for a final concentration of 1 µM 
oligomycin, 1 µM FCCP, 0.5 µM antimycin A and rotenone combined in ports A, B 
and C respectively.  Port D was loaded with 25 µl of experimental media.  The loaded 
sensor cartridge was then placed in the XF analyser for calibration of oxygen and pH 
levels.  Following calibration, the cells were removed from the incubator and placed 
in the analyser.  Baseline measures of oxygen consumption are determined prior to 
injections.  Each measure that the analyser makes consists of a 3-minute mix time 
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and a 4-minute read cycle.  The mitochondrial stress test was then performed by 
sequential addition of oligomycin from port A, FCCP from port B, antimycin A and 
rotenone in port C and media in port D.  Three measures of oxygen consumption 
were taken for each injection. 
4.2.5 Normalisation for Protein Content 
Wells were normalised for protein content so that results across plates and cell types 
could be compared.  Following the assay, the plate was removed from the analyser 
and all media was removed from all wells.  Complete M lysis buffer (20 µl) was added 
to each well, cells were then scraped from the surface and placed on ice.  A working 
reagent at a 50:1 ratio was made of bicinchoninic acid and 4% cupric sulphate.  200 
µl of the working reagent was added to each well.  The full contents of each well was 
transferred to a clean 96 well, black walled plate with clear bottom.  The plate was 
covered and incubated for 30 minutes at 37°C. 
A standard curve was prepared alongside the unknowns.  A serial dilution of a 2 
mg/ml Bovine Serum Albumin (BSA) was made to produce samples between 0.02 
mg/ml and 2 mg/ml.  20 µl of each standard was added in triplicate to a black walled, 
clear bottom plate and 200 µl of working reagent was added.  The plate was 
incubated at 37°C for 30 minutes. 
Plates were read on a Tecan Infinite M200 spectrophotometer (Tecan, Austria) at an 
absorbance of 562 nm. 
4.2.6 ATP Quantification 
Intracellular ATP was measured using an ATP content assay (Abcam, Cambridge).  
Cells were seeded at 1 x 104 cells per well in black walled, clear bottom 96 well plate.  
B-13 cells were left over-night to attach and B-13/ H cells were left for 7 days in DEX 
media to transdifferentiate (media changes every 2-3 days).  On the day of the 
experiment troglitazone was added to cells at concentrations between 0 µM and  
100 µM.  First, cells were washed with PBS before addition of 90 µl unsupplemented 
experimental media to each well.  Troglitazone concentrations were made at 10x 
concentration and 10 µl was then added to wells.  Measures were performed in 
triplicate.  Cells were incubated for 1 hour at 37 °C 5% CO2.  The rest of the assay 
was performed as described in the manufacturer’s instructions.  Briefly, 50 µl of 
detergent was added to each well to lyse cells and stabilise ATP and the plate was 
shaken on an orbital shaker for 5 minutes.  50 µl of luciferin substrate was added to 
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each and the plate was shaken again for 5 minutes before a final dark adaption for 
10 minutes.  Luminescence was then read using a Tecan Infinite M200 plate reader.  
The assay is based on the production of light which caused the reaction of ATP with 
luciferase and D- luciferin.  The emitted light is proportional to ATP concentration. 
4.2.7 Lactate Quantification 
Cells were seeded at 1 x 104 cells per well in 96 well, black walled, clear bottom 
plates.  B-13 cells were left to attach overnight and B-13/H cells were treated for 7 
days with DEX media (media changes every 2-3 days).  Following attachment or 
transdifferentiation the media in the wells was replaced with un-supplemented 
experimental media and cells were treated with a range of concentrations of 
troglitazone (0 µM- 100 µM) for 24 hours.  The rest of the assay was performed as 
per the manufacturer’s instructions.  Briefly, following troglitazone treatment, samples 
of the assay media were taken from the wells and diluted 1 in 10,000 with lactate 
assay buffer and the total volume was adjusted to 50 µl.  A reaction mix for each well 
was prepared containing 47.6 µl assay buffer, 0.4 µl probe and 2 µl enzyme mix for 
each well.  The plate was incubated at room temperature for 30 minute.  
Fluorescence was measured using a Tecan Infinite M200 plate reader at excitation 
535 nm and emission 587 nm. 
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4.3 Results  
4.3.1 Optimisation of Extracellular Flux Analysis  
The first injection of 1 µM oligomycin was designed to inhibit ATP production and 
drop oxygen consumption.  As oxygen consumption and ATP production are very 
closely linked, the levels of oxygen consumption should almost drop to zero after 
oligomycin addition.  Figure 4.2 showed that both 1 µM and 2 µM oligomycin 
additions produced a similar response Therefore, in subsequent experiments 1 µM 
oligomycin was chosen as optimal in order to prevent any inadvertent toxicity from 
higher concentrations of oligomycin.  Similarly, for FCCP, 1 µM total concentration 
was selected for further experiments.  0.5 µM FCCP was not sufficient to maximise 
oxygen consumption as a further rise in oxygen consumption was seen when a 
second injection of FCCP was added to the well.  A total of 1 µM was therefore 
selected for subsequent experiments.  2 µM FCCP was shown to decrease oxygen 
consumption again (data not shown) indicative of toxicity.  An excess of rotenone and 
antimycin A was required.  This was shown with 0.5 µM of each.  Finally, it was 
observed that 5,000 cells per well was the optimum number for B-13/H cells 
compared to 10,000 cells per well for B-13 cells (figure 4.2). 
 
Figure 4.2: Optimisation of Mitochondrial Stress Test.  The Xfe 96 format allows for 
optimisation to be completed in one assay.   3 baseline measures of oxygen 
consumption were measured and a subsequent 3 measures for each injection.  The 
first injection from port A, Oligmoycin.  The second and third injections from ports B 
and C were both 0.5 µM FCCP to give a total concentration of 1 µM.  The final 
injection from port D was 0.5µM Antimycin A and Rotenone combined.  5, 000 cells 
per well was optimum for B-13/H cells. In contrast, a higher response was achieved 
from 10,000 B-13 cells per well than 5, 000. 
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4.3.2 The Effect of Troglitazone on Mitochondrial Respiration  
Hepatocytes are highly metabolically active cells and figure 4.3 clearly demonstrated 
that the B-13/H hepatocyte like cells were similarly more metabolically active than the 
B-13 cells.  Even without drug treatment, in control cells, there was a marked 
difference between the oxygen consumption in B-13 cells compared to B-13/H cells.  
While baseline measures of oxygen consumption were very similar, when stimulated 
with 1 µM FCCP, B-13/H cells had a much greater spare capacity and reached a 
much higher level of maximal respiration.  The data showed that B-13 cells were 
functioning much closer to their metabolic limit than B-13/H cells due to a larger 
reserve capacity of oxygen consumption. 
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Figure 4.3: Effect of different concentrations of troglitazone on mitochondrial 
respiration following 24-hour incubation at 37°C.  (A) At concentrations between 0.5 
µM and 5 µM there was a steady increase in the baseline measures of oxygen 
consumption.  Beyond which point there was a gradual decline up to the maximum 
concentration of 100 µM (B) Basal oxygen consumption was decreased in B-13/H 
cells with increased troglitazone concentration.  The spare respiratory capacity was 
reduced at all concentrations apart from 0.5 µM.  (n=8 ±SEM, *P<0.05, **P<0.01, 
***P<0.001). 
There were significant differences between B-13 and B-13/H cells in terms of their 
mitochondrial response to troglitazone.  In B-13 cells treated with different 
concentrations of troglitazone it was observed that at the lower end of the 
concentration range, 0.5 µM- 5 µM, there was an increase in oxygen consumption. At 
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concentrations above this there was a gradual decline in oxygen consumption.  
Rates did not, however, reduce past control levels and even at 100 µM troglitazone 
the basal level of respiration was not significantly different to that seen in untreated 
cells.  Spare respiratory capacity remained significantly elevated above control levels 
at concentrations of troglitazone of 1 µM and above.  Troglitazone seemed to 
stimulate an increase in respiration but also worthy of note is that the cells were not 
functioning closer to their respiratory limit and instead the maximum respiratory 
capacity increased similarly to basal levels. 
In contrast, B-13/H cells were much more susceptible to the effects of troglitazone.  
There was a concentration dependent decrease in oxygen consumption with an 
increase in troglitazone concentration.  At concentrations of 25 µM and above, the 
level of oxygen consumption was significantly less than in untreated cells.  
Furthermore, unlike B-13 cells, at concentrations above 1 µM it was seen that the 
maximum level of respiration also decreased compared to untreated cells.  It was 
seen that, despite the reductions, cells still operated at approximately 40% of 
maximal capacity until 75 µM, at which point the mitochondrial activity was much 
closer to the maximal level. 
Figure 4.4A showed that the pattern of oxygen consumption at basal levels of 
respiration is similar to the pattern of oxygen consumption for ATP production in both 
B-13 and B-13/H cells.  In the B-13 cells there was in increase in oxygen 
consumption for ATP production up to 5 µM troglitazone, after which point there was 
a decrease.  However, the levels of oxygen consumption did not decrease 
significantly below control levels other than in cells exposed to the maximum 
concentration of troglitazone (100 µM).  In the B-13/H cells, oxygen consumption for 
ATP production remained elevated above control levels up to 50 µM at which point 
there was a significant decline in oxygen consumption. 
In addition to this, there was also a decrease in observed in proton leak that was 
concentration dependent in B-13/H cells, as troglitazone concentration increased 
there was a decrease in proton leak, this was significantly lower than untreated cells 
at concentrations above 5 µM.  Conversely, in B-13 cells there was a significant 
increase in proton leak at concentrations above 0.5 µM. 
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Figure 4.4: Effect of different concentrations of troglitazone on mitochondrial 
functions following 24 hr incubation at 37°C. (A) ATP Production: B-13 cells showed 
elevated oxygen consumption above control cells compared to B-13/H cells where 
there was a steady decline.  (B) Proton Leak:  In B-13 cells there was a sustained 
increase in proton leak.  In B-13/H cells there was a decrease in proton leak at levels 
that were significantly lower than control cells at troglitazone concentrations of 10 µM 
and above. (C) Non-mitochondrial respiration:  Oxygen consumed for purposes other 
than oxidative phosphorylation.  (n=8 ±SEM, *P<0.05, **P<0.01, ***P<0.001) 
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4.3.3 Cellular ATP levels in Response to Troglitazone 
The mitochondrial stress test cannot determine ATP levels within cells directly and 
can only indicate an increase or decrease in the oxygen consumed to produce ATP. 
Therefore, to clarify extracellular flux data that showed an increase in the oxygen 
consumption for ATP production in B-13 cells, ATP quantification assays were 
performed.  As seen in figure 4.5 both B-13 and B-13/H cells showed a concentration 
dependent decrease in levels of ATP within cells.  The effect was less pronounced in 
B-13 cells with only a troglitazone concentration of 50 µM causing a significant 
reduction below the level of an untreated control.  Conversely, all concentrations of 
troglitazone caused a reduction in ATP levels that were significantly lower than 
untreated controls in B-13/H cells.  
 
Figure 4.5: Cellular ATP level in response to 1hr troglitazone treatment.   Data 
presented as mean of 3 replicates ±SD (*P<0.05, **P<0.01, ***P<0.001) 
4.3.4 Lactate Production Following Troglitazone Treatment  
There was a significant difference in lactate levels present in the B-13 and B-13/H 
cells.  Figure 4.6 shows that troglitazone had no effect on lactate production in B-13 
cells whereas there was an elevated lactate production in B-13/H cells that was 
significantly higher than untreated controls at concentrations of 10 µM and above.   
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Figure 4.6: Effect of troglitazone on lactate production in B-13 and B-13/H cells.  
Cells were treated for 24 hrs with a range of concentrations of troglitazone.  
Troglitazone did not significantly change the level of lactate present in B-13 cells at 
any of the treatment concentrations.  There was a significant increase in the levels of 
lactate present in B-13/H cells following treatment with troglitazone at concentrations 
of 10 µM and above, however, this was not concentration dependent and there was 
no linear relationship.  Data is presented as mean of 3 replicates ±SD, **P<0.01. 
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4.4 Discussion 
Mitochondrial dysfunction is more frequently becoming associated with drug induced 
liver injury and in recent years has been the underlying reason for several high-profile 
drug withdrawals from the market, including troglitazone in 2000.  Therefore, a great 
deal of work has been done to develop a high throughput screen for mitochondrial 
liabilities in NCEs in order to provide a more comprehensive overview of potential 
drug toxicities. 
Extracellular flux analysis offers a realistic option for preclinical drug screening.  Not 
only does the technique allow for rapid measurement of oxygen consumption, the 
unique micro-chamber set up allows for multiple drug additions to be made with the 
refreshing of media and return to baseline levels before each new addition. This 
means that multiple mitochondrial parameters can be measured in a single 
experiment.  For example, when studying mitochondrial stress, the technique can 
provide information on maximum respiratory capacity, reserve respiratory capacity, 
ATP production and proton leak.  The results of a mitochondrial stress test, therefore, 
can help to determine specific locations of mitochondrial damage or areas for further 
study.  Changes in any of the aforementioned parameters can be indicative of 
mitochondrial dysfunction. 
In order to obtain the most reliable and accurate respiration data, the XF assay first 
had to be optimised for the specific cell line being used.  For example, in the assay 
described here, both pancreatic acinar cells and hepatic like cells are used.  
Hepatocyte cells are highly metabolically active due to their role in metabolism of 
endogenous and exogenous compounds.  Hepatocytes contain many more 
mitochondria than pancreatic acinar cells and will therefore have a different metabolic 
profile.  This was demonstrated in figure 4.2, the largest response was in B-13/H 
cells at 5,000 cells per well, a similar number of B-13 cells with all other conditions 
the same showed a baseline oxygen consumption level approximately 4 times 
smaller.  10,000 B-13 cells per well however, showed the clearly defined responses 
to the different drug injections that were expected.   
Following optimisation under baseline condition cells were subsequently challenged 
with troglitazone in order to establish its effects on respiration, however, it is also 
pertinent to mention that even before the addition of troglitazone there were distinct 
differences between B-13 and B-13/H cells in untreated control conditions.  While 
basal levels of oxygen consumption were very similar, when stimulated with the 
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uncoupler, FCCP, it was observed that the B-13/H cells had a much greater reserve 
capacity for respiration than the B-13 cells.  This is in line with what would be 
expected from hepatocyte cells, which, as the first line of defence within the liver, 
need to be able to respond quickly to external stressors.  Furthermore, the B-13/H 
response could be as a result of them having a greater number of mitochondria than 
the B-13 cells which would also be expected from highly metabolically active cells 
such as hepatocytes.  This suggests that the B-13/H cells have hepatocyte like 
behaviour which would be crucial if they were to be used in preclinical testing.  
Regarding further work in this area, it would be of interest to study the mitochondrial 
profile of primary hepatocytes to see if there are similar levels of respiration in B-13/H 
cells and a primary counterpart. 
Troglitazone provides an important case study in the argument for the use of 
mitochondrial testing in drug development.  Over the years, the mechanism of toxicity 
has been widely disputed due to conflicting evidence of damage between cell 
models.  For example, depleted ATP levels are often reported in troglitazone toxicity 
(Tirmenstein et al., 2002; Rachek et al., 2009; Hu et al., 2015). However Bova et al. 
found that after 24 hours exposure, troglitazone did not significantly alter ATP levels 
in HepG2 cells (Bova et al., 2005).  Furthermore, Narayanan et al. argued that 
damage found to mitochondria was caused by oxidative stress whereas Masubuchi 
suggested that while oxidative stress might be present in troglitazone toxicity it is 
secondary to already dysfunctional mitochondria (Narayanan et al., 2003; Masubuchi 
et al., 2006).  In recent years it has become accepted, however, that there is a likely 
role for mitochondrial dysfunction.  As such, B-13 and B-13/H cells were 
subsequently treated with a range of concentrations of troglitazone and mitochondrial 
effects were studied.  As troglitazone showed only moderate toxicity in B-13 cells 
compared to B-13/H cells and when mitochondrial stress was studied it was found 
that there was a stimulatory effect of troglitazone in B-13 cells.  At the lower end of 
the concentration range (0.5 µM- 5 µM) there was an increase in basal oxygen 
consumption after which there was a gradual decline at higher concentrations.  
However, levels of oxygen consumption did not drop below that seen in untreated 
cells.  An increase in oxygen consumption indicated a drive to produce ATP and this 
was matched by the oxygen consumption for ATP production profile seen in figure 
4.5.  Conversely, when ATP levels were measured after an hour there was already 
shown to be a decline in ATP content within the cells compared to an untreated 
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control. This suggested that while there was an increase in demand for ATP, it was 
not matched with an increase in supply.  While ATP production cannot be measured 
directly using the mitochondrial stress test, ATP production is very closely linked to 
oxygen consumption as the demand for ATP stimulates the ETC and thus oxygen 
consumption.  Therefore, by adding oligomycin to inhibit ATP synthase, the 
difference in oxygen consumption before and after addition gave a reflection of the 
changes in ATP production by giving a measure of the oxygen consumed to produce 
ATP.   
When the data for proton leak was analysed it was found that B-13 cells were much 
‘leakier’ than B-13/H cells.  This indicated that troglitazone possibly uncoupled proton 
transport and ATP synthase. It is expected that uncouplers of respiration will increase 
oxygen consumption within mitochondria (Attene-Ramos et al., 2013).  Therefore, it 
is likely that while troglitazone was not lethal to B-13 cells it was able to elicit damage 
in cells that made the production of ATP inefficient.  
Conversely, B-13/H cells showed that with an increase in troglitazone concentration 
there was a concurrent decrease in oxygen consumption, associated with an 
inhibition of electron flow through the ETC.  As to be expected from a shut down in 
electron transport, there was a decrease in oxygen consumed for ATP production. 
However, unlike B-13 cells, this was corroborated by the ATP quantification assay 
which showed a significant reduction in ATP levels within cells.  A drop in proton leak 
was observed in the B-13H cells that was concentration dependent in response to 
troglitazone.  This, again, was a different response to that seen in the B-13 cells and, 
again, indicated a slowdown of transport within the ETC.  Fewer H+ ions pumped out 
of the matrix would also reduce the build-up of an electrochemical gradient and 
reduce the ions available for transport back into the matrix when uncoupled with 
FCCP.  Nandanaciva et al. similarly showed that depending upon the cell type being 
studied; troglitazone can elicit opposing mitochondrial effects.  HepG2 cells exposed 
to troglitazone showed an immediate inhibition of respiration in contrast to 
cardiomyocytes, which, like the B-13 cells, responded with an increase in oxygen 
consumption and troglitazone appeared to have a stimulatory effect (Nadanaciva et 
al., 2012). 
Dan et al. reported similar findings to those found in B-13/H cells here.  It was found 
that 24 hours troglitazone pre-treatment of HepaRG cells caused a reduction in 
respiration rate at basal levels in cells that was lower than observed in untreated 
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cells.  The sensitivity to FCCP was also reduced, as shown by a decrease in the 
maximum respiratory capacity (Hu et al., 2015). 
When oxidative phosphorylation is inhibited, a cell will compensate for reduced 
energy production by upregulating glycolysis (Dykens et al., 2008) a by-product of 
which is lactate formation due to a decrease in the oxidation of pyruvate. When 
lactate was measured in the media of B-13/H cells following 24 hours’ exposure to 
troglitazone, it was found that there was a significant increase in lactate at all 
concentrations above 10 µM.  The effect was not concentration dependent and it 
appeared that 10 µM was a threshold point. However, this suggests that there was a 
compensatory effect in B-13/H cells where ATP production switched to glycolysis 
rather than oxidative phosphorylation.  It has previously been found that ATP 
depletion was also linked to an increase in lactate efflux in HepG2 cells that had 
been treated with phenformin (Dykens et al., 2008). On the other hand, there was no 
change in lactate concentration in B-13 cells compared to an untreated control, 
suggesting that oxidative phosphorylation was still functional. 
The data presented here showed that, following a transdifferentiation period of 7 
days, the cells have a fundamentally different phenotype from the original B-13 cell 
type.  The significant differences in responses to troglitazone by B-13 and B-13/H 
cells were unexpected as there appeared to be two distinct mechanisms of action- 
stimulatory in B-13 cells and inhibitory in B-13/H cells.  To further understand the 
mechanisms behind this, additional work would need to be done to elucidate what 
caused these differences.  For example, hepatocytes have a larger variety of drug 
metabolising enzymes that pancreatic cells.  It could therefore be possible that a 
metabolite of troglitazone rather than the parent compound could be contributing to 
the mitochondrial toxicities seen in B-13/H cells.  To investigate this further it would 
be possible to use inhibitors of drug metabolising enzymes in order to see how the 
toxicity of troglitazone is affected.  For example, the sulphation inhibitor, 
phenobarbital, was used by Kostrubsky et al, to investigate the toxicity of parent 
compound vs metabolite in human hepatocytes.  While it was observed that rather 
than reducing toxicity, inhibition of sulphation aggravated toxicity, there are conflicting 
arguments and it has previously been reported that sulphate metabolites can induce 
cellular damage (Kostrubsky et al., 2000; Funk et al., 2001).   
The XF assay for mitochondrial stress can provide information on multiple 
parameters of mitochondrial respiration in a single assay, providing many 
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advantages over the traditional Clark electrode set up which is low throughput and 
time consuming.  The XF assay provides fast reliable information about mitochondrial 
function.  It is however, limited in its ability to decipher between different complex 
dysfunctions of the ETC.  In order to gain a full overview of mitochondrial function, XF 
assays must be combined with other techniques that are able to provide information 
on specific mitochondrial complex toxicities.  This has been done previously by 
measuring the activity of oxidative phosphorylation complexes that have been 
immunocaptured from mitochondria on 96 well plates coated with monoclonal 
antibodies raised against complex I, II, III, IV and V.  In doing so it was possible to 
localise drug damage to a specific complex (Nadanaciva et al., 2007; Dykens et al., 
2008).  Nadanaciva found that troglitazone was able to inhibit complexes II, III, IV 
and V (Nadanaciva et al., 2007).  In addition to this, further information could be 
gained from adapting the current XF techniques.  A simple modification would be the 
addition of troglitazone during the experiment as an injection rather than as a pre-
treatment.  This would enable the immediate effects of troglitazone on cells to be 
established and would also provide more information on the uncoupling ability of 
troglitazone in B-13 cells to see if it gives a similar response to that seen with FCCP. 
Furthermore, as well as mitochondrial stress testing, XF assays can also be used to 
determine extracellular acidification (ECAR) which provides a measure of glycolysis 
by using pH sensors to detect proton concentration in the sample. 
 Predictive toxicology is a complex process, there is a great variation in tissue 
response, and that was clearly highlighted here.  The transdifferentiation of a 
pancreatic cell into a hepatocyte like cell produced vastly different metabolic profiles 
with differing responses to a known toxin.  Furthermore, due to the nature of the 
many detoxifying reactions that generate metabolites that can be toxic in their own 
right within hepatocytes as well as the ability of cells to compensate for injury, it is 
difficult to attribute a mechanism of action.  However, the data shown here also show 
the importance of investigating mitochondrial dysfunction early in the drug 
development stage as there can be stark differences is cellular response to a 
compound.  Finally, the XF analyses were also able to show that there are metabolic 
differences following transdifferentiation of the B-13 cells into B-13/H cells adding 
further weight to the argument that this cell line has the potential to be developed into 
an alternative cell model for the study of drug toxicity.  
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5.1 Introduction  
5.1.1 Extrapolation of animal data to humans 
The data presented in previous chapters have so far displayed the potential of B-
13/H cells to provide an alternative hepatocyte model that requires no animal donor 
and can be supplied on demand and in potentially unlimited numbers.  These cells 
represent an important advance in drug screening technology. However, to have 
clear clinical relevance and optimise the advantages offered by this new approach a 
human equivalent model of the B13/H cell system is required. 
Before a new drug can be tested in humans, extensive research must first be done in 
animal models in order to establish exposure limits and dosage. Typically this 
includes 2 mammalian species, one rodent and one non-rodent (Peters, 2005).  
While whole animal studies are typically the most informative, there is an important 
role for in vitro test models in preclinical development.  In order to identify potential 
tissue specific toxicities in whole animal studies, in vitro cell models can be used to 
highlight ‘at risk’ tissues.  In vitro assessments can be carried out quickly and 
inexpensively as cell based assays lend themselves to high throughput screening 
(McKim Jr, 2010).  Once these preliminary assessments have been completed, then 
human cells and the data derived from them becomes much more important. Whilst 
many important drug metabolising enzymes are conserved between species, their 
highly substrate specific nature means that slight differences in structure can cause 
huge differences in functionality. 
One of the most important questions in pre-clinical toxicology is “can data generated 
from animal models be successfully extrapolated to humans?”.  Pharmacokinetic 
data is reasonably well extrapolated when there is a clear idea of the endpoint being 
studied and when considerations for body weight are taken into account.  For 
example, rodents have a short life span and can be produced in large numbers, 
therefore, are useful in early preliminary studies where a large amount of data is 
needed quickly.  In addition to this, a short life span means rodents are useful for 
generating data regarding acute exposure to drugs.  Large animals, such as dogs, 
live much longer than rodents and can therefore provide useful information in 
longitudinal studies of chronic toxicity and due to being a more similar size to humans 
it gives the opportunity to adjust dosage for size (Martignoni et al., 2006). 
Most drugs and chemicals induce hepatic cytochrome P450 enzymes (Graham and 
Lake, 2008).  CYP enzymes are one of the most highly conserved entities between 
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humans and animals and are found in virtually all organs (predominantly the liver).  
CYP enzymes are therefore critical in metabolism and consequently in 
pharmacokinetic studies. However, small changes in CYP isoform structure and 
expression profile can lead to large differences in metabolic capacity making 
extrapolation of data between animals and humans quite complicated (Martignoni et 
al., 2006). 
CYP 2E1 is an isoform expressed in the liver that is well conserved between humans 
and rats.  It is only inducible by a few drugs including ethanol and caffeine. With 
regard to CYP 2E1, the rat is therefore a good model of human response and data 
extrapolation holds well (Martignoni et al., 2006). 
The CYP 1A subfamily of enzymes plays a role in the metabolism of environmental 
carcinogens, polyaromatic hydrocarbons and arylamines.  The CYP 1A subfamily is 
also well conserved between humans and rats, showing 80% similarity. However, it 
also provides an important example of how extrapolation does not always work.  The 
anti-ulcer drug, omeprazole, induced CYP 1A2 in humans but not in rats, therefore 
this would not have been noticed in rodent based pre-clinical studies (Martignoni et 
al., 2006). 
The CYP 3A family is the most important CYP family in humans.  It accounts for 30% 
of all microsomal CYP content and plays a role in the metabolism of 50% of all drugs 
as well as the metabolism of some endogenous compounds including steroids and 
bile acid (Graham and Lake, 2008).  In humans there are 4 main isoforms: CYP 3A1, 
3A23, 3A2, 3A9, 3A18 and 3A62.  There is not a lot of parity between the human and 
rat CYP 3A family and as such the rat does not provide an effective model of CYP 3A 
expression.  Although CYP 3A is highly inducible in rats, the most abundant CYP 
isoform in the rat liver is CYP 2C and in addition to this, the typical inducer of CYP 3A 
in research in humans is rifampicin which is unable to induce CYP 3A in rats 
(Martignoni et al., 2006). 
There are other important considerations when extrapolating data besides 
metabolising enzymes.  When extrapolating data, it is important to understand the 
effect of size and weight on metabolism.  Rats have a much larger liver to body 
weight ratio.  The percentage of liver weight as total body weight is much higher in 
rats than in humans, this means that rats can often metabolise and clear drugs 
quicker than humans due to a higher content of microsomal CYP enzymes per gram 
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of body weight (Martignoni et al., 2006).  This is thought, in part, to explain why 
troglitazone toxicity was not observed during in vivo experiments in rats.  
Troglitazone showed hepatotoxicity in the clinic, but experimentally, only ‘acceptable’ 
levels of toxicity were seen which included microvesicular steatosis and liver 
enlargement in monkeys (Bedoucha et al., 2001; Smith, 2003; Boelsterli and Lim, 
2007).  No toxicity was observed in rats, possibly due to faster clearance in rats and 
less exposure to the drug.  Interestingly, it has been reported that while toxicity is not 
observed in rats in vivo, rat cells grown in vitro are susceptible to troglitazone when 
grown in monolayer, thought to be due to a reduced rate of clearance.  Subsequently 
rat hepatocytes were grown in 3D culture and exposed to lower concentrations of 
troglitazone for 21 days.  These experiments showed that in vivo and in vitro data 
correlated, which suggested that gel entrapment of cells could be the way forward in 
terms of generating reliable data that reflects in vivo effects (Shen et al., 2012).  
Furthermore, it is known that troglitazone is primarily metabolised by CYP 3A in 
humans, which, as previously stated, is not well modelled in rats. 
Understanding the differences in metabolism between rats and humans can help 
inform studies to ensure that the data generated is as valuable as possible.  Using in 
vitro and in vivo animal experiments to combine data along with computational  
in silico simulations, enables a tiered and comprehensive system to be developed for 
preclinical tests that can inform clinical dosage regimens.  There is also a 
considerable drive to reduce the number of animals used in medical research, 
including pre-clinical toxicology and to that end developing alternative in vitro models 
that can successfully predict toxicity in humans is of paramount importance (as 
evidenced by The National Centre for the Replacement, Refinement and Reduction 
of Animals in Research).  
The B-13/H cell line has shown great promise in providing an unlimited, on demand 
supply of hepatocytes without the need for a donor.  Despite this, a human 
alternative would provide much more relevant data, especially if supplementary 
whole animal studies are to be reduced.  Furthermore, the successful development of 
a human hepatocyte cell line would also have potential in cell replacement therapy 
and transplantation. 
Anecdotally, it has been observed that patients on long term steroid treatment have 
the development of hepatocyte like cells within their pancreas.  In addition to this, it 
was found by Fairhall et al. that pancreatic tissue taken from a patient on long term 
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systemic glucocorticoid therapy (at least 20 years) contained hepatocyte like cells 
that were not seen in the cells of patients who were not exposed to glucocorticoid 
therapy.  These cells also expressed liver markers at levels comparable to human 
hepatocytes (Fairhall et al., 2013b).  This work was built upon with the observation 
that human pancreatic acinar cells (HPAC) showed a slowed proliferation in 
response to dexamethasone in a manner similar to B-13/H cells and thus indicated 
that there may be other similarities between the two cell lines.  It was therefore 
hypothesised that HPAC cells could provide a human alternative to the B-13/H cell 
line (Fairhall, 2013).  HPAC cells are a pancreatic adenocarcinoma epithelial cell line 
that was derived from a pancreatic adenocarcinoma after engraftment into nude 
mice.  The HPAC cell line was also the first reported human adenocarcinoma cell line 
to express a functional glucocorticoid receptor (GR) (Norman et al., 1994).    It was 
first found by Normal et al in 1994 that DEX could slow the growth of HPACs 
(Norman et al., 1994).  In addition to this, Sumitran-Holgersson et al. found that 
human foetal pancreatic (HFP) cells were treated with fibroblast growth factor 2 and 
DEX, a liver phenotype was induced.  When characterised for pancreatic and hepatic 
markers it was found that the cells had lost pancreatic markers and expressed the 
hepatic markers albumin and cytokeratin 19 at the mRNA and protein level.  Cells 
were also successfully grafted into nude mice in which they retained their hepatic 
phenotype (Sumitran-Holgersson et al., 2009).  Fairhall has also reported that cell 
morphology changed following DEX treatment, becoming more tightly packed and 
rounded in shape with distinct cell boundaries (Fairhall et al., 2013b).   
Therefore, it was hypothesised that the hepatic-like cells derived from the DEX 
treatment of HPACs could potentially be developed into a human version of the B-
13/H cell line.  Unpublished work by the Wright group at Newcastle University has 
shown that two variants of the differentiated HPAC cell line have been produced to 
date, known as the H-13 and H-14 cells lines.  Both cell lines are transfected with 
slightly different DNA plasmids expressing different liver markers prior to 
transdifferentiation in DEX media.  H-13 cells are transfected with HNF4a and H-14 
cells with HNF1a.  HNF4a and HNF1a are human nuclear factors that regulate the 
expression of several hepatic genes and are mostly involved in early development of 
the liver (Pontoglio, 2000; Babeu and Boudreau, 2014).  Specifically, HNF4a is 
involved in the transcription of genes involved in the regulation of metabolism, cell 
junctions, differentiation and proliferation; it is crucial for early embryonic 
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development and subsequent function of the adult liver (Babeu and Boudreau, 2014).  
HNF1a, on the other hand, is a key regulator of glucose homeostasis and is involved 
in the regulation of albumin, beta fibrinogen and α1 anytitrypsin (Pontoglio, 2000). 
Despite initial promising findings, there have also been problems with the 
maintenance of a differentiated phenotype suggesting that there is still a great deal of 
development to be done before the HPACs can provide a suitable progenitor to 
hepatocyte like cells (Fairhall, 2013).  However, if a greater understanding of the 
differentiation process can be established there is huge potential for the development 
of a human cell model for preclinical toxicology. 
5.1.2 Aims  
 To test two variants of differentiated HPACs, H-13 and H-14 to investigate 
their responses to the hepatotoxin troglitazone. 
 To investigate if H-13 and H-14 cells responded in a similar way to B-13/H 
cells following exposure troglitazone.  
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5.2 Methods  
5.2.1 Materials 
Unless otherwise stated all materials were supplied by Sigma Aldrich (Poole, UK) 
5.2.2 Cell Provision 
HPAC, H-13 and H-14 cells were a gift from Prof. Matthew Wright (Newcastle 
University), cells were maintained and cultured by Dr. Emma Fairhall (Newcastle 
University) before being provided for experimentation as a confluent monolayer in 96-
well plates. 
5.2.3 HPAC Cell Culture 
HPAC cells originate from a 64-year old Caucasian female.  Cells were derived in 
1985 from a nude mouse xenograft of the primary tumour.  HPAC cells were routinely 
cultured in low glucose (1000 mg/l) DMEM which was supplemented with 10% FBS, 
500 U/ml penicillin and streptomycin, 2 mM L-Glutamine and 1% amphotericin B.  
Cells were incubated at 37°C in 95% air and 5% CO2.  The medium was changed 
every 2-3 days. 
When cells reached 70-90% confluence, the cells were passaged.  The medium was 
removed from the flask and the cell layer was washed once with pre-warmed PBS to 
remove traces of media.  As cells were adherent, 2 ml of 10x trypsin in EDTA was 
added to the flask.  The flask was gently tilted back and forth and then tapped gently 
to encourage the detachment of the cell layer from the surface.  8 ml of culture 
medium was then added to the flask to inhibit the action of the trypsin and the full 10 
ml was then transferred to a 15ml falcon tube which was then centrifuged at 2000 
rpm for 5 minutes.  Supernatant was subsequently removed and the cell pellet was 
re-suspended in fresh medium for counting using a haemocytometer.  Finally, cells 
were seeded as required, either into a fresh t75 culture flask for maintenance of the 
stock or for a specific experiment.   
5.2.4 H-13 and H-14 Cell Culture 
H-13 and H-14 cells were routinely cultured before being seeded at the relevant 
density into the relevant experimental plate in media containing 10 nM 
dexamethasone made from a serial dilution of a 100 µM stock in ethanol. 
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5.2.5 Resazurin Cell Viability Assay 
HPAC, H-13 and H-14 cells were routinely cultured and seeded into 96 wells plates 
by Dr Emma Fairhall prior to experimentation.  On the day of the experiment, the 
media was removed and cells were washed with PBS, media was replaced with 
unsupplemented DMEM containing a range of concentrations of troglitazone (1 µM-
500 µM).  Cells were incubated at 37 °C for 3, 6 and 24 hours.  Cell viability was 
measured by adding resazurin (0.03% w/v) to each well.  Resorufin, produced as a 
result of bioreduction of resazurin was measured fluorometrically at excitation 530 
nm and emission 590 nm using the Tecan-I plate reader. 
5.2.6 ATP Quantification 
Intracellular ATP was measured using an ATP content assay (Abcam, Cambridge).    
On the day of the experiment troglitazone was added to cells at concentrations 
between 0 µM and 100 µM.  First, cells were washed with PBS before addition of  
90 µl unsupplemented experimental media to each well.  Troglitazone concentrations 
were made at 10x concentration and 10 µl was then added to wells.  Measures were 
performed in triplicate.  Cells were incubated for 1 hour at 37 °C 5% CO2.  The rest of 
the assay was performed as described in the manufacturer’s instructions.  Briefly,  
50 µl of detergent was added to each well to lyse cells and stabilise ATP and the 
plate was shaken on an orbital shaker for 5 minutes.  50 µl of luciferin substrate was 
added to each and the plate was shaken again for 5 minutes before a final dark 
adaption for 10 minutes.  Luminescence was then read using a Tecan Infinite M200 
plate reader.  The assay is based on the production of light which was caused by the 
reaction of ATP with luciferase and D- luciferin.  The emitted light was proportional to 
ATP concentration. 
  
Chapter 5: Human Equivalents 
128 
 
5.3 Results 
It was observed in the H-13 cells that while the responses were not linear and there 
were some anomalous points (figure 5.1B, 10 µM and 25 µM), there was a definite 
trend to suggest that troglitazone was toxic.  While 5 µM- 25 µM troglitazone 
appeared to have similar levels of toxicity, at concentrations of ≥50 µM, cytotoxicity 
was concentration dependent.  There was no obvious time effect of troglitazone and 
maximum viability at concentrations of ≥ 100 µM was approximately 40% at 3, 6 and 
24-hour time points. 
Figure 5.1 showed that there was a difference in response observed between the 
cells before and after differentiation.  While toxicity was observed in the HPAC cells, 
they were less susceptible than the differentiated H-13 cells at all time points, for 
example at a 3-hour time point troglitazone concentrations below 100 µM did not 
cause a reduction in viability in the undifferentiated HPAC cells whereas a decrease 
in viability was seen at all concentrations in the H-13 cells.  Furthermore, unlike the 
H-13 cells there was a time effect of troglitazone.  Maximum levels of toxicity, 
however, were comparable to those levels seen in the H-13 cells.  The response of 
H-14 cells to troglitazone treatment was slightly different to that observed in the H-13 
cells. 
Although toxicity was observed in H-14 cells and there was vulnerability to 
troglitazone, the H-14 cells did not display significantly different toxicity to that 
observed in the undifferentiated HPAC cells at 3 hours and 6 hours (figure 5.2A and 
B).  The response was, however, concentration dependent.  Interestingly, at a 24-
hour time point, it appeared that troglitazone was more toxic to the HPAC cells than 
the H-14 cells (figure 5.2C). 
Compared to H-13 cells, the H-14 cells produced more consistent responses and 
responded in a concentration dependent manner to troglitazone. The time effect of 
troglitazone toxicity only occurred between 3 hours and 6 hours.  Unexpectedly, 
troglitazone toxicity did not continue to worsen. 
Figure 5.3 compared the response seen in the B-13/H cells to those seen in the 
HPAC progenitor cells and the differentiated HPACs at a 24-hour time point. It was 
observed that the B-13/H cells showed a much more consistent response and were 
also much more susceptible to troglitazone toxicity, at all concentrations of 
troglitazone, viability was less than that observed in either the H-13 or H-14 cells.  
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The biggest different was observed at 50 µM where B-13/H viability was 60% less 
than that seen in H-14 cells (which showed no loss of viability) and 30% less than the 
H-14 cells.  H-13 cells showed a response more similar to the B-13 cells than the H-
14 cells in that there was a concentration dependent decrease in viability in response 
to troglitazone, however at concentrations > 5 µM the response in B-13 cells was 
approximately 20% lower than H-13 cells.  Conversely, in the undifferentiated state it 
was the H-14 cells that showed the most similarity with the B-13 cells, comparable 
responses were seen between B-13 and undifferentiated H-14 cells, there was a 
concentration dependent decline in viability.  In undifferentiated H-13 cells there was 
no drop in viability observed until a troglitazone concentration of 75 µM. 
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Figure 5.1: The comparison of troglitazone toxicity in H-13 with their undifferentiated 
counterparts over 24 hours. At concentrations of 50 µM and above there was a 
concentration and time dependent effect observed in the H-13 cells.  H-13 cells were 
more susceptible to the toxic effects of troglitazone than their undifferentiated HPAC 
counterpart, this was most evident at a 3-hour time point as viability in the 
undifferentiated cells were not significantly lower than an untreated control until the 
maximum concentration of 500 µM was reached. (A) 3-hours (B) 6- hours (C) 24-
hours.  (*P<0.05, ***P<0.001) 
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Figure 5.2: The comparison of troglitazone toxicity in H-14 with their undifferentiated 
counterparts over 24 hours. The H-14 cells showed a time and concentration 
dependent decrease in viability, in the undifferentiated counterpart, a concentration 
dependent decrease in viability was only observed at a 24-hour time-point. (A) 3-
hours, (B) 6-hours, (C) 24-hours. (*P<0.05, **P<0.01, ***P<0.001) 
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Figure 5.3: Comparison of troglitazone toxicity after 24-hour exposure between 
rodent and human cells lines.  (A) In B-13/H cells there was a concentration 
dependent decrease in cell viability, this same concentration dependent response 
was observed in H-13 and H-14 cells, however, the effect was most significant in the 
B-13/H cells, H-14 cells were least susceptible to the toxic effects of troglitazone.  (B) 
B-13 cells showed a plateau in viability at concentrations of 50 µM and above.  HPAC 
cells showed a concentration dependent drop in viability with the undifferentiated H-
14 cells being more susceptible to the effects of troglitazone than the H-13 cells. 
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damage.  Part of the assessment of mitochondrial damage was to measure the ATP 
levels within cells.  This was repeated, therefore, in the H-13 and  
H-14 cells in order to determine whether comparable damage occurred in the 
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within cells.  The effect was more pronounced in the H-13 cells than the H-14 cells 
with ATP levels typically 10-15% greater in the H-13 cells at troglitazone 
concentrations between 1µM and 50 µM.  In the H-13 cells at concentrations ≥ 25 µM 
ATP levels were less than 50% of those observed in control cells without troglitazone 
treatment. 
 
Figure 5.4: ATP levels in H-13 and H-14 cells treated with troglitazone for 1 hour.  At 
concentrations of 5 µM and above there was a concentration dependent decrease in 
ATP levels present in both H-13 and H-14 cells.  A similar pattern of ATP reduction 
was seen in both cells lines. (*P<0.05, **P<0.01, ***P<0.001) 
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5.4 Discussion  
The data presented here support the initial findings by the Wright group that HPAC 
cells respond in a similar way to B-13 cells when treated with DEX to produce a 
hepatic like phenotype.  Interesting differences were noted however, between the H-
13 and H-14 cells.  While H-14 cells were shown to be susceptible to troglitazone 
toxicity in a concentration dependent manner, this was not significantly different to 
the toxicity seen in the HPAC cells prior to differentiation.  This raised the question of 
whether the HPAC cells were susceptible to troglitazone or whether the differentiated 
H-14 cells were less susceptible than other hepatocyte like cells.  When compared to 
undifferentiated H-13 and B-13 cells it was observed that undifferentiated H-14 cells 
had a similar toxicity profile to B-13 cells up to concentrations of 75 µM.  However, 
when data from the differentiated cells was compared to B-13/H cells and H-13 cells, 
the H-14 cells were not as susceptible to toxicity from troglitazone.  This suggested 
that the H-14 cells had not fully differentiated or that their hepatocyte profile did not 
contain a full complement of functional drug metabolising enzymes. This is a 
common problem seen with many other human hepatocyte models (Guillouzo et al., 
2007; Hart et al., 2010; Gerets et al., 2012).  Conversely it was seen that the H-13 
cells were susceptible to troglitazone.  While the response at 6 hours was variable it 
was observed that there was a decline in cellular viability with higher concentrations 
of troglitazone; this effect was seen at each time point.  At a 3 and 24-hour time 
point, there was a concentration dependent decrease in viability in response to 
troglitazone exposure.  The response at 6 hours was variable at the lower end of the 
concentration range, however, a decline in viability at concentrations of 50 µM and 
above was observed. This suggested that troglitazone was toxic to the H-13 cells 
and, when compared to undifferentiated HPAC cells, H-13 cells were significantly 
more susceptible.  In addition to this, it appeared that troglitazone caused acute 
toxicity in H-13 cells as toxicity at concentrations ≥100 µM was not time dependent 
and toxicity did not worsen after 3 hours up to a maximum of 24 hours.  Furthermore, 
it is also worthy of note that there appeared to be troglitazone-dependent increase H-
13 progenitor HPAC cells. This is likely to be due to a continuation in proliferation of 
the cells and a lack of troglitazone related toxicity.  
When compared to B-13/H cells at a 24-hour time point it was observed that the H-13 
cells were less susceptible to troglitazone than the rodent B-13/H cells.  This could 
possibly be due to the B-13/H cells being hypersensitive due to being grown in 
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monolayer.  As previously discussed in section 5.1.1, the artificial environment in 
which cells are tested has led to false positive results with regards to troglitazone 
toxicity (Shen 2011).  This highlights the importance of differences between human 
and animal models.  It has been suggested that troglitazone toxicity might have been 
missed in animal studies due to the nature of the rodents chosen.  Healthy, 
physiologically normal animals were employed in drug screens but patients receiving 
troglitazone treatment were diabetic and usually obese. This patient group may 
already have disease related mitochondrial dysfunction which would predispose them 
to being more vulnerable to troglitazone toxicity (St. Peter et al., 2001; Smith, 2003).  
However, toxicity was observed in H-13 cells that was greater than in undifferentiated 
HPAC cells suggesting that DEX caused fundamental genotypic changes in the cells 
that caused them to become more hepatic. 
With that in mind, subsequently ATP levels in H-13 and H-14 cells were measured in 
order to begin to establish if similar outcomes of toxicity were observed in the 
differentiated HPACs as was observed in the B-13/H cells.  It is widely reported that 
troglitazone elicits toxicity through mitochondrial damage (Tirmenstein et al., 2002; 
Masubuchi et al., 2006; Rachek et al., 2009; Nadanaciva et al., 2012; Hu et al., 
2015).  An indicator of mitochondrial dysfunction is a drop in ATP content as 
damaged mitochondria with a dysfunctional electron transport chain no longer 
effectively produce ATP.  It was shown in Chapter 4 that in the B-13/H cells there 
was a drop in ATP levels that was supported by extracellular flux analysis which 
showed a concomitant drop in oxygen consumed for ATP production.  It was found 
that there was a concentration dependent decrease in ATP levels seen with 
increasing troglitazone concentration in both H-13 and H-14 cells.  The effect was 
more pronounced in the H-13 than the H-14 cells, suggesting that there was a 
greater degree of mitochondrial dysfunction in the H-13 cells.  This, combined, with 
the toxicity data might suggest that the H-13 cells were a more susceptible 
alternative to H-14 cells as they appear from these initial experiments to behave 
more like hepatocytes.  It has previously been found that troglitazone is similarly able 
to reduce ATP levels in human hepatocytes; however, the decrease was far greater 
in the human hepatocytes.  Rachek et al. found that concentrations of troglitazone ≥ 
10 µM reduced ATP levels to less than 50% of an untreated control and a maximum 
concentration of 50 µM reduced levels to approximately 4% of that seen in an 
untreated control (Rachek et al., 2009).  The data presented here suggest that 
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troglitazone produced some degree of mitochondrial damage that affected ATP 
production in both the H-13 and 
H-14 cells.  This suggested that troglitazone might be able to elicit cellular damage 
but is not lethal.  It is also interesting to note that the only difference between the H-
13 and H-14 cells are the transcription factors used to create the cells.  HNF4a is 
known to be required for PXR and CAR mediated transcriptional activation of 
CYP3A4 (Hwang-Verslues and Sladek, 2010).  It is also known that CYP3A4 is the 
primary CYP enzyme involved in the metabolism of troglitazone (He et al., 2001; 
Hewitt et al., 2002; Sahi et al., 2003).  Therefore, it is possible that this explains the 
greater susceptibility of H-13 cells than H-14 cells to the toxic effects of troglitazone. 
This would also suggest a role for metabolism in the mechanism of troglitazone 
toxicity.  Before these cells can be fully characterised, however, there is much work 
that remains to be done. The response to troglitazone wasn’t linear in the H-13 cells 
at 6 hours due to an anomalous result suggesting that perhaps the cells behave 
inconsistently. 
Work reported here has shown that the B-13/H cell line can be humanised, thus 
limiting the problems faced with further drug extrapolation.  Probert et al reported that 
the B-13 cell line could be stably transfected with human CYP 1A2 and the 
subsequently derived B-13/H cells expressed functional CYP 1A2 at the mRNA and 
protein level.  This was shown by their ability to metabolise methoxyresorufin, an 
inducer of CYP 1A2 in humans (Probert et al., 2014).  Until the time when a human 
cell line is fully developed, a humanised line would offer a useful alternative. 
The data presented here add to the current body of research for the development of 
a human alternative to the B-13/H cell line.  The growth factors used appear to have 
a marked effect on the functionality of differentiated cells.  The H-13 cells which were 
transfected with HNF4a were far more susceptible to the effects of troglitazone than 
H-14 cells which showed no marked difference in cytotoxicity from the 
undifferentiated HPAC cells.  While it is possible that this may be due to the fact that 
HNF4a is required for the activation of the main troglitazone metabolising CYP 
enzyme, CYP3A4, investigating CYP induction could be important in understanding 
why these differences occur and crucial in optimising the process of differentiation 
and ultimately in producing a new cell line. 
Given time constraints it was not possible to test the undifferentiated HPACs for ATP 
content in response to troglitazone.  This would have been the obvious next step in 
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order to make comparisons following differentiation and to understand if similar 
damage was seen in response to troglitazone prior to DEX treatment.  Ideally more 
detailed experiments would be performed on the H-13 and H-14 cells so that a full 
comparison with the B-13/H cells could also be made, including extracellular flux 
analysis and lactate assays to determine if mitochondrial damage was also a 
contributing factor to the cytotoxicity observed.  
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6.1 General Discussion  
High attrition rates and a pressure to reduce the number of animal used in 
pharmacokinetic studies are driving reform of preclinical testing.  It has been reported 
that in recent years expenditure by the pharmaceutical industry on research and 
development has increased by 80% whereas productivity has decreased by 43% 
(Ahuja and Sharma, 2014).  This lack of efficiency has largely been attributed to a 
failure to predict toxicity in the early screening process, with 40% of NCEs failing to 
progress past the preclinical safety testing phase (McKim Jr, 2010).  Furthermore, it 
has been suggested that cardiac and hepatic toxicity contribute disproportionately to 
drug withdrawals from the market (Stevens and Baker, 2009).  Therefore, a hepatic 
cell model that does not require an animal donor would represent a significant 
development in this reform.  While many hepatic models do exist for this purpose 
they are fraught with reliability issues owing to a lack of functional metabolic enzyme 
profiles and while human hepatocytes are available for studies they have a tendency 
to dedifferentiate in culture and have an inability to proliferate (Marek et al., 2003).  
The B-13 cell line presents a potential alternative as a progenitor to a hepatocyte-like 
cell line, B-13/H.  It is a donor free cell line that can be produced in unlimited 
numbers, on demand.   
The primary aims of this thesis was to investigate and characterise the B-13/H 
toxicity profile when tested with known hepatotoxins.  Particular focus was placed on 
identifying mitochondrial dysfunction, as this is increasingly becoming implicated in 
the aetiology of drug induced toxicity and particularly hepatotoxicity.  Troglitazone 
was withdrawn from the market in 2000 after reports of severe liver injury.  
Mitochondrial liabilities have since been associated with the toxicity that resulted in 
its withdrawal (Dykens and Will, 2007; Ahuja and Sharma, 2014).  Troglitazone, 
therefore, presented the ideal challenge for the B-13 and B-13/H cells in order to 
study its potential for mitochondrial dysfunction in hepatocytes. 
Menadione is a chemical that is commonly used for research purposes to produce 
cytotoxicity.  It has a well characterised toxicity profile and elicits damage through a 
redox cycling mechanism due to a quinone moiety in its chemical structure (Klotz et 
al., 2014).  It is known that the chemical structure of troglitazone also contains a 
quinone moiety and thus it was hypothesised that troglitazone may also be capable 
of causing oxidative stress through a redox cycling mechanism.   
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As a general assessment of the differences between the B-13 and B-13/H cells when 
exposed to troglitazone, a viability assay was performed.  If DEX treatment had 
caused a functional hepatic genotype within the B-13/H cells it was anticipated that a 
drug with known hepatotoxic effects would elicit greater toxicity in the B-13/H cells 
than the B-13 cells.  It was subsequently found that menadione caused much greater 
cytotoxicity in the B-13/H cells compared to a minimal loss in viability shown by B-13 
cells.  This finding supported the idea that following transdifferentiation, B-13/H cells 
developed a significantly different metabolic profile.  This was supported by data 
generated from a troglitazone viability assay.  This time, while there was cytotoxicity 
observed in both cell lines the drop in viability was much greater in the B-13/H cells 
than the B-13.  A plateau was observed in B-13 cells exposed to troglitazone, beyond 
which there was no further loss.  This was an interesting finding as it suggested that 
troglitazone could be toxic to B-13 cells without the need for metabolism by the 
abundant CYP enzymes found in hepatocytes and consequently that the parent 
compound itself may elicit damage.  This finding could also suggest that troglitazone 
toxicity might be a cumulative effect of the parent drug and its metabolites.  This 
could be investigated by using inhibitors of metabolic enzymes such as CYP3A which 
is known to be the primary CYP family that metabolises troglitazone in rodents (He et 
al., 2001).  Therefore, if metabolism played a role in hepatocyte toxicity, this would be 
inhibited and any maintenance of cell viability would indicate a role for metabolism in 
toxicity.  For example, it was found that troglitazone sulphate, to a much greater 
extent than troglitazone, could elicit damage through competitive inhibition of the 
BSEP in rats (Funk et al., 2001). 
It is known that menadione can undergo redox cycling and is thought that due to 
similar structural features, troglitazone and quinone metabolites of troglitazone will 
also be able to redox cycle.  The most common accepted technique for measuring 
ROS is the use of fluorescent dyes which undergo redox reactions to form a 
fluorescent by-product.  The amount of fluorescence detected is proportional to the 
amount of ROS produced.  This technique is unreliable and has a tendency to lack 
specificity for the ROS species of interest, often showing cross reactivity with multiple 
ROS (Yazdani, 2015).  Therefore, one of the aims of this project was to develop a 
platform with which O2¯ production could be measured intra- and extracellularly.  
Knowing that the most common site of ROS production is the mitochondria due to a 
leak in the channel of electrons along the electron transport chain forming O2¯ within 
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the mitochondrial matrix it would represent a major step forward if ROS could be 
measured near the site of production intracellularly as O2¯ is rapidly dismutated by 
endogenous antioxidants making extracelluar detection quite difficult.  A combined 
platform in which O2¯ could be detected both intracelluarlly using PEBBLE 
nanosensors and extracellularly using electrochemistry would give a much better 
understanding of drug induced ROS. 
Unfortunately, as shown by the data presented in Chapter 2, the development of a 
functional nanosensor to detect ROS was far more challenging than anticipated and 
while progress was made in understanding the limitations and the requirements for a 
functional sensor, no experimental data was able to be obtained from the intracellular 
environment of B-13 or B-13/H cells.  Dye retention within the sensor matrix 
appeared to be the main issue with the sensor development.  The nature of ROS 
responsive dyes means that their chemical structure is compact and makes the dye 
molecules smaller than the gaps in the polyacrylamide matrix.  This lead to a 
situation during the washing stages of the manufacture process where the dye was 
rinsed from the nanosensor mix into the solvent.  Subsequently, in calibration 
experiments, it was observed that the sensors did not respond to an enzyme system 
in which O2¯ was produced.  It was shown as a proof-of concept that a pH 
nanosensor could be successfully calibrated and it has been shown previously that 
PEBBLE nanosensors can be successfully utilised in the detection of changes in pH 
in cellular lysosomal compartments (Zhang et al., 2015) and in whole C. elegans 
worms (Chauhan et al., 2013).  Therefore, with further developmental work it is 
hoped that a ROS nanosensor can also be developed.  Future work on this aspect of 
the project would require investigating how to make the dye molecules larger without 
affecting functionality of the dye, this could possibly be achieved by the covalent 
binding of dextran, an inert carbohydrate chain, to the dye molecule which should 
make it physically larger thus preventing the leaching from the dye matrix.  Following 
on from successful dye entrapment it would be pertinent to produce a calibration 
curve in a cell free system to optimise the signal obtained.  At this stage it would then 
be possible to internalise the nanosensors into the cells to obtain measures of the 
intracellular environment. 
The electrochemistry for the measures of the extracellular environment also saw 
some variable results.  While it was possible to obtain a response from B-13/H cells 
to menadione it was found that the signal obtained was 100 times smaller than that 
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seen in calibration experiments so whether this was a true response or not is unclear.  
Furthermore, no signal at all could be obtained from cells used past 5 days 
transdifferentiation or with the use of troglitazone.  The extracellular sensing method, 
therefore, may not have been sensitive enough to detect O2¯ using the experimental 
set up described.  The calibration curve was produced using a stirred system and it is 
suspected that this may be key to the erratic signals obtained from the cell based 
system which was unstirred and thus there may not have been even distribution of 
the drug throughout the medium.   
Further methods for assessing drug-induced mitochondrial dysfunction were 
assessed.  Mitochondrial functionality can be examined using measures of oxygen 
consumption as oxygen is required for the production of ATP in healthy mitochondria.  
A change in oxygen consumption rate is indicative of mitochondrial dysfunction.  
Traditionally these measures have been made using a Clark electrode, however, in 
recent years, significant progress has been made in the development of new 
technologies for oxygen sensing. The Seahorse Extracellular Flux Analyser offers a 
wide range of mitochondrial assessment criteria which added significant value to this 
research.  The technique allows for high throughput screening by using a 96-well 
plate format and a multiple injection strategy allows for multiple measures from a 
single well allowing for large amounts of data to be generated in a short amount of 
time (Brand and Nicholls, 2011).  This would be a particular benefit in the preclinical 
testing environment as resources have to be accurately targeted.   
The Extracellular Flux Analyser was used to perform mitochondrial stress tests on the 
B-13 and B-13/H cells in response to troglitazone challenge.  Previously data 
suggested that troglitazone elicited greater loss of viability in B-13/H cells than the B-
13 cells. It was hypothesised that this difference was due to DEX treatment creating 
a hepatic-like phenotype in the B13/H cells. Subsequently, troglitazone would be 
expected to cause mitochondrial dysfunction that would be shown as a concentration 
dependent drop in oxygen consumption rate.  The findings produced from B-13/H 
cells analysis supported these assertions.  A concentration dependent decrease in 
oxygen consumption rate was observed suggesting a depression of mitochondrial 
respiration which was indicative of mitochondrial dysfunction.  This finding was 
supported by an ATP quantification assay which showed a concentration dependent 
decrease in the total ATP content within the cells following troglitazone exposure.   
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Results obtained from B-13 cells were unexpected.  Troglitazone was seen to be 
significantly less toxic to the B-13 cells when compared to B13/H cells. This would 
suggest that there would be negligible differences in the oxygen consumption rate 
seen when B13 cells were incubated with troglitazone.  Whilst B13 cell oxygen 
consumption rate did not fall below levels seen in untreated cells there was an 
increase in oxygen consumption seen with lower concentrations of troglitazone.  ATP 
quantification assays showed that there was a slight decrease in cellular ATP levels 
despite the oxygen consumption rate for ATP production increasing.  This suggested 
that there were inefficiencies in the electron transport chain and the transport of 
electrons may not have been linked to the production of ATP.  This was supported by 
an observed increase in proton leak.  A lactate assay showed that in the B-13 cells 
there was a large increase in the amount of lactate present in cells suggesting that B-
13 cells were using glycolysis as a mechanism to produce ATP as a compensatory 
mechanism for the dysfunction in mitochondria.   
The extracellular flux data was particularly interesting as it displayed distinct 
functional differences between the B-13 and B-13/H cells and suggested that the 
DEX treatment did cause the cells to undergo genotypic as well as phenotypic 
changes.  To confirm the suggestion that glycolysis played a compensatory role for 
ATP production in cells, further work would utilise the glycolysis stress test function of 
the Extracellular Flux Analyser to measure the extracellular acidification rate in cells 
as lactate production is the main contributor to acidification within cells (Dykens and 
Will, 2007). 
Currently in development is a human cell line derived from HPAC cells.  While still in 
the very early stages of development, the preliminary results here have already 
highlighted a difference in response between the two hepatic cell lines, H-13 and  
H-14, to troglitazone treatment.  The H-13 cells showed a greater tendency for 
hepatic behaviour than the H-14 cells.  Toxicity observed in the H-14 cells was not 
significantly different to that seen in the undifferentiated HPAC cells.  The potential 
for further work on the H-13 and H-14 cells is beyond the scope of this one project.  
However, with regards to troglitazone it would be interesting to establish a profile for 
mitochondrial respiration within the cells.  It was found that, despite hepatocytes 
being much more metabolically active than pancreatic cells, that the B-13 and B-13/H 
cells showed remarkably similar basal levels of respiration until challenged with a 
toxin.  Therefore, further work could involve extracellular flux analysis of the H-13 and 
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H-14 cells to see if their basal levels of respiration are different and if, when treated 
with troglitazone, there was a difference in mitochondrial response.  If the H-13 still 
behaved more like hepatocytes than H-14 cells it would be expected that their 
oxygen consumption rate would decrease in response troglitazone.    
One of the greatest challenges that pharma companies face when doing preclinical 
toxicity testing is extrapolating the data generated in animals to humans.  Indeed, 
while the data presented here, from a rat cell line, supports the reports in current 
literature that troglitazone is hepatotoxic, this was not seen in the preclinical toxicity 
studies in whole rat models.  It has been suggested that rodent hepatocytes grown in 
monolayer are more sensitive due to a reduced rate of clearance and thus show a 
false positive result.  Further work could be done to investigate this by growing the B-
13 cells in 3D culture.  It has previously been shown by Richter et al. that when B-13 
cells were grown in a 3D bioreactor that they were able to successfully 
transdifferentiate into B-13/H cells and aggregate in a 3D configuration.  Hepatocyte 
formation was confirmed by an increase in expression of hepatocyte specific 
markers; albumin, cytokeratin 18, CEBP-β and CYP2E1.  The B-13/H cells were 
stably maintained for a 2-week period (Richter et al., 2015).  It would therefore be of 
interest to study the effects of troglitazone on the B-13/H cells grown in 3D culture in 
order to determine whether the cells showed a comparable response to those seen in 
whole animal studies.  Finally, it would ultimately be of interest to try and grow the H-
13 and H-14 cells in a 3D bioreactor in order to determine if a response can be 
generated that is similar to the response seen in humans following troglitazone 
treatment.   
The data presented here show that the B-13 cell line represents an in vitro cell model 
with huge developmental potential as a progenitor of B-13/H hepatocyte like cells.  
The hepatic response of the B-13/H cells to challenge with a known hepatotoxin 
opens the door for further development of the cell line as an alternative in vitro model 
that could potentially inform the use of further animal models, thus reducing the 
number of animals required.  The ultimate goal however, still remains to be the 
development of a human hepatocyte cell line that can be produced on demand and in 
unlimited numbers.  Initial work using the HPAC cell line is promising but many 
challenges still remain and elucidating the molecular mechanisms behind 
differentiation is crucial in forming a robust in vitro model for preclinical toxicity testing 
and beyond. 
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